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Object  The  primary objective  of this thesis was to  establish  the  pattern  of 
change  in  haemostatic  systems  in  patients  following  a  subarachnoid 
haemorrhage  (SAH).  I  hypothesise  that  following  a  SAH  there  is  an 
undefined  period  of  increasing  hypercoagulability,  which  if  present  would 
predispose to ischaemic stroke.
Methods.  This  was  a  prospective,  observational  study  on  67  consecutive 
patients  admitted  with  a  primary diagnosis  of SAH.  There were  24  males, 
median age 47.5 years  (25-75) and 43 females,  median  age  53 years  (23- 
80).
Blood  was  taken  at 4  time  periods  (<48hours,  4-5,  9-10  and  15-16  days) 
following  the  ictus  depending  on  the  day  of  hospital  admission,  and  on 
regular intervals during the hospital stay.  In addition, a sample was taken at 
3  months from the ictus. A Thromboelastograph  (TEG) profile  performed  at 
37°C,  and  the  routine  coagulation  studies,  International  Normalised  Ratio 
(INR)  and  Activated  Partial  Thromboplastin  Time  Ratio  (APTR)  were 
obtained  at  each  of  these  time  points.  In  addition  a  full  blood  count, 
biochemical  profile,  and  plasma for coagulation  and  fibrinolytic assays was 
also taken.
Results.  The  results demonstrated that SAH  patients were hypercoagulable 
immediately following the ictus, when compared with the blood sample taken 
3 months later.  In addition we observed the development of an  increasingly 
hypercoagulable state for the first 21  days following the ictus. This increase 
in  coagulation  was  demonstrated  against  a  background  of  haemodilution 
during this time.
2Conclusions.  This  highly  significant  data  demonstrates  that  SAH  patients 
become  increasingly  hypercoagulable  over  time  (maximum  21  days) 
following the  ictus. This  prothrombotic tendency has reversed  by 3  months. 
This  may  provide  a  new  direction  in  the  treatment  of  symptomatic 
vasospasm.
In addition, an in-vitro study using TEG has been performed  in 20 volunteer 
subjects to assess whether haemodilution  ‘per se’  has an  intrinsic affect on 
coagulation  specific  to  the  dilutent  itself.  This  study  demonstrates  that 
haemodilution does alter coagulation profiles measured using TEG. Different 
crystalloid  and  colloid  fluids  used  to  achieve  haemodilution  produce 
qualitatively consistent but quantitatively very different effects on coagulation 
in-vitro.
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16Introduction
This  thesis  commences  with  a  discussion  of  modern  theories  of  blood 
coagulation  in  man  and  its  control  in  vivo.  I  then  go  on  to  describe  the 
standard, routine coagulation tests performed clinically to assess coagulation 
mechanisms, and their limitations.
I  then  describe  in  detail  the  principles  of  thromboelastography  (TEG),  a 
coagulation  test  suggested  to  be  the  most  sensitive  assessment  of 
hypercoagulation.  I  explain  the  significance  of each  of the  TEG  variables, 
how they are  affected  by  particular blood  components,  and  how the test  is 
complimentary to the data generated in standard clinical tests of coagulation. 
I  then  discuss  how  TEG  has  been  used  previously  in  experimental  and 
clinical studies.
TEG  forms  the  cornerstone  of  the  experimental  studies  into  coagulation 
changes following subarachnoid haemorrhage (SAH) in this thesis. Thus, the 
thesis  commences  with  3  control  studies  into  this  technique.  The  first 
assesses the  reproducibility of a  TEG  measurement from  a  single  citrated 
blood sample in a control population. The second aims to ascertain the range 
of TEG variables in a control  population, and  examines whether age and/or 
sex may affect its value. There is then a discussion of the evidence for a sex 
difference  in  coagulation  mechanisms,  based  on  the  results  of the  study. 
Finally,  the  reproducibility of a  TEG  measurement  in  a  single  subject  over 
time  is  assessed  in  a  control  population.  This  was  central  to  the  clinical 
studies  were  serial  measurements  of coagulation  were  obtained  over time 
following a SAH. This study is followed by a short discussion of the evidence 
for cyclical or circadian change in coagulation in man.
17This  section  is  followed  by  the  experimental  studies  into  haemostasis 
following  subarachnoid  haemorrhage,  which  form  the  central  part  of  the 
thesis. This commences with  a  comprehensive literature  review of previous 
work in this and related fields.
There  is  first  an  explanation  of  subarachnoid  haemorrhage  (SAH),  its 
incidence  and  aetiology.  Then  an  explanation  of  how  coagulation 
mechanisms  and  changes  may  have  a  direct  impact  on  the  outcome  of 
patients  with  SAH  and  a  review  of  previous  haematological  studies  in  the 
SAH.
There  is  then  a  discussion  of  the  previous  work  in  related  neurosurgical 
fields.  This  deals  with  coagulation  changes  following  intracerebral 
haemorrhage and head injury, and explains potential mechanisms by which 
intracranial  pathology may affect coagulation  mechanisms.  This  is followed 
by the  more  widely  studied  field  of ischaemic  stroke  and  how coagulation 
manipulation is used as a primary form of management in this condition. 
There is then a review of one of the major controversies in SAH, the timing of 
aneurysm  surgery.  This  is  directly  relevant  to  the  present  studies.  If 
coagulation could be manipulated so that patients are hypercoagulable to the 
point  at  which  an  aneurysm  is  secured  following  a  SAH,  but  then 
anticoagulated  during  the  period  of  maximal  ischaemia,  this  may  have  a 
direct impact on  patient outcome.  Previous work to prevent rebleeding from 
intracranial aneurysms using antifibrinolytic drugs is presented.
The greatest cause of morbidity following SAH  is cerebral ischaemia.  In the 
presence  of  cerebral  ischaemia,  hypercoagulation  may  predispose  to  a 
worse  neurological  outcome,  through  further  ischaemic  deficit.  The
18mechanisms,  management and  outcome from  cerebral  ischaemia following 
SAH are discussed comprehensively.
Recently a novel new method of securing cerebral aneurysms following SAH 
has become available as an alternative to intracranial surgery and aneurysm 
clipping.  Endovascular  coiling  is  becoming  increasingly  utilised  in 
neurosurgical  centres.  Thus,  there  is  then  a  discussion  of how  surgery  as 
opposed  to  endovascular  therapy  may  affect  coagulation  and  cerebral 
ischaemia following SAH.
There is then a review of the more general topic of the metabolic response of 
the human body to trauma. SAH and surgery provide a major trauma to the 
human  body,  and  homeostatic  mechanisms  may  be  directly  relevant  to 
results of these experimental studies.
The  discussion  is  then  broadened  to  include  previous  work  in  the  field  of 
coagulation  and  surgery  in  general.  Followed  by  previous  studies  into 
coagulation  changes  and  other  neurosurgical  procedures,  excluding 
aneurysm surgery following SAH. This includes a review of previous work in 
the surgical field using TEG.
The literature review concludes with sections dealing with how issues related 
to  the  management  of  SAH  patients  may  directly  affect  coagulation 
mechanisms.  This  includes  the  affects  of  anaesthetic  agents,  intravenous 
fluids,  gender  and  immobilisation,  together  with  other  risk  factors  for 
thrombosis in the surgical patient.
Experimental  study  1   examines  how  the  standard  haematological  indices 
(haemoglobin concentration, haematocrit, red cell count, white cell count and 
platelet count),  and the standard  coagulation  indices (prothrombin time and
19activated  partial  thromboplastin  time) change  serially following  a  SAH  in  a 
consecutive series of 67 patients.
Experimental  study  2  examines  how  the  TEG  variables  R,  K,  Angle,  MA, 
TMA and G change serially following a SAH.
Experimental  study  3  examines  how  the  plasma  markers  of  coagulation 
(thrombin-antithrombin  and  prothrombin  fragments  1+2)  and  fibrinolysis 
(plasmin-antiplasmin  and  d-dimer),  and  source  fibrinogen  change  serially 
following a SAH.
Experimental  study  4  examines  whether  intracranial  surgery  performed 
during  the  period  following  a  SAH  affects  the  coagulation  profile  in  these 
patients.
It has been suggested that the severity of neurological deficits resulting from 
cerebral  ischaemia  following  a  SAH  correlates  with  the  amount  of  basal 
subarachnoid  blood  on  the  admission  CT  scan.  Experimental  study  5 
examines  whether  haemostatic  parameters  (measured  using  TEG)  reflect 
the  severity of subarachnoid  blood  on  the  admission  CT  (measured  using 
Fisher  grading).  In  addition  the  serial  TEG  data  is  examined  for  the 
confounding variables of age and gender.
There then follows a discussion of the findings of experimental studies 1   to 5 
and conclusions.
The final part of this thesis looks at a central part in the management of SAH. 
So-called ‘triple H’ therapy (Hypertension, hypervolaemia and haemodilution) 
has  become  the  definitive  management  strategy  in  preventing  ischaemic 
outcome  following  SAH.  The  core  of  this  theory  in  intravascular  volume 
loading,  but controversy exists as to which fluid  regimens best achieve this,
20and  experimental  evidence  has  proved  contradictory.  Experimental  study 6 
examines in-vitro using TEG whether different crystalloid and colloid infusion 
fluids have an intrinsic effect on coagulation, specific to the dilutent itself, and 
thus may be contributing to the observed changes in coagulation in patients 
following SAH.
21Haemostasis
‘Normal haemostasis  -   the  controlled activation  of clot formation  and 
clot  lysis  that  stops  haemorrhage  without  permitting  inappropriate 
thrombosis'
Haemostasis  is  a  physiological  mechanism  that  maintains  blood  in  a  fluid 
state within the circulation  and the  process whereby haemorrhage following 
vascular injury is arrested  (Fig.  1).  The coagulation of blood  is mediated  by 
cellular components  and  soluble  plasma  proteins.  In  response  to  vascular 
injury,  circulating  platelets  adhere,  aggregate,  and  provide  cell  surface 
phospholipid for the assembly of blood  clotting enzyme complexes  (Fig.  2). 
The extrinsic pathway of blood coagulation is initiated when blood is exposed 
to non-vascular cell  bound tissue factor in the subendothelial space. Tissue 
factor  binds  to  activated  factor  VII,  and  the  resulting  enzyme  complex 
activates factors IX and X of the intrinsic and common coagulation pathways 
respectively. Factor IX activated by the tissue factor pathway in turn activates 
additional factor X,  in a  reaction which  is greatly accelerated  by a cofactor, 
factor VIII. Once activated, factor X converts prothrombin to thrombin (factor 
I la)  in  a  reaction  that  is  accelerated  by  factor  V.  In  the  final  step  of  the 
coagulation  pathway,  thrombin  cleaves  fibrinogen  to  generate  fibrin 
monomers,  which  then  polymerise  and  link  to  one  another  to  form  a 
chemically stable  clot.  Thrombin  also  feeds  back  to  activate  cofactors  VIII 
and V, thereby amplifying the coagulation mechanism.
The blood coagulation cascade has the ability to transduce a small initiating 
stimulus  into  a  large  fibrin  clot.  The  potentially  explosive  nature  of  this 
cascade is offset by natural anticoagulant mechanisms. The maintenance of
22adequate blood flow and the regulation of cell surface activity limit the local 
accumulation  of  activated  blood  clotting  enzymes  and  complexes. 
Antithrombin  III  is  a  plasma  protein  that  inhibits  the  activity  of  the  serine 
proteases  of  the  intrinsic  and  common  coagulation  pathways.  In  the 
presence  of  endogenous  heparan  sulphate,  the  rate  of  inactivation  is 
increased  by  a  factor  of  several  thousand.  In  the  presence  of 
thrombomodulin  bound  to  endothelial  cells,  thrombin  activates  protein  C, 
which  in  turn  cleaves  activated  factors  VIII  and  V.  Like  other  reactions  in 
haemostasis,  this  one  is  accelerated  by  a  cofactor,  in  this  case  protein  S. 
The tissue factor pathway inhibitor is a lipoprotein associated plasma protein 
that forms a quaternary complex with tissue factor and activated factors VII 
and X, thereby inhibiting the extrinsic coagulation  pathway.  Finally,  a series 
of linked enzymatic reactions generates plasmin, a serine protease that acts 
on fibrin to dissolve preformed clots.
Congenital  and  acquired  hypercoagulable  states  arise  when  there  is  an 
imbalance between the anticoagulant and  prothrombotic activities of plasma 
in  which  the  prothrombotic activities  predominate(Rosing  et al.,  2001).  The 
mechanisms that underlie the thrombotic phenotype are defined by Virchow’s 
triad(Virchow,  1856), these are; a decrease in blood flow, injury to the vessel 
wall,  and  a  change  in  the  systemic  balance  of  procoagulant  and 
anticoagulant factors.  One  might therefore  predict that the loss of a  certain 
anticoagulant would  cause  a  shift  in  the  haemostatic  balance  and  thereby 
promote  a  diffuse  thrombotic  diathesis.  This  prediction  however,  does  not 
hold true. In fact, systemic alterations in the haemostatic mechanism typically 
give rise to local thrombotic lesions in discrete segments of the vascular tree.
23The  pathophysiological  basis  for these  observations  is  poorly  understood. 
The  conventional  wisdom  is  that  the  focal  lesions  are  attributable  to 
superimposed defects in the vascular wall or blood flow.  In other words, the 
phenotypic  state  of systemic  hypercoagulable  states  rests  on  the  ability  of 
these  two  local  mechanisms  to  compensate  for  a  uniform  change  in  the 
haemostatic  balance.  It  is  now  believed  that the focal  nature of thrombotic 
lesions is better understood  in the context of signalling pathways specific to 
the vascular bed.
According  to  this  model,  the  endothelium  integrates  different  extracellular 
signals  and  cellular responses  in  different  regions of the vascular tree.  On 
the  one  hand,  the  endothelium  is  exposed  to  diverse  environmental  cues, 
including those from integrins and growth factors, haemodynamic forces, and 
cell  to  cell  signalling.  On  the  other  hand,  the  ability  of the  endothelium  to 
transduce a given signal is regulated  in  both space and time. As a  result of 
these  variables,  endothelial  cell  derived  procoagulant  and  anticoagulant 
activities are differentially expressed throughout the vascular tree. The focal 
thrombotic phenotype that is associated with a systemic loss of anticoagulant 
function  reflects  the  critical  role  of that  particular  mechanism  in  restricted 
sites of the vasculature.
Fibrinolysis  (Fig.  3)  is  the  process  whereby fibrin  is  degraded  by  plasmin. 
The  circulating  proenzyme  plasminogen  is  activated  to  plasmin  following 
injury by tissue plasminogen activator (TPA) and urokinase-like plasminogen 
activator (UPA) released from damaged or activated cells.
24Plasmin digests fibrin (or fibrinogen) into fibrin degradation  products (FDPs) 
and also degrades factors V and VII.  Free plasmin  is inactivated  by plasma 
< x 2-antiplasmin and a2-macroglogulin.
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Figure 1. The haemostatic response to injury.
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Taken from: Mehta, A and Hoffbrand V. Haematology at a Glance. 2000. Blackwell, Oxford, UK.
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28Hypercoagulability in humans
Hypercoagulable states arise from an imbalance between  procoagulant and 
anticoagulant forces. A striking feature of these conditions is the focal nature 
of  the  thrombotic  diathesis.  For  example,  congenital  deficiencies  of 
antithrombin  III,  protein  C,  and  protein  S  are  associated  with  an  increased 
incidence  of  deep  vein  thrombosis  of the  lower  but  not  upper  limbs,  and 
deficiency states  involving  these  proteins  do  not confer a  predisposition  to 
arterial thrombosis. An exception to this is a mutation of the heparin binding 
site  of  antithrombin  III.  In  this  case  the  antithrombin  III  does  not  bind  to 
heparin and is therefore much less efficient at inhibiting thrombin and other, 
more proximal enzymes in the coagulation cascade. The resulting thrombotic 
phenotype  involves  both  arteries  and  veins.  Factor  V  Leiden  is  usually 
associated with an increased risk of deep vein thrombosis in leg and cerebral 
veins, but may also confer an increased risk of acute myocardial infarction in 
young women who smoke. The prothrombin G20210A mutation predisposes 
patients to deep vein thrombosis in the legs and brain, and may be a genetic 
risk factor for both stroke and ischaemic heart disease.
Several  acquired  hypercoagulable  states  are  also  associated  with  vascular 
bed  specific  thrombosis.  Paroxysmal  nocturnal  haemoglobinuria  and  the 
myeloproliferative diseases are characterised by an unusually high incidence 
of  thrombosis  of  the  hepatic,  portal  and  mesenteric  veins.  Patients  with 
antiphospholipid  antibody  syndrome  have  a  propensity to form  clots  within 
particular venous and arterial segments of the vascular tree,  including blood 
vessels of the retina and  placenta.  Warfarin  induced  necrosis of the skin  is 
associated with extensive thrombosis of the postcapillary venules and  small
29veins  within  subcutaneous  adipose  tissue.  The  microthrombotic  lesions 
characteristic  of  thrombotic  thrombocytopenic  purpura  and  the  haemolytic 
uraemic syndrome are detectable in all organs with the notable exception of 
the liver and the lungs.
On  the  one  hand,  each  of these  disorders  is  characterised  by  a  systemic 
dysfunction  of  the  haemostatic  pathway  resulting  in  the  absence  of  a 
circulating natural anticoagulant or the presence of an activated cell surface 
membrane.  On  the other hand,  each  condition  is  associated  with  a  unique 
and  restricted  phenotype.  How can  these diverse  responses to  a  systemic 
problem  be  explained?  According  to  Virchow’s  triad,  the  phenotype  must 
arise  from  local  changes  in  blood  flow,  disruption  of the  vascular wall,  or 
vascular  bed  restricted  alterations  in  the  balance  of  anticoagulant  and 
procoagulant factors.
Blood  flow  limits  the  extent  of the  procoagulant  response,  and  its  relative 
deficiency may underlie the tendency for thrombi to develop in certain  parts 
of the vascular tree.  However,  blood flow is not the principal determinant of 
haemostatic control  in  all  vascular beds.  Local  disruption  of the  integrity of 
the blood vessel wall may also have an important effect on certain thrombotic 
phenotypes.  For example, surgery puts patients with congenital deficiencies 
of  protein  C,  protein  S,  or  antithrombin  III  at  particularly  high  risk  of 
perioperative deep vein thrombosis.  However, similar procedures in patients 
with factor V Leiden deficiency do not confer an increased risk of thrombosis. 
Moreover, the loss of integrity of the vessel wall caused  by the rupture of a 
coronary atheromatous  plaque  does  not  lead  to  a  higher  rate  of occlusive 
thrombus in  patients with defects of protein C,  protein  S, or antithrombin  III
30pathways.  Indeed the very absence of association between the loss of these 
natural anticoagulant mechanisms and the incidence of myocardial infarction 
suggests  that  these  particular  pathways  are  relatively  unimportant 
contributors  to the  haemostatic  balance  of the  coronary vasculature.  Such 
epidemiological  observations  provide  strong  support  for  the  existence  of 
regionally distinct haemostatic balances.
In addition, a further explanation for the focal nature of haemostatic control is 
found  in  the  uneven  distribution  of various  anticoagulant and  procoagulant 
factors throughout the vascular tree(Rosenberg, Aird, 1999).
The  mechanisms favouring  hypercoagulability  may differ following  different 
forms  of  trauma.  In  addition,  it  appears  likely  that  post  traumatic 
hypercoagulability is a systemic phenomenon(Dahl, 1999).
Thromboplastin.  Although  the  brain  contains  the  highest  concentration  of 
thromboplastin  in  the  human  body(Bjorklid  et  al.,  1977;  Bjorklid,  Storm, 
1977),  and  it  is  speculated  that trauma,  infarction  and  surgery to the  brain 
results  in  the  release  of  tissue  thromboplastin,  and  activation  of  the 
coagulation cascade, there is no direct evidence to support this(Hamilton et 
al., 1994).
Tissue  Factor.  Tissue  factor  (TF)  is  the  primary  cellular  initiator  of  blood 
coagulation  and  the  most potent trigger of blood  coagulation  known  today. 
The adventitia surrounding the major blood vessels, the brain, and the bone 
marrow  are  the  structures  with  high  levels  of  TF(Dahl,  1999).  The 
concentration of TF is reported to be greater in the cortical grey matter than 
in white  matter(del-Zoppo et al.,  1992).  It  is  reported  to  be associated with 
non  capillary microvessels  in the cerebral cortex and with the adventitia,  as
31seen in superficial cerebral vessels(Dahl,  1999;  Fujii et al., 2001). Thus, the 
entry  of  blood  into  the  subarachnoid  space  may  cause  a  considerable 
amount  of  TF  release  into  the  systemic  circulation  through  injury  to 
superficial  brain  tissues,  including  superficial  cerebral  arteries,  resulting  in 
systemic haemostatic activation.
Endothelial  cells.  Endothelial  cells  lose  their  non-thrombogenic  properties 
when  stimulated  by thrombin  and  certain cytokines, which trigger synthesis 
and expression of TF on their luminal and subcellular surfaces. Tissue factor 
pathway  inhibitor,  the  major down  regulator of the  procoagulant activity  of 
tissue factor-factor Vila, is synthesised and secreted by the endothelial cells. 
The protein C anticoagulant pathway plays a critical role in controlling blood 
coagulation.  The  receptor  for  protein  C  is  bound  to  the  endothelium  and 
accelerates protein  C activation.  It is  known that this  receptor can  be down 
regulated by pro-inflammatory cytokines, such as IL-1 p.
Vascular bed specific signalling pathways
The  endothelium  is  involved  in  a  wide  range  of  homeostatic  processes, 
including  the  maintenance  of  blood  fluidity,  the  control  of vasomotor tone, 
and  the  transfer  of  nutrients  and  cells  between  blood  and  the  underlying 
tissue. On the anticoagulant side the endothelium releases heparan sulphate 
and  prostacyclin,  expresses  thrombomodulin,  tissue  type  plasminogen 
activator,  tissue  factor  pathway  inhibitor,  and  endothelial  nitric  oxide 
synthase, and  provides a non thrombogenic cell surface membrane.  On the 
procoagulant  side,  the  endothelial  cells  release  von  Willebrand  factor  and 
plasminogen  activator  inhibitor  type  1,  express  receptors  for  cell  surface 
tissue factor and thrombin, expose critical binding sites for coagulation factor
32complexes, and attracts platelets and monocytes to sites of activation. Under 
normal  conditions,  a  delicate  balance  between  the  anticoagulant  and 
procoagulant  activities  of  the  endothelium  is  achieved  by  a  series  of 
regulatory  linking  mechanisms.  These  mechanisms  are  capable  of 
integrating multiple signals to generate a response that varies both in space 
and  time,  so  that  within  any  given  segment  of  the  vascular  tree,  the 
endothelium  is capable of shifting the haemostatic balance from  moment to 
moment.  The temporal  and  spatial  nature  of these  regulatory  mechanisms 
endows  the  haemostatic  system  with  tremendous  flexibility.  At  the  same 
time,  these  very  properties  make  the  endothelium  vulnerable  to  focal 
dysfunction and pathophysiological disorders.
Extracellular signals
There are an array of signals residing in the microenvironment that regulate 
the  procoagulant  and  anticoagulant  properties  of  the  endothelium.  These 
signals  include  growth  factors,  cytokines,  mechanical  forces,  circulating 
lipoproteins, coagulation factors, components of the extracellular matrix, and 
neighbouring  cells.  The  extracellular  signals  are  transduced  by  endothelial 
cell  signalling  networks,  resulting  in  alterations  in  procoagulant  and 
anticoagulant mRNA, protein and function.
Cell subtype specific signalling pathways
A  second  mechanism  that  contributes  to  the  generation  of  vascular  bed 
specific  phenotypes  is  signalling  pathways  specific  to  cell  subtype. 
Endothelial cells from various vascular beds have different responses to the 
same signals. In addition, the signalling pathways for endothelial cells involve 
regulating a whole series of gene networks.
33Transcription regulation
A  final  mechanism  underlying  the  generation  of  vascular  bed  specific 
phenotypes  is  found  at the  level  of transcription.  Transcription  control  is  a 
regulatory  linking  mechanism.  It  is  generally  believed  that  tissue  specific 
genes are regulated  by common  mechanisms in different cells of the same 
lineage. The overall expression of a single gene may be mediated by distinct 
vascular  bed  specific  signalling  pathways  that  begin  in  the  extracellular 
milieu  and  end  in  separate sites on the  promoter gene region  of the gene. 
This expanded  repertoire of interactions between  DNA and  protein  provides 
the  endothelium  with  an  even  greater  capacity  for  integrating  multiple 
extracellular signals.
34Principles of Thromboelastography
The use of Thromboelastography (TEG), an in-vitro bench test in monitoring 
haemostasis is based on two assumptions:
The end result of the haemostatic process is the production of a clot.
The clot’s physical  properties (rate,  strength, and  stability) can therefore be 
used to assess the haemostatic process.
TEG  measures  the  clots  physical  properties  by  the  use  of  a  special 
cylindrical cup that holds the blood  and  is oscillated through an angle of 4° 
45’ (Fig. 4).  Each rotation cycle lasts 10 seconds. A pin is suspended in the 
blood by a torsion wire that is monitored for motion. This wire acts as a strain 
gauge. The torque of the rotating cup is transmitted to the immersed pin only 
after  fibrin-platelet  bonding  has  linked  the  cup  and  the  pin  together.  The 
strength  of  these  fibrin-platelet  bonds  affects  the  magnitude  of  the  pin 
motion. Thus, the magnitude of the output is directly related to the strength of 
the formed clot. As the clot retracts or lyses, these bonds are broken and the 
transfer of cup motion  is diminished. The  rotation of the  pin  is converted to 
an electrical signal which is monitored by computer(Mallett, Cox, 1992).
The  whole  haemostatic  process  from  the  time  of  the  initial  platelet-fibrin 
interaction,  through  platelet aggregation,  clot strengthening  and  fibrin  cross 
linkage  right through  to  eventual  clot  lysis  can  be  assessed  from  the TEG 
tracing  (Fig.  5).  The  diagnosis  of  coagulation  factor  activity  deficiency, 
platelet  abnormalities,  dysfibrinogenaemias,  fibrinolysis,  or  diffuse 
intravascular  coagulation  can  all  be  made  from  a  single 
thromboelastogram(Tuman et al., 1987).
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Figure 4. Schematic diagram of TEG apparatus.
The cup rotates about the pin every 10 secs. As the fibrin strands start to 
form they couple the motion of the pin to the cup. This sets up a strain on the 
wire which is read by an electromagnetic transducer to produce a 
characteristic TEG trace.
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Figure 5. The TEG tracing.
This schematic representation of a TEG trace shows how TEG allows an 
assessment of the whole haemostatic process from the onset of coagulation 
to fibrinolysis.
37TEG parameters
To  evaluate  the  graphic  information  of  the  TEG  analyser  quantitatively, 
parameters of clot formation and lysis are obtained (Fig. 6).
R or R-Time The time from the start of a sample run until the first significant 
levels of detectable clot formation  (amplitude 2mm  in TEG tracing).  This  is 
the time point at which  most traditional coagulation assays such as  PT and 
APTT,  reach  their  end  points.  R-time  is  prolonged  by  anticoagulants  and 
factor  deficiencies  and  shortened  by  hypercoagulable  conditions.  R  is 
exquisitely sensitive to the presence of heparin and is a highly accurate and 
reproducible monitor of low dose heparin prophylaxis.
K or K-Time The time from the measurement of R until a fixed  level of clot 
firmness is reached (amplitude 20mm).  K-time is a measure of the speed of 
clot kinetics to reach a certain clot strength. K is thus shortened by increased 
fibrinogen  and  to  a  lesser extent  by  platelet function,  and  is  prolonged  by 
anticoagulants that affect both.
Angle (a)  The  angle  is  closely  related  to  K-time,  since  they are  both  a 
function of the rate of polymerisation. The angle is more comprehensive than 
K-time, since there are hypocoagulable conditions in which the final  level of 
clot firmness does not reach an amplitude of 20mm.
MA  Maximum  Amplitude.  Measurement  of the  maximum  strength  of the 
developed  clot.  Clot  strength  is  the  result of  platelet  number and  function, 
and to a lesser extent by fibrin.  Platelet abnormalities whether qualitative or 
quantitative substantially disturb the MA.
TMA  Time to maximum amplitude.
38G  Shear  elastic  modulus  strength  measured  in  dyn/cm2.  If  A  is  the 
amplitude  of  the  sample  it  is  calculated  by  the  formula  G=5000A/(100A). 
Note that A  is  equal to  MA  until  MA  is  reached.  The value of G  increases 
exponentially  in  proportion  to the  amplitude  (A) of the TEG  tracing,  and  is 
more  sensitive to  small  changes  in  clot strength  or  breakdown  than  is  the 
amplitude in mm.
It is important to appreciate that an essential difference between the clotting 
of  blood  in  vivo  and  the  clotting  of  blood  in  the  thromboelastogram  is  the 
presence/absence  of  the  vessel  wall.  If  the  haemostatic  defect  is  due  to 
interference  with  the  normal  interaction  of the  platelets  with  the  vascular 
endothelium,  rather than with the platelet aggregation  responses or platelet 
involvement  in  the  coagulation  sequence,  then  the  TEG  MA  will  not  be 
affected(Mallett, Cox, 1992). It is for this reason that the effect of certain anti­
inflammatory  agents  such  as  aspirin  on  platelets  are  not  demonstrated  by 
TEG(Gibbs, Sear, 1995).
The MA parameter of the TEG, and to a lesser extent the K time, has been 
shown by Oshita and colleagues(Oshita et al., 1999a) to be directly related to 
the platelet count in diluted plasma samples.
As  well  as  providing  data  on  the  initiation  of  coagulation,  if  the  trace  is 
allowed  to  proceed  it  can  also  supply  information  detailing  the  process  of 
fibrinolysis. The LY30 and LY60 parameters measure percent lysis at 30 and 
60  minutes  after  MA  is  reached.  The  LY30  and  LY60  measurements  are 
based on a reduction of the area under the TEG tracing from the time MA is 
measured  until  30  (or  60)  minutes  after  MA.  The  A30  and  A60  are  point
39measures of amplitude at time points after MA. The lysis time provides more 
information about the process of fibrinolysis as a whole.
Figure 7 demonstrates the value of lysis time. Thirty minutes after MA,  the 
amplitudes of both tracings read zero.  However, the LY30 parameters of the 
two tracings are radically different.  In the top tracing, the shaded area under 
the  curve  is  approximately  15%  of  the  rectangular  area  (the  rectangle 
represents the area under the curve if there had been no fibrinolysis). Thus, 
the  LY30  is  approximately  85%.  In  the  bottom  tracing,  the  shaded  area 
comprises about 85% of the rectangle. This makes the LY30 approximately 
15%.
The  A30  and  A60  represent  the  fibrinolytic  status  at  exactly  30  and  60 
minutes  after  MA  is  reached.  LY30  and  LY60  represent  the  fibrinolytic 
process that took place during those 30 or 60 minutes.
TEG can also be used to monitor the effects of antifibrinolytic therapy in the 
clinical setting(Mallett, Cox,  1992) and has become a routine haematological 
index in hepatic and cardiac surgery.
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Figure 6. The TEG tracing parameters of coagulation R, K, Angle and 
MA.
41Figure 7. The lysis time (LY).
The value of this parameter is that at 30 minutes following the MA, the 
amplitude of the 2 traces is zero. However, in the top trace far more 
fibrinolysis has taken place. This is only appreciated by calculating the lysis 
time.
42TEG sample types
In general TEG can be performed on native whole blood.  However, samples 
can be modified in vitro to speed up analysis, determine if a possible therapy 
might be of benefit, or reverse a clinical condition (e.g. heparinisation).
These techniques involve the addition of the following reagents to the native 
whole blood sample:
Activators (celite, tissue factor, thrombin)
Heparin neutralises (heparinase, protamine)
Platelet blockers (ReoPro, dipyridamole, ticlopine)
Antifibrinolytic drugs (epsilon-amino-caproic acid, tranexamic acid, aprotinin) 
If native whole blood is used for analysis then the time between phlebotomy 
and  starting the sample run  must be less than  5  minutes.  In circumstances 
when this is not possible sodium-citrated whole blood samples can be used. 
Citrated samples must be recalcified before analysis but give the investigator 
about 2 hours before the run must be commenced.
Temperature effect
TEG samples are generally run at 37°C. However, the apparatus does allow 
the investigator to change this and assess coagulation at other temperatures 
such as the use of hypothermia for severe head injuries.
Data analysis
The tracings can be analysed both qualitatively and quantitatively (Figs 8 and 
9).
Quantitative  data  is  readily  transferable  from  the  TEG  software  into 
commercial statistical packages such as Microsoft Excel and SPSS.
43Anticoagulants/hemophilia 
Factor Deficiency 
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Platelet Blockers
Thrombocytopeniaf 
Tbrombocytopathy 
R -  Normal; K = Prolonged;
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Fibrinolysis (UK, $K or tJA) 
Pretence of t-Pk 
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Ly60> 15.0%; WBCLI60 < 85%
Hypercoagulation
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D IC  
Stage  1
Hypercoagulable state with 
secondary fibrinolysis
Stage 2
Hypocoagutable state
Figure 8. Qualitative TEG data(Mallett, Cox, 1992).
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Figure 9. Quantitative TEG data.
A characteristic trace from a patient following a SAH. Each of the TEG 
parameters is generated automatically from the TEG software as the 
analysis proceeds.
45Mechanisms of haemostasis
Haemostasis  is  a  dynamic,  extremely  complex  process,  involving  many 
interacting  factors,  which  include  coagulation  and  fibrinolytic  proteins, 
activators, inhibitors and cellular elements.
Once  the  coagulation  cascade  is  activated,  whether  through  the  intrinsic 
pathway, the extrinsic pathway, or a combination of both, thrombin is formed. 
The  thrombin  cleaves  soluble  fibrinogen  into  fibrin  monomers,  which 
spontaneously  polymerise  to  form  protofibril  strands  that  undergo  linear 
extension,  branching,  and  lateral  association  leading  to  the formation  of a 
three dimensional  network of fibrin fibres. A unique property of this  network 
structure  is  that  it  behaves  as  a  rigid  elastic  solid,  capable  of  resisting 
deforming shear stress of flowing blood(Khurana et al., 1997).
Resistance to  the deforming  shear  stress  of the  network  of fibrin  fibres  is 
enhanced further by platelets, which are also activated by thrombin. Platelets 
achieve this in two ways. Firstly, they enhance fibrin polymerisation by acting 
as nodes or network branch points. Secondly, they stabilise and significantly 
enhance the structural rigidity of the fibrin network(Khurana et al., 1997). 
Platelet  GPIIb/llla  receptors  bind  the  polymerised  fibrin  network  to  the 
platelets actin cytoskeleton(Khurana et al.,  1997). Through this receptor the 
platelets transmit a contractility force to the fibrin  network (Fig.10).  It is the 
kinetics,  strength  and  stability of this  process that is  measured  by the TEG 
analyser.  Each parameter represents a different aspect of the clots physical 
properties.
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Figure 10. Platelet adhesion.
Subendothelial microfibrils bind vWF which in turn binds platelets at the 
glycoprotein 1b (GP1b) receptor. This binding exposes the platelet 
glycoprotein llb/llla receptor which binds further with vWF. The GP llb/llla 
receptor also binds fibrinogen to allow platelet-platelet aggregation. The 
platelet glycoprotein la receptor binds directly to collagen.
Taken from: Mehta, A and Hoffbrand V. Haematology at a Glance. 2000. Blackwell, Oxford, UK.
47Standard coagulation tests
The  older  view  of  separate  intrinsic  and  extrinsic  coagulation  systems  is 
being  abandoned,  along  with  the  waterfall  description  of  coagulation 
mechanisms  with  one  enzyme  working  after  another,  associated  with 
mechanisms  of  feedback  amplification  and  inhibition  in  a  plasma  milieu. 
These  concepts  have  been  replaced  by  a  theory  of  enzyme  complexes 
existing on the surface of cells, exchanging substrates until the final product, 
fibrin, is formed(Mann,  1984). The cell surfaces with most importance in this 
process are those of the platelets, which once activated adhere to the site of 
injury. They localise the clotting process, enhance their activity, and  protect 
the enzyme complexes from the inhibitors that circulate to protect against the 
propagation of the clotting process downstream.
Since  prothrombin  time  (PT)  and  activated  partial  thromboplastin  time 
(APTT)  are  plasma  tests  designed  with  substitutes  for  platelet  surfaces,  it 
can  be  understood  how these  tests  may  not  agree with  whole  blood  TEG 
analysis.  Haemostasis is a balance between the coagulation system forming 
fibrin  and  the  fibrinolytic  system  breaking  it  down.  Measuring  isolated 
components of these systems ignores the interactive  nature of the process. 
In  addition  quantitatively  measuring  a  specific  factor  or  protein  gives  no 
indication of its function in vivo(Miller et al.,  1997).  Functional activity is also 
dependent on the presence and  activity of activators,  inhibitors and  cellular 
elements.  Clotting  is a dynamic  process which  is difficult to  measure  using 
stated end  points, which  provide no information about the quality of the clot 
or the dynamics of its formation(Mallett, Cox, 1992).
48In  addition,  routine  laboratory tests  are generally  performed  on  centrifuged 
plasma  fractions  and  examine  only  isolated  portions  of  the  coagulation 
cascade, thereby overlooking  important interactions essential to the  clinical 
evaluation  of clotting  and  bleeding  syndromes(Mallett,  Cox,  1992).  Routine 
tests end with the formation of the first fibrin strands, whereas TEG begins at 
this  point  and  continues  to  generate  data  as  clotting  continues  through  to 
eventual clot lysis or retraction(Spiess et al., 1987).
The  PT  is an  in vitro  measure of the extrinsic pathway and  is  prolonged  in 
deficiencies/defects  in  factors  II,  V,  VII  and  X,  but  is  not  affected  by 
deficiencies in factors VIII,  IX, and XI and the contact activation factors. The 
PT  is  performed  by measuring the time  it takes to form  a  clot after adding 
calcium  and  a  tissue  extract  to  plasma(Heesen  et  al.,  1997b).  The  APTT 
measures  activity  of  the  intrinsic  pathway  and  is  prolonged  by 
deficiencies/defects in factors  II, V,  IX, X, XI, and XII,  but is not affected  by 
deficiencies  in  factor  VII.  Both  tests  are  sensitive  to  defects  in  the  final 
common  pathway.  These  tests  do  not  exclude  defects  resulting  from  the 
vascular  wall,  platelet  functional  defects,  some  cases  of  von  Willebrand 
disease or problems related to fibrinolysis.
Howland et al(Howland et al., 1974b) have compared TEG, PT and APPT for 
intraoperative  coagulation  monitoring  in  patients  undergoing  non-cardiac 
surgical  procedures.  The  TEG  provided  information  on  hypercoagulability, 
platelet  function,  and  fibrinolysis  that  other tests  did  not  give,  and  it  was 
concluded that TEG  provided  an  extremely reliable guide for intraoperative 
therapy.
49TEG  provides an  integrated  profile of the whole blood  haemostatic system. 
Earlier studies have shown a correlation between TEG variables and routine 
coagulation  tests  (platelet  count,  PT,  APTT,  antithrombin  III, 
fibrinogen)(Artang et al., 2000; Zuckerman et al., 1981).
Endothelium
The inner lining of the whole circulatory system consists of a single layer of 
cells,  the  endothelium.  In  the  capillaries  an  exchange  of  nutrients  and 
hormones  takes  place  facilitated  by  the  relatively  large  exposure  of 
endothelial  surface  area  to  a  relatively  small  volume  of  blood.  Endothelial 
cells  from  microvessels  make  a  much  larger  contribution  to  circulating 
plasma  factors  that  reflect  endothelial  functioning,  than  those  from  large 
vessels.
The endothelium contributes to the maintenance of blood fluidity by 3 groups 
of  mechanisms.  (A)  It  harbours  factors  that  interrupt  the  coagulation 
cascade,  such  as  antithrombin  III,  the  protein  C  receptor thrombomodulin, 
and  tissue  factor  pathway  inhibitor.  (B)  It  prevents  platelet  activation  and 
aggregation  by  the  production  of  nitric  oxide  and  prostacyclin, 
exonucleotidases  and  surface  heparan  sulphates.  (C)  It  can  trigger  and 
control fibrinolysis  by the synthesis and  release of tissue type plasminogen 
activator and  its  inhibitor  PAI-1.  The  general  properties  of the  endothelium 
are  subject  to  adaptation  by  environmental  factors,  such  as  inflammatory 
mediators  and  shear  forces.  Interleukin-1  and  tumour  necrosis  factor-a 
reduce  the  antithrombotic  properties  of  the  endothelium(van  Hinsbergh, 
2001).
50Clinical applications of TEG
Thromboelastography  (TEG)  provides  a  comprehensive  and  permanent 
graphic documentation of the overall clotting  process, from the formation  of 
the  first  fibrin  strands  to  clot  dissolution.  TEG  measures  the  viscoelastic 
properties  of  the  blood  clot,  and  is  said  to  be  both  objective  and 
reproducible(Artang  et  al.,  2000;  Khurana  et  al.,  1997;  Mallett,  Cox,  1992; 
Orlikowski et al., 1996; Spiess et al., 1987; Spiess et al., 1995).
TEG  was  developed  first  by  Hartert  in  1948(Hartert,  1948).  It  remained 
largely  a  research  tool  until  recent  years,  when  the  search  for  a  quick, 
clinically useful ‘bedside’ test of coagulation rediscovered the value of TEG. 
Besides  being  useful  in  the  detection  of impaired  coagulation,  it  has  been 
suggested to be the most sensitive method for detecting a hypercoagulable 
state(Arcelus  et  al.,  1995;  Heather  et  al.,  1980;  Howland  et  al.,  1974b; 
Howland et al.,  1974a). Routine clotting studies are notoriously insensitive in 
this respect(Gibbs et al., 1994).
TEG  has  been  used  to  demonstrate  a  hypercoagulable  state  in  cancer 
patients(Raina et al., 1985), and a progressively hypercoagulable state in the 
first 7 days following open  abdominal and  laparoscopic surgery (Arcelus et 
al., 1995). A tendency to hypercoagulable TEG variables has been shown on 
the first postoperative day following laparoscopic cholecystectomy(Caprini et 
al.,  1995).  It has also been suggested that TEG  can  be used to predict the 
incidence  of venous  thromboembolism  in  high  risk  patients(Arcelus  et  al., 
1995;  Caprini et al.,  1995;  Heather et al.,  1980;  Pivalizza et al.,  1997),  and 
monitor the effects of anticoagulant medications(Arcelus et al.,  1995; Gibbs, 
Sear, 1995; Gottlieb et al., 1999), in particular the effects of low dose heparin
51therapy(Gibbs, Bell,  1998). TEG has been used to show maintenance of clot 
strength  in  stored  and  pooled  blood  platelets  for  transfusion(Reid  et  al.,
1998).
Artang  et  al(Artang  et  al.,  2000)  demonstrated  an  increased  procoagulant 
activity  in  TEG  variables  in  ischaemic  heart disease  patients  compared  to 
healthy volunteers. However, the TEG did not hold enough diagnostic power 
to differentiate between non-coronary chest pain, unstable angina and acute 
myocardial infarction.
TEG  has  been  used  to  suggest that  extradural  anaesthesia  is  superior to 
general  anaesthesia  when  using  lower  or  upper  limb  tourniquets  in 
orthopaedic  patients.  These  authors  suggested  that  the  increased 
coagulation  associated  with  surgical/tourniquet  pain  was  less with  regional 
anaesthesia(Kohro et al., 1998).
In  animal  studies  TEG  has  been  used  to  demonstrate  hypercoagulability 
induced by carcinoma(Raina et al., 1985).
TEG has been used to assess coagulation in pre-eclampsia(Orlikowski et al., 
1991; Orlikowski et al.,  1996) and the safety of epidural catheter placements 
in these women(James,  Neil,  1995;  Mallett,  PLATT,  1991;  Orlikowski et al., 
1992; Sharma et al., 1999). These studies have shown the development of a 
hypercoagulable state during  pregnancy which was  not detected with  other 
coagulation  tests(Orlikowski  et  al.,  1992).  It  has  also  been  used  to 
investigate  the  effect  of  local  anaesthetics  on  coagulation(Porter  et  al.,
1999).
TEG has shown a functional maturity of coagulation in neonates and children 
despite  quantitative  deficiencies  in  the  coagulation  system  for  the  first  6
52months of life(Miller et al.,  1997). TEG has also been shown to have a high 
sensitivity  and  specificity  in  predicting  neonatal  sepsis where  alterations  in 
the  vascular endothelium  and  thrombin  generation  are  thought  to  underlie 
the pathophysiology(Grant, Hadley, 1997).
Handa and  colleagues demonstrated  it to be an effective screening test for 
prothrombotic  states,  thus  preventing  expensive  screening  tests  in  a 
significant  proportion  of these  patients(Handa  et  al.,  1997).  Modified  TEG 
using  antiplatelet  compounds  has  been  used  to  determine  the  relative 
contributions of fibrinogen and platelets to clot strength(Gottumukkala et al.,
1999).
However,  by far the  major clinical  role  identified  at this  time,  has  been  in 
assessing the need for blood  products (platelets,  FFP,  cryoprecipitate etc.), 
in actively bleeding surgical patients(Mallett, Cox,  1992; Oshita et al.,  1999b; 
Spiess et al., 1987; Whitten, Greilich, 2000), or in patients with enhanced risk 
factors  for a  bleeding  diatheses  (Mongan,  Hosking,  1992;  Pivalizza,  1996; 
Pivalizza et al.,  1996; Spiess et al.,  1995). The ever increasing demands on 
blood  banks for finite resources, together with the risk of transfusion  related 
infection  has  led  to  a  need  to justify and  give  blood  products  in  a directed 
manner.  TEG  directed  therapy  has  been  shown  to  reduce  transfusion 
requirement  in  cardiopulmonary  bypass  patients  without  increasing  post­
operative haemorrhage(von Kier, Royston, 1998).
TEG is increasingly used in patients undergoing procedures with a significant 
haemorrhagic potential, such as liver transplantation and resection(Chapin et 
al.,  1989;  Howland  et  al.,  1974a)  and  cardiopulmonary  bypass 
surgery(Mongan,  Hosking,  1992; von  Kier,  Royston,  1998). TEG appears to
53be superior to  routine coagulation tests in  predicting  peri and  postoperative 
bleeding  in  patients  undergoing  liver  transplantation  and  cardiac 
surgery(Artang et al., 2000; Essell et al., 1993; Spiess et al., 1987; Tuman et 
al., 1994).
TEG has previously found little use in the field of neurosurgery.
54Procedure of TEG analysis used in all studies
The TEG® model 3000 analyser and computer system from the Haemoscope 
Corporation  was  used  in  all  studies.  All  disposables  and  reagents  are 
available  through  Haemoscope  unless  otherwise  stated.  Use  of  the  TEG 
analyser  is  described  in  detail  in  the  user  manual:  Thrombelastograph® 
Coagulation Analyser User Manual, Haemoscope Corporation.
Procedure
TEG analysis of citrated whole blood samples requires prior collection of 3.6 
ml of blood into test tubes containing 0.105M (3.2%) buffered sodium citrate 
(Vacutainer™ [Ref 367914]).
After  mixing  of  blood  and  citrate  by gentle  inversion  3 times,  samples  are 
stored  at room temperature.  No further agitation  of the sample takes  place 
until  immediately  prior  to  analysis.  TEG  analysis  should  be  commenced 
between  1   and  3  hours  following  blood  sampling(Bowbrick  et  al.,  2000; 
Camenzind et al., 1998).
Using  a  reverse  pipette  technique,  20  pi  0.2M  calcium  chloride  (CaCI2)  is 
dispensed  into the cup of the analyser.  A  reverse  pipette technique avoids 
the formation of air bubbles in the sample. The calcium chloride was placed 
in the cup first to prevent any surface activation of the blood sample without 
recording, which might occur if performed in reverse order.
Immediately prior to analysis, each citrated whole blood sample is mixed  by 
gently inverting the tube 5 times. Then 340 pi is then dispensed into the cup. 
Mixing of the blood and CaCb is achieved by 5 cycles of gentle lowering and 
raising the pin column. The pin is then left in the sample and automated TEG
55analysis  commenced  via  a  computer  interface  (TEG®  Analytic  Software 
Version 2.99.70x, Haemoscope Corporation 1995).
After starting the analysis, a drop of mineral oil (Haemoscope Ref. No. #302- 
895)  is  placed  on  the  surface  of  the  sample.  This  prevents  artefacts 
secondary to evaporation and drying of the sample.
Quality control
Daily  assessment  of  the  analyser  balance,  baseline  and  operating 
temperature was performed.
Monthly  calibration  of the  analyser  using  Level  I  and  Level  II  coagulation 
controls (Haemoscope Corporation, Skokie, IL, USA) was carried out. 
Precautions
Standard safety precautions whilst handling blood samples were taken at all 
times.
Some common pitfalls
Difficult or slow collection during blood sampling.
Heparin contamination when sampling through arterial lines.
Addition of an incorrect volume of blood to the citrated test tube.
Delay in mixing blood with citrated anticoagulant.
Prolonged or sub-optimal blood storage prior to analysis.
Manufacturer details 
Haemoscope Corporation 
7855 Gross Point Road, Unit G-4,
Skokie, IL, 60077 USA 
www.haemoscope.com
56Control studies
Although  the  TEG  proprietary  software  generates  a  reference  range  of 
‘normal’  values  for a  specific  sample  type,  it  is  unclear  how these  ranges 
were  collected,  and  on  what  population  of  people/patients.  There  is  little 
published control data for TEG, and what has been published suggests that 
TEG  variables  are  sensitive  to  blood  sampling  techniques  and  sample 
handling.
I  have  assessed  the  reproducibility  of  TEG  from  a  single  sample  and 
assessed its reproducibility over time. Its stability over time was central to the 
clinical  studies  as  I  went  on  to  see  how  TEG  profiles  changed  over time 
following a subarachnoid haemorrhage (SAH).
I  have  produced  reference  values  for  the  TEG  variables  in  a  control 
population  using  the  sampling  techniques  and  sample  handling  methods 
employed  in  the  clinical  studies.  I  have  assessed  the  effects  of  age  and 
gender on TEG variables.  The  reference  ranges generated  by sample type 
from  the  TEG  software  make  no  distinction  for age  or gender,  suggesting 
that there is  no difference.  Stability with  regard  to gender was  important to 
the  clinical  studies  on  SAH  as  this  condition  has  a  distinct  female 
preponderance.
Control study 1
The  primary  aim  of this  study was  to  assess  the  reproducibility  of a  TEG 
tracing from a single citrated blood sample in a control population i.e. that the 
machine was a reproducible measure of coagulation.
Control study 2
57The primary aim of this study was to ascertain the ranges for TEG variables 
in a control population.
The secondary aim of this study was to assess the effect of gender and age 
on haemostatic parameters as measured by TEG in a control population. 
Control study 3
The primary aim of this study is to ascertain the reproducibility of TEG over 
time in a control population.
58Control study 1
The  primary  aim  of this  study was  to  assess  the  reproducibility  of a  TEG 
tracing from a single citrated blood sample in a control population.
Method
For this  study 20  subjects were  enrolled,  10  male  (mean  age  31.4  yrs  SD 
5.1) and 10 female (mean age 30.6 yrs SD 10.9).
Citrated whole blood was sampled from each subject and  each  sample  run 
simultaneously through 2 separate TEG channels.
Sampling
Peripheral venous blood from an antecubital vein was sampled through a 19- 
gauge butterfly needle into a 3.6 ml ‘blue-capped’ Vacutainer polypropylene 
tube,  containing  0.5  ml  of  3.2%  (0.105M)  sodium  citrate  (pH  7.4) 
(Vacutainer™ [Ref 367914]).  Smaller gauge  needles were  avoided  as they 
precipitate haemolysis and activate clotting mechanisms.
Whenever  possible,  blood  samples  were  obtained  without  the  use  of  a 
tourniquet, to reduce the likelihood of in vitro coagulation activation(Miller et 
al.,  1995).  If a tourniquet was used,  it was applied for venous access only, 
and it was removed as blood was collected.
The  tube  was  then  inverted  3  times  in  order to  mix  the  blood  and  citrate 
immediately  after  sampling.  Care  must  be  taken  not  to  shake  the  sample 
violently  as  this  may  itself  activate  coagulation.  This  citrated  whole  blood 
sample (CWB) was then left to stand for 60 minutes at room temperature.
It  is  important  to  standardise  storage  time  as  it  has  been  previously 
demonstrated that some TEG  parameters can decrease with time,  perhaps 
due  to  a  decrease  in  fibrinogen  and  platelets  with  storage  in  citrated
59tubes(Willschke  et  al.,  1999).  Others  have  observed  a  tendency  to 
hypercoagulation in the first 30 minutes of storage(Camenzind et al., 1998). 
Blood  collection  and  handling  is  a  major  source  of  bias  in  haemostatic 
analysis.  Ex-vivo  ‘contact’  activation  of the  coagulation  cascade  cannot  be 
completely avoided and must be limited to a minimum by standardised blood 
sampling.  Poor venepuncture or prolonged  venous occlusion  may  result  in 
an  increase  of  haemostatic  reactions  including  thrombin  and  plasmin 
activity(Winkler, 1996).
Blood sampling and TEG analysis was carried out in a standard manner for 
each control study.
Exclusions
Any  person,  who  had  a  known  coagulation  disorder,  was  taking 
anticoagulant  medication,  had  taken  a  non-steroidal  anti-inflammatory 
medication  in  the  preceding  2 weeks,  or was taking  the  oral  contraceptive 
pill,  was  excluded  from  participation  in  the  study.  Pregnant  and  paediatric 
(<18 yrs) subjects were also excluded.
Consent
All  control  studies were voluntary and  verbal  consent was taken from  each 
participant.  Participants  were  instructed  in  the  aims,  procedures  and 
methods involved in the study. Any participant could withdraw from the study 
at any time.  No  participants  received  remuneration  for their involvement  in 
the study.
60Ethical approval
All  studies  were  approved  by  the  joint  medical  ethics  committee  of  the 
Institute  of  Neurology  and  University  College  Hospitals  Trust  (Ref.  No. 
99/N037)
Statistical analysis
The  mean  values for each  TEG  parameter were  calculated,  along  with  its 
standard  deviation  in  order to  give  an  indication  of the  reference  range  of 
each  variable  in  a  control  population.  Since  2  readings were  available  for 
each  sample,  the  mean  difference  between  samples,  with  its  standard 
deviation and 95% confidence interval is presented.
An  estimate  of  within  person  standard  deviation  was  calculated  from  the 
formula:
Mean of the difference X1-X2 * V2
The  coefficient of variance for each  TEG  variable was  calculated  from  the 
formula:
(Mean of the difference X1-X2 * V2) * Mean of total population x 100 
Results 
R time
Since TEG  analysis was  performed  twice  on  each  sample,  2  values for  R 
were available for each  individual,  R1  and  R2.  The  mean value for R in  all 
subjects  was  639.15  s,  with  a  standard  deviation  of  90.88  s.  The  mean 
difference between the two measurements of R (R1-R2) was 21.4 s, with a 
standard deviation of 46.68 s. The 95% confidence limits were 0.96 to 41.86 
s (Table 1).
61The estimate of within person standard deviation for R time was 15.15 s. The
coefficient of variation was 2.37% (Table 2).
K time
The  mean  K time for the  population  was  159.65  s  (SD  90.88).  The  mean 
difference K1-K2 was -3.1  s (SD  12.42). The 95% confidence limits were -  
8.54 to 2.34 s (Table 1).
The estimate of within person standard deviation for K time was 2.19 s. The 
coefficient of variation was 1.37% (Table 2).
Angle
The  mean  angle  for the  population  was  55.24  deg  (SD  7.23).  The  mean 
difference  Angle1-Angle2  was  -0.38  deg  (SD  2.24).  The  95%  confidence 
limits were -1.36 to 0.6 deg (Table 1).
The  estimate  of within  person  standard  deviation  for Angle  was  0.27  deg. 
The coefficient of variation was 0.49% (Table 2).
MA
The  mean  MA  for  the  population  was  52.15  mm  (SD  4.2).  The  mean 
difference MA1-MA2 was 1.45 mm (SD 3.1). The 95% confidence limits were 
0.29 to 2.81  mm (Table 1).
The estimate of within person standard deviation for MA was  1.03 mm. The 
coefficient of variation was 1.97% (Table 2).
Shear elastic modulus G
The  mean  G  value for the  population  was  5538.58  dyn/cm2  (SD  932.43). 
The  mean  difference  G1-G2  was  348.5  dyn/cm2  (SD  614.77).  The  95% 
confidence limits were 79.07 to 617.93 dyn/cm2 (Table 1).
62The estimate of within person standard deviation for G was 246.43 dyn/cm2.
The coefficient of variation was 4.45% (Table 2).
63R1  - R2 s 
Ks
K1  - K2 s 
Angle deg 
A1  - A2 deg 
MA mm
MA1  - MA2 mm 
G dyn/cm2 
G1  - G2 dyn/cm2
639.15 90.88 39.82
21.4 46.68 20.46
159.65 45.04 19.74
-3.1 12.42 5.44
55.24 7.23 3.17
-0.38 2.24 0.98
55.15 4.2 1.84
1.45 3.1 1.36
5538.58 932.43 408.65
348.5 614.77 269.43
Table 1. Summary statistics of TEG variables in control study 1.
SD = Standard deviation, Cl = Confidence interval.
I  15.13 2.19 0.27 1.03 246.4
2.37 1.37 0.49 1.97 4.45
Table 2. Summary statistics of agreement between X1  and X2 in each of 
the 20 subjects for the TEG variables R, K, Angle, MA and G.
64Discussion
The  interassay  coefficient  of  variation  of  the  APTT  test,  calculated  on  a 
normal plasma sample repeated 12 times is 3.5%(Fourel et al., 1993).
For tissue factor stimulated citrated whole blood TEG analysis, Khurana et al 
showed  an  intrasubject coefficient of variation to  be  1.4%  +/-  0.2% for MA 
and  4.4%+/-  1.3%  for  G  when  TEG  analysis  was  repeated  8  times  on  8 
separate subjects. The intraclass correlation coefficient was r=0.96(Khurana 
et al., 1997).
Surprisingly, there is no other published  study to address the subject of the 
reproducibility of TEG on a given blood sample.  No control data is available 
from the manufacturers (Haemoscope Corp.,Skokie, IL, USA).
My results suggest that the TEG is a highly reproducible measurement, and 
is  at the  very  least comparable to  APPT(Fourel  et  al.,  1993).  The  K time, 
Angle  and  MA  provide  the  most  reproducible  measurement.  As  G  is  a 
derived  variable  from  MA  in  order  to  exponentially  enhance  the 
measurement [G  = 5000 x MA +  (100 -  MA)],  it is not surprising that it has 
the greatest coefficient of variation, and is the least reproducible measure. 
The reproducibility of the TEG is demonstrated in Figs 11  to 15. The value of 
each TEG  parameter X1  is  plotted  against the  second  measurement X2.  If 
the  measurements  had  agreed  exactly  then  they  would  all  lie  on  the 
illustrated line of equality.
Conclusion
TEG is a reproducible measurement of coagulation on a single citrated blood 
sample.
65R
900
850
800
750
700
(A
CM   650 
O'
600
550
500
450
400
400 450 500 550 600 650 700 750 800 850 900
R1 s
Figure 11. Scatter plot of R1 against R2.
Scatter diagram of the first series of measurements for R plotted against the 
second series in the 20 normal controls. Had all the measurements agreed 
exactly, the points would all lie on the line of equality. All data points are 
close, indicating a good reproducibility of the test.
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Figure 12. Scatter plot of K1 and K2.
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Figure 13. Scatter plot of Anglel  and Angle2.
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Figure 14. Scatter plot of MA1  and MA2.
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Figure 15. Scatter plot of G1  and G2.
70Control study 2
The primary aim of this study was to ascertain ranges for TEG variables in a 
control population.
The secondary aim of this study was to assess the effect of gender and age 
on haemostatic parameters as measured by TEG in a control population. 
Method
Using  opportunity  sampling  40  participants  (20  male,  20  female),  were 
recruited  to take  part in  the  study.  The  mean  age of study population  was 
30.65 yrs (SD 8.84): females 28.85 yrs (SD 9.48) and males 32.45 yrs (SD 
7.97) (Fig. 16 and Table 3).
Sampling as described in control study 1.
Exclusions as for control study 1.
Statistical analysis
The mean, standard deviation and 95% confidence intervals for each of the 
TEG variables, was calculated for the population of 40 subjects.
Using  Microsoft  Excel  software,  an  ANOVA  regression  analysis  was 
performed on each of the TEG parameters (R,  K, Angle, MA and G) for age 
and sex in each of the 40 subjects.
Results
The mean value of R was 574.7 s (SD 141.3) and 95% confidence interval of 
+/- 43.8 s. The mean value of K was 175.4 s (SD 52.3) and 95% confidence 
interval of +/-  16.2 s. The mean value of the Angle was 52.95 deg (SD 7.8) 
and 95% confidence interval of +/- 2.4 deg. The mean value for MA was 53.4 
mm (SD 4.1) and 95% confidence interval of +/-1.3 mm. The mean value for 
G was 5791.8 dyn/cm2 (SD 997.3) and 95% confidence interval of +/- 309.1
71dyn/cm2. This gives an indication of the ranges of these variables in a control 
population using the sampling methods and exclusions described (Table 4). 
When R was regressed for age and sex there was no statistically significant 
difference identified F(2,39) = 2.76; p>0.05 (Tables 5,  10 and  11, and Figure 
17). However, for each of the other TEG parameters there was a statistically 
significant  trend  towards  hypercoagulability  in  the  female  controls  when 
compared with the males. There was no association between the age of the 
control subject and any TEG variable studied (Tables 5 to 9).
Thus,  the  mean  K  time  was  significantly  shorter  in  female  than  in  male 
controls F(2,39) = 8.55; p<0.001  (Tables 6 and 10). The angle was greater in 
females F(2,39) = 8.92; p<0.001  (Tables 7,  10 and  12, and  Figure  18). The 
MA was greater in females F(2,39) = 10.02; p<0.001  (Tables 8 and  10). And 
the value for G  was  on  average  higher in  females  F(2,39)  =  8.22;p<0.001 
(Tables 9,10 and13, and Figure 19).
These  results  demonstrate female  controls  lean  towards  hypercoagulability 
when  compared  with  males.  This  difference  could  not  be  explained  by  a 
difference in age between the sample populations.
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Figure 16. Scatter diagram of the age distribution in the control 
population.
The individual values, group mean and 95% confidence intervals are 
displayed. A breakdown for male and female controls is also presented.
7330.65
8.84
2.74
28.8
9.48
4.16
32.45
7.97
3.49
Table 3. The age distribution in the control population.
The age distribution of the control population with the group mean, standard 
deviation and 95% confidence intervals are displayed. A breakdown for male 
and female controls is also presented.
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574.7 141.3 4343
175.4 52.3 16.2
52.95 7.8 2.4
53.4 4.1 1.3
5791 997.3 309.1
Table 4. Summary statistics of TEG parameters in control subjects.
SD = standard deviation, Cl = Confidence interval
75Regression Statistics
Multiple R 0.36
R Square 0.13
Adjusted R 0.08
Square
Standard Error 135.30
Observations 40
ANOVA
df SS MS F Significance F
Regression 2 100896.37 50448.19 2.76 0.08
Residual 37 677326.4 18306.11
Total 39 778222.78
Coefficients Standard
Error
tStat P-value Lower 95% Upper
95%
Intercept 374.40 92.63 4.04 0.00 186.72 562.08
sex 81.24 43.73 1.86 0.07 -7.36 169.84
age 2.56 2.51 1.02 0.31 -2.52 7.64
Table 5. Analysis of the effects of gender and age on R in controls.
Using p<0.05 to determine significance, regression analysis of R for effects 
of gender and age revealed that neither age nor gender produced a 
significant effect on R (p>0.05).
76Regression Statistics
Multiple R  0.56
R Square  0.32
Adjusted R  0.28
Square
Standard Error  44.42
Observations  40
ANOVA
df ss MS F Significance F
Regression 2 33738.69 16869.34 8.55 0.0008
Residual 37 73004.91 1973.11
Total 39 106743.6
Coefficients Standard
Error
tStat P-value Lower 95% Upper
95%
Intercept 93.05 30.41 3.06 0.004 31.43 154.66
sex 58.66 14.36 4.09 0.0002 29.58 87.75
age -0.18 0.82 -0.22 0.82 -1.85 1.48
Table 6. Analysis of the effects of gender and age on K in controls.
Using p<0.05 to determine significance, regression analysis of K for effects 
of gender and age revealed that gender (but not age) produced a significant 
effect on K (p<0.001).
77Regression Statistics
Multiple R  0.57
R Square  0.33
Adjusted R  0.29
Square
Standard Error  6.61
Observations  40
ANOVA
df ss MS F Significance F
Regression 2 778.87 389.43 8.92 0.0007
Residual 37 1614.53 43.64
Total 39 2393.4
Coefficients Standard
Error
tStat P-value Lower 95% Upper
95%
Intercept 65.16 4.52 14.41 9.40E-17 56.00 74.32
sex -8.94 2.13 -4.19 0.0002 -13.27 -4.62
age 0.04 0.12 0.32 0.75 -0.21 0.29
Table 7. Analysis of the effects of gender and age on Angle in controls.
Using p<0.05 to determine significance, regression analysis of Angle for 
effects of gender and age revealed that gender (but not age) produced a 
significant effect on Angle (p<0.001).
78Regression Statistics
Multiple R  0.59
R Square  0.35
Adjusted R  0.32
Square
Standard Error  3.36
Observations  40
ANOVA
df SS MS F Significance F
Regression 2 226.59 113.30 10.02 0.0003
Residual 37 418.51 11.31
Total 39 645.1
Coefficients Standard
Error
tStat P-value Lower 95% Upper
95%
Intercept 59.33 2.30 25.77 3.096E-25 54.67 64.00
sex -4.84 1.09 -4.47 7.14E-05 -7.06 -2.66
age 0.04 0.06 0.71 0.48 -0.08 0.17
Table 8. Analysis of the effects of gender and age on MA in controls.
Using p<0.05 to determine significance, regression analysis of MA for effects 
of gender and age revealed that gender (but not age) produced a significant 
effect on MA (p<0.001).
79Regression Statistics
Multiple R 0.55
R Square 0.31
Adjusted R 0.27
Square
Standard Error 852.00
Observations 40
ANOVA
df  SS MS F Significance F
Regression
Residual
Total
2  11933878 
37  26858648 
39  38792526
5966939
725909.41
8.22 0.001
Coefficients  Standard 
Error
t Stat P-value Lower 95% Upper
95%
Intercept
sex
age
7092.02  583.28 
-1116.3  275.35 
12.21  15.78
12.16  1.725E-14 
-4.05  0.0002 
0.77  0.44
5910.18
-1674.21
-19.76
8273.9
-558.39
44.18
Table 9. Analysis of the effects of gender and age on G in controls.
Using p<0.05 to determine significance, regression analysis of G for effects 
of gender and age revealed that gender (but not age) produced a significant 
effect on G (p<0.001).
80N  Female  Male  F  P-value
Mean (SD)  Mean (SD)
R 40 529.45 619.90 2.76 0.07
(94.25) (166.64)
K 40 146.40 204.40 8.55 0.0002
(36.56) (50.11)
Angle 40 57.35 48.55 8.92 0.0002
(2.25) (6.81)
MA 40 55.75 51.05 10.2 7.14E-05
(2.25) (4.15)
G 40 6327.98 5255.63 8.22 0.0002
(591.96) (1042.15)
Table 10. Summary table showing the F and P values for the regression 
analysis of gender on all TEG variables in controls.
SD = Standard Deviation.
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All  574.68  141.26  43.78
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Figure 17. Scatter diagram of R in control subjects.
There was no significant difference between males and females for TEG 
parameter R (p>0.05).
Table 11. Summary table of R in control subjects.
Table showing the mean, SD and Cl for All subjects, female subjects and 
male subjects for TEG variable R.
82All  Females  Males
Mean  Standard  Confidence
Deviation  Interval
All 52.95 7.83 2.23
Females 57.35 6.23 2.73
Males 48.55 6.81 2.99
Figure 18. Scatter diagram of Angle in control subjects.
There was a significant difference between males and females for TEG 
parameter Angle (p<0.001).
Table 12. Summary table of Angle in control subjects.
Table showing the mean, SD and Cl for All subjects, female subjects and 
male subjects for TEG variable Angle.
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All  5791.8  997.34  309.67
Females  6327.98  591.96  259.43
Males  5255.36  1042.15  456.13
Figure 19. Scatter diagram of G in control subjects.
There was a significant difference between males and females for TEG 
parameter G (p<0.001).
Table 13. Summary table of G in control subjects.
Table showing the mean, SD and Cl for All subjects, female subjects and 
male subjects for TEG variable G.
84Discussion
The routinely performed coagulation tests PT, APPT,  I NR and fibrinogen, do 
not have different reference ranges for men and women.  However, Fourel et 
al(Fourel  et  al.,  1993) found  that  APPT  reduced  with  age,  was  quicker  in 
females than  males,  and  is  highest for people  of blood  group  O.  It  is well 
established  that each  laboratory should  establish  its own  reference  ranges 
for these tests(Fourel et al., 1993).
The  TEG  software  generates  reference  ranges  dependent  on  the  sample 
type chosen, and gives a single range for each TEG parameter, independent 
of sex. Recent evaluation studies of the platelet function analyser PFA-100®, 
have  failed  to  identify  any difference  in  platelet function  related  to  sex  or 
OCP use(Bock et al., 1999).
Most  control  and  study  TEG  populations  have  not  allowed  for  any  sex 
difference  in  coagulation  variables  and  are  not  controlled  for this  variable. 
Indeed,  Procidano  and  co-workers  suggested  in  a  study  on  777  subjects 
(271  males, 506 females) that neither age nor gender had any influence on 
TEG variables(Prodicano et al., 1983).
However,  Gorton  et  al(Gorton  et  al.,  2000)  have  recently  used  TEG  to 
suggest that women  have  more whole  blood  coagulability than  men.  They 
demonstrated  an  increasing  trend  through  men,  nonpregnant  women  to 
pregnant women.  It  has  been  suggested  that the  physiology of pregnancy 
results  in  a  hypercoagulable  state  that  prepares  the  parturient  for  the 
haemorrhage  of  childbirth(Whitten,  Greilich,  2000).  Pregnant  women  have 
also been shown to have higher TAT and  PF  1   and 2 complexes, than age
85matched  non-pregnant controls.  These complexes were  shown  to  increase 
with advancing gestational age(Levine et al., 1996).
The data reported by Gorton et al was compromised  by the fact that half of 
the  50  nonpregnant women  studied  were taking  the  oral  contraceptive  pill 
(OCP).  Interestingly however,  they reported  no difference  in TEG variables 
between those volunteers taking the OCP and those who were not.
Gorton et al argued that their data supported the sex differences in markers 
of thrombotic  tendency  observed  by  Lowe  et  al(Lowe  et  al.,  1997).  They 
concluded  that  endogenous  hormones  may  have  a  roll  in  sex-related 
differences in the incidence of deep vein thrombosis and thromboembolism. 
Lowe et al(Lowe et al.,  1997) had randomly sampled  1958 men and women 
aged  25-75 yrs as  part of the third  MONICA survey  in  Glasgow,  Scotland. 
They  showed  that  pre-menopausal  women  generally  had  higher  levels  of 
fibrinogen  and  prothrombin  F1  and  2,  and  lower  levels  of  Factor  IX,  and 
protein  S  than  men.  Post-menopausal  women  had  higher  levels  of 
fibrinogen, Factor VII and Factor IX than pre-menopausal women.
Clues  as  to  the  effects  that  sex  hormones  may  play  on  coagulation 
responses can be ascertained by looking at the changes observed following 
the introduction of the oral contraceptive pill. The use of oral contraceptives 
is associated with altered plasma concentrations of many components of the 
coagulation  and  fibrinolytic  systems,  increased  plasma  levels  of  markers 
indicating  in  vivo  coagulation  and  fibrinolysis,  and  a  modified  response  to 
challenge tests both in vivo and in vitro(Levine et al., 1996; Winkler, 1998). 
Differences in fibrinogen, thrombin-antithrombin (TAT), prothrombin fragment 
1   and 2, antithrombin  III,  protein C,  protein S, tissue plasminogen activator,
86plasminogen  and  plasminogen  activator  inhibitor  have  all  been  observed 
after starting combined oral contraceptive preparations(Prasad et al.,  1999). 
Though in this study a dynamic balance between coagulation and fibrinolysis 
was  observed  with  no  predisposition  to  thrombosis  after  starting  the 
preparations.  However,  other studies  have suggested that in women taking 
the  oral  contraceptive  pill,  an  increase  in  the  activity  of the  procoagulant 
Factor  VII,  Factor  X,  and  fibrinogen  occurs,  and  a  fall  in  anticoagulant 
antithrombin  III  may predominate(1999a).  Further studies  have  shown  that 
the  effect  on  coagulation  factors  is  highly  dependant  on  the  hormone 
combination  used(Dykes  et  al.,  2001;  Mackie  et  al.,  2001;  Viegas  et  al., 
1996; Winkler et al., 1998) and the route of administration(Bulent-Tiras et al., 
2001; Viegas et al.,  1996). The use of ethinylestradiol is associated with an 
increase of plasma  concentrations  of fibrinogen,  plasminogen,  Factors  VII, 
VIII,  X  and  XIII,  but also  coagulation  inhibitors  such  as  protein  C(Winkler, 
1996).  Progesterone only contraceptive  pills  produce little or much  reduced 
haemostatic alteration(Winkler et al., 1998).
Following the introduction of the oral contraceptive pill the 1960’s, it became 
recognised  that  venous  thrombosis  and  pulmonary  emboli  and  later 
myocardial  infarction and stroke were associated with  its use(Rosing et al., 
1999;  Vandenbroucke  et  al.,  2001).  The  newer,  lower  dose  oestrogen 
preparations were considered safer, with the changes in haemostatic factors 
smaller, inconsistent in direction and mostly within the normal range.
However, recent studies have challenged the concept that reducing the dose 
of oestrogen in oral contraceptives eliminates the risk of venous thrombosis. 
These  studies  have  suggested  that  progestagins,  individual  genetic
87susceptibility  to  the  thrombogenic  effect  of  oral  contraceptives,  and  new 
insights into haemostatic changes in women, may all play a role in the risk of 
thrombosis(Vandenbroucke  et  al.,  2001).  It  has  been  suggested  that 
exogenous  hormone  administration  results  in  an  acquired  resistance  to 
protein  C,  which  may  underlie  its  prothrombotic  tendency(Rosing  et  al.,
1999).  This  resistance  appears  dependent  on  the  particular  OCP  formula 
used, in particular the progestagen used(Rosing et al., 2001).
Arterial thrombosis  is also a complication of oral contraceptive therapy,  but 
interestingly,  the  risk factors  differ from  those  for venous  thrombosis.  For 
example, smoking increases the risk of myocardial infarction associated with 
the  use  of  oral  contraceptives,  but  has  no  material  effect  on  the  risk  of 
venous  thrombosis.  In  contrast,  several  prothrombotic  genetic  defects  are 
strong  risk factors for venous  thrombosis  and  increase the  risk associated 
with oral contraceptive  use(Girolami  et al.,  2001),  but most are likely to  be 
only weak risk factors for myocardial  infarction  or stroke(Vandenbroucke et 
al., 2001).
Little clinical work has been directed at coagulation differences between the 
sexes.  However,  stroke  incidence  is  higher in  young women than  in  young 
men  between  the  ages  of  15  and  35  years  and  there  is  a  significant 
association  of  stroke  with  pregnancy(Jaigobin,  Silver,  2000).  Jaigobin 
reported  an  incidence for stroke  both  ischaemic  (arterial  and  venous)  and 
haemorrhagic of 69  strokes  per  100000  during  pregnancy.  This  compares 
with  an  incidence  in  the  population  as  a  whole  of  3.5  per  100000  for 
ischaemic stroke. While there were reasons to explain some of this dramatic 
difference in terms of the aetiology of the incident population studied, there is
88consensus  that  the  incidence  of  all  stroke  forms  appears  higher  during 
pregnancy.  It  is thought that the  risk  is  greatest  in  the  postpartum  period. 
Aetiological  factors  include  eclampsia  and  pre-eclampsia,  coagulopathy, 
hormonal  and  blood  volume  changes,  and  dehydration.  Most studies  have 
also reported a decrease in both thromboembolic and haemorrhagic stroke in 
women using HRT(Brighouse, 2001).
Kalaria  et  al(Kalaria  et  al.,  2000)  looked  at  gender  related  differences  in 
thrombogenic  factors  predicting  recurrent  cardiac  events  in  patients  after 
acute myocardial infarction. They measured multiple factors in 791  men and 
254  women,  2  months  following  infarction.  In  univariate  analysis  of 
haemostatic factors, levels of d-dimer, Factor VII, activated Factor VII (Vila), 
fibrinogen, and von Willebrand factor were significantly higher in women.  In 
multivariate  logistic  regression,  fibrinogen,  Factor  VII  and  Vila  remained 
significantly higher. In addition, elevated Factor Vila levels were a significant 
predictor  of  further  cardiac  events  in  women.  The  authors  propose  an 
enhanced thrombogenic state in women compared with men following acute 
myocardial  infarction.  They suggest genetic differences,  sex hormones and 
environmental factors such as obesity, smoking and lipid levels, as possible 
explanations for their findings.
Until  recently,  it  had  never  previously  been  suggested  that  there  were 
differences in TEG variables between male and female controls. The results 
of this  study  show  similar findings  to  those  of  Gorton  et  al(Gorton  et  al.,
2000), in that females were hypercoagulable in comparison to males.  I  have 
shown that these findings were not a product of a difference in ages between 
the 2 populations studied.
89It is interesting to note that the only TEG parameter in which I have failed to 
demonstrate a difference in  male and female controls  is the  R time.  This  is 
contrary to the findings of Gorton et al(Gorton et al., 2000) who did observe a 
significant difference in the R time.  It has been suggested that the R time is 
comparable to the PT and APPT, as it is the time point at which the first fibrin 
strands start to form.  Thus,  it appears that the first detectable signs of clot 
formation  are  identified  at the  same  time  in  males  and  females.  This  data 
also suggests that the routine tests PT and APPT would not have picked up 
the sex differences in coagulation profiles identified with TEG.
The  additional  TEG  variables  (K,  Angle,  MA  and  G)  are  said  to  give 
information  not available from  routine  coagulation  studies.  The  K time was 
shorter  and  the  Angle  greater  in  females.  This  suggests  that  once  a  clot 
starts  to  form,  the  rate  of  fibrin  build  up  and  cross-linking  is  greater  in 
females.
The observed changes in  MA and  G show that females on average have a 
higher maximal  value.  MA and  G  are directly dependent on fibrinogen  and 
platelet function. These results suggest that the final clot strength is greater 
in female controls, than in age matched males.
The  results  suggest  that  in  the  control  population  studied,  females  tend 
towards hypercoagulability. This could be linked to the fact that women have 
naturally  lower concentrations of the  natural  anticoagulants  (protein  C  and 
protein  S)(Dykes et al.,  2001),  and  higher concentrations  of procoagulants 
(factor VIII)(Lowe et al., 1997; Woodward et al., 1997).
90Kapiotis  et  al(Kapiotis  et  al.,  1998)  found  that  Factor  VII  levels  changed 
during the menstrual cycle and they argued that this supported the idea that 
coagulation factors may be up or down regulated by sex hormones. 
Mendelsohn et al(Mendelsohn, Karas,  1999) have also proposed the idea of 
a  protective  effect  of  oestrogen.  If  oestrogen  lowered  the  coagulability  of 
females,  its  mechanism would  be to  protect against the  naturally occurring 
increased  coagulability.  Sagripanti  and  Carpi(Sagripanti,  Carpi,  1998) 
demonstrated that the menopause is accompanied by a significant increase 
in TAT  levels.  The mean TAT levels  in  postmenopausal women  are  higher 
than  in age  matched  males. This may explain the cardiovascular protective 
effect  of  HRT  in  postmenopausal  women(Brighouse,  2001).  In  addition, 
young women have significantly lower plasma concentrations of antithrombin 
III  compared to males of similar age.  The occurrence of the menopause  is 
accompanied  by  a  significant  increase  in  antithrombin  III,  fibrinogen  and 
Factor  VII  concentrations(Dolan  et  al.,  1994).  Significant  sex  differences 
have  also  been  observed  in  the  plasma  concentrations  of  tissue  factor 
pathway inhibitor(Sagripanti, Carpi, 1998).
Further evidence of a  sex hormone  influence  on  coagulation  is taken from 
the  clinical  and  experimental  studies  into the effects of HRT.  Several  large 
studies  have  consistently  shown  an  increased  risk  of  venous 
thromboembolism in women using  HRT(Daly et al.,  1996;  Hoibraaten et al., 
1999;  Jick  et  al.,  1996;  Perez-Gutthann  et  al.,  1997).  HRT  affects 
haematological  variables  relating  to  coagulation  and  fibrinolysis,  such  that 
there is an increase in thrombin  production, thrombin activity Factor VII  and 
protein C, and a decrease in antithrombin III, protein S and fibrinogen(Koh et
91al.,  1998;  Meade,  1997;  Winkler  et  al.,  2000).  In  addition,  vWF,  soluble 
thrombomodulin, and tPA are all significantly reduced after 6 weeks of HRT 
treatment(Lip et al., 1997). Winkler et al(Winkler et al., 2000) have suggested 
that  the  overall  haemostatic  balance  is  shifted  towards  a  profibrinolytic 
response  by the  commencement of  HRT.  Other groups,  have  argued  that 
there  is  no  consistent  evidence  of  a  prothrombotic  tendency  in  HRT 
patients(Douketis  et  al.,  2000)  and  Koh  et  al(Koh  et  al.,  1998)  have 
suggested  that  the  procoagulatory  response  is  matched  by  an  equivalent 
increase in fibrinolysis.
The  hepatic  expression  of  genes  for  several  coagulation  and  fibrinolytic 
proteins  are  also  known  to  be  regulated  through  oestrogen 
receptors(Mendelsohn,  Karas,  1999).  It  appears  that  the  net  effect  of 
oestrogens on coagulation depends on the form used, the dose, the method 
of administration and the duration of therapy.
Indirect effects of sex hormones on haemostasis may be due to changes of 
the  vasomotor  tone  in  vessel  walls,  to  activation  of  endothelial  cells  or 
stimulation  of the  bone  marrow  resulting  in  alterations  of  blood  flow,  and 
activation  of  coagulation,  fibrinolysis  and  blood  rheology(Winkler,  1996).  It 
has  been  suggested  that  the  postmenopausal  increased  risk  of  arterial 
disease  is  partly  mediated  via  changes  in  haemostatic  variables  as  a 
consequence of oestrogen deficiency(Winkler et al., 2000).
Jem et al(Jern et al.,  1991) demonstrated that compared to males, females 
showed lesser stress induced responses in Factor VII:C, vWF:Ag and tPA, in 
spite of a similar degree of sympatho-adrenal activation.
92Thus,  sex steroids  may  influence  haemostatic function  via  genomic effects 
on gene expression or via  non-genomic effects on the activation of plasma 
membranes.  It  is  conceivable  that  both  mechanisms  are  involved  in  vivo. 
Steroids  may derange the  reservoir of factors and  inhibitors  as well  as the 
assembly of intra and extracellular cofactors thereby inducing or enhancing a 
latent imbalance of pro/anticoagulatory and pro/antifibrinolytic forces(Winkler, 
1996).
This study demonstrates that extreme care must be taken when using TEG 
for  clinical  and  research  purposes.  Observed  changes  must  always  be 
referenced to the sex of the subject.  It can be seen from Figures  17,18 and 
19,  that  the  overall  mean  value  for  each  of  the  TEG  parameters  is  an 
average of the  hypercoagulable females  and  the  relatively  hypocoagulable 
males.  In  assessing  the  potentially  small  changes  observed  in  research 
studies, this must always be taken into account, to ensure that bias and thus 
incorrect conclusions do not occur. Although the sample size was not large, 
male and female controls were well  matched  for age,  the exclusion  criteria 
for  confounding  factors  such  as  drugs  were  rigorously  enforced,  and  the 
levels of significance in the data are extremely high.
Conclusion
There are sex differences in TEG variables in a control population.  Females 
tend  to  be  hypercoagulable.  Within  the  range  of  the  control  population 
studied, there was no effect of age on TEG variables.
We  question  the  clinical  and  research  applicability  of  the  sample  type 
directed  reference  ranges  generated  with  the  commercially  available  TEG 
software.
93Control study 3
The primary aim of this study is to ascertain the reproducibility of TEG over 
time in a control population.
Method
A total of 20 of the subjects in  control  study 2, were sampled for a second 
time 14 days following their first test. This group comprised 10 females mean 
age 25.9 yrs (SD 6.51), and 10 males mean age 33.9 yrs (SD 10.48). 
Statistical analysis
To compare the results in the same subject 14 days apart, a paired sample t- 
test was performed.
Results
The t-tests comparing the values for R, MA and G showed that there was no 
statistical  difference  between  the  samples  taken  14  days  apart for  R,  t  = 
0.699, df = 19, p>0.05 (Tables 14 and  17, and Figure 20); MA, t = -1.137, df 
=  19, p>0.05 (Tables 14 and  19, and Figure 22); and G, t = -1.163, df =  19, 
p>0.05 (Table 14).
The t-test comparing the K time however, showed that there was a difference 
between the 2  samples, t = 2.883, df =  19,  p<0.05 (Tables  14 and  18,  and 
Figure  21).  A  similarly  significant  result  was  also  observed  for  the  angle 
value, t = -2.578, df = 19, p<0.05 (Table 14).
These  results  posed  the  question  was  it  the  machine  or the  subjects  that 
were not stable over time? Having identified differences related to sex in the 
control  data,  paired  t-tests  were  carried  out  on  the  male  and  female  data 
separately (Tables 15 and 16).
94These  results  demonstrated  that  there  was  no  statistically  significant 
difference for any TEG variable in male controls. However, for females there 
was still a significant difference for K time, t = 2.761, df = 9, p<0.05, and for 
Angle t = -2.701, df = 9, p<0.05.
95N  Day 0  Day 14  Mean  t  Significance
________ Mean (SD)_____Mean (SD)_____Difference__________________Value
R 20 529.65 503.5 26.15 0.699 0.493
(162.80) (158.29)
K 20 187.90 157.80 30.10 2.883 0.010
(55.42) (49.55)
Angle 20 51.68 55.65 -3.98 -2.578 0.018
(8.14) (7.92)
MA 20 53.68 55.65 -1.98 -1.137 0.270
(4.81) (5.42)
G 20 5910.38 6439.68 -526.30 -1.163 0.259
(1197.48) (1451.97)
Table 14. Summary table of paired t-tests for all TEG variables on 
samples taken 14 days apart.
Using p<0.05 to determine significance, paired t-tests were carried out on all 
five TEG parameters to see if the samples taken on day 0 were statistically 
different from those taken 14 days later.
There was no significant difference in TEG parameters R (p>0.05), MA 
(p>0.05) and G (p>0.05).
There were significant differences for TEG parameters K (p<0.05) and Angle 
(p<0.05).
96Table 15. Males
N Day 0 
Mean  (SD)
Day 14 
Mean (SD)
Mean
Difference
t Significance
Value
R 10 587.10 517.30 69.80 1.179 0.268
(202.78) (168.54)
K 10 212.30 182.70 29.60 1.611 0.142
(57.73) (50.94)
Angle 10 48.40 51.65 -3.25 -1.238 0.247
(7.87) (7.97)
MA 10 51.35 53.85 -2.50 -7.78 0.457
(5.47) (6.09)
G 10 5419.25 6011.40 -592.15 -0.738 0.479
(1412.78) (15.9.90)
Table 16. Females
N Day 0 
Mean  (SD)
Day 14 
Mean (SD)
Mean
Difference
T Significance
Value
R 10 472.20 489.70 -17.50 -0.394 0.703
(86.61) (155.13)
K 10 163.50 132.90 30.60 2.761 0.022
(42.77) (34.80)
Angle 10 54.95 59.65 -4.70 -2.701 0.024
(7.35) (5.76)
MA 10 56.00 57.45 -1.45 -0.948 0.368
(2.64) (4.21)
G 10 6401.50 6867.95 -466.45 -0.973 0.356
(703.76) (1327.89)
Table 15. Summary table of paired t-tests for males.
Table 16. Summary table of paired t-tests for females.
Using p<0.05 to determine significance, paired t-tests were carried out on all 
five TEG parameters for males and females separately to see if the samples 
taken on day 0 were statistically different from those taken 14 days later. 
There was no significant difference found for any of the TEG parameters in 
males. There was no significant difference found for the TEG parameters R 
(p>0.05), MA (p>0.05) and G (p>0.05) in the females.
However, significant differences for TEG parameters R (p<0.05) and Angle 
(p<0.05) remained for females.
97Using a significance level of p<0.05 you could expect simply by chance, 1  
test in 20 to prove significant. A total of 15 t-tests had been performed on this 
data and 4 had shown significance. The K time and Angle however, are 
closely related and dependent on each other. Thus, additional statistical 
analysis was carried out to investigate these findings further.
A regression analysis was performed on the square of the difference 
between the TEG variables taken on day 0 and on day 14. The data was 
regressed for age and sex. The rationale behind this was that a positive 
difference between variables would have been cancelled out by a negative 
difference, since the test is a comparison of means. By using the square of 
the difference, the difference is always positive, and always emphasised in 
the statistical analysis.
Using ANOVA regression analysis, no significant difference was observed in 
any TEG parameter (R, K, Angle, MA and G) between day 0 and day 14, in 
male or in female controls (Appendix VI, Tables 1  to 5).
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Figure 20. Scatter diagram of R on samples taken 14 days apart.
There was no significant difference between Day 0 and Day 14 for TEG 
parameter R (p>0.05).
Table 17. Summary table of R on samples taken 14 days apart.
Table showing the mean, SD and Cl on day 0 and day 14.
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Figure 21. Scatter diagram of K on samples taken 14 days apart.
There was no significant difference between Day 0 and Day 14 for TEG 
parameter K (p>0.05).
Table 18. Summary table of K on samples taken 14 days apart.
Table showing the mean, SD and Cl on day 0 and day 14.
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Figure 22. Scatter diagram of MA on samples taken 14 days apart.
There was no significant difference between Day 0 and Day 14 for TEG 
parameter MA (p>0.05).
Table 19. Summary table of MA on samples taken 14 days apart.
Table showing the mean, SD and Cl on day 0 and day 14.
101Discussion
No previous published study has attempted to ascertain the reproducibility of 
TEG parameters over time in a control population. In this study, I have failed 
to  demonstrate  any  difference  in  TEG  variables  performed  14  days  apart. 
Thus, TEG appears a highly reproducible measure of coagulation over time.
It  is  possible that  I  have  failed  to  identify a  real  difference.  This would  be 
possible  if the  changes were  cyclical,  and  especially if based  on  a  28  day 
cycle.  The  samples  could  have  been  taken  at  random  times  during  a 
circadian or menstrual cycle that affects coagulation.
Changes in coagulation factors have been observed during the female cycle. 
Kapiotis  et  al(Kapiotis  et  al.,  1998)  found  that  Factor  VII  levels  changed 
during the menstrual cycle and they argued that this supported the idea that 
coagulation factors may be up or down regulated by sex hormones.
Jem et al(Jem et al.,  1991) have shown that both gender and  physiological 
variations in female sex hormones may modulate the haemostatic response 
to  psychosocial  stress.  At  rest  they  compared  coagulation  markers  in  the 
follicular and luteal  phases of the cycle in 9 women. The platelet count was 
higher in the follicular phase.  The  haematocrit and  vWF  concentration  was 
higher in the luteal phase. The resting levels of factor VII:C, VII:Ag, tPA and 
PAI  were  all  unchanged  at  rest.  This  paper  also  provided  evidence  for  a 
different haemostatic stress response between males and females. Wramsby 
et  al  observed  very  little  change  in  the  response  to  activated  protein  C 
throughout the female cycle(Wramsby et al., 2001).
102Jespersen and  Kluft(Jespersen,  Kluft,  1986) provided evidence of a cyclical 
change  of  tPA  inhibition,  and  showed  how  this  changed  following  the 
administration of differing OCPs.
It would  be  logical to assume that during the female cycle there would  be 
equal time periods of hypo and  hypercoagulability,  presumably mediated  by 
endogenous  hormones.  This  study  was  not  controlled  for  the  menstrual 
stage of female controls.  By chance you would expect half to have been  in 
the  hypocoagulable  phase  and  half to  be  in  the  hypercoagulable  stage,  if 
these phases existed. Therefore, half the changes would be positive and half 
negative.  Thus,  these  changes  could  have  cancelled  each  other  out, 
revealing  statistically  no change.  I  have attempted  to circumvent this  by  in 
addition  analysing  the  square  of the  difference  between  the  values.  This 
should  have amplified  any difference  present.  Regression  of this data  also 
failed to reveal any difference in the TEG variables over time.
Control  study  2  shows  that  there  does  appear  to  be  differences  in  TEG 
parameters  between  males  and  females.  This  is  presumably  under  some 
form of hormonal control or influence. Therefore, it would not be surprising to 
observe a change in coagulation with the female cycle.
TEG  parameters appear to  be  hypercoagulable  in  pregnancy(Gorton  et al.,
2000), suggesting a hormonal association. Oestrogen plasma levels change 
with different phases of the menstrual cycle. As oestrogen is known to effect 
the levels of certain clotting factors,  it would  be logical that this could  affect 
the  process  of  coagulation.  Therefore  cyclical  changes  in  hormones  may 
mean a cyclical change in the mechanisms of haemostasis.
103The  effects  that  sex  hormones  play  on  coagulation  responses  can  be 
ascertained by looking at the changes observed following the introduction of 
the  oral  contraceptive  pill.  Differences  in  fibrinogen,  thrombin-antithrombin 
(TAT),  prothrombin fragment  1   and  2, antithrombin  III,  protein  C,  protein  S, 
tissue  plasminogen  activator,  plasminogen  and  plasminogen  activator 
inhibitor have  all  been  observed  after starting  combined  oral  contraceptive 
preparations(Prasad  et  al.,  1999).  Other  studies  have  observed  that  in 
women taking the oral contraceptive pill, there is an increase in the activity of 
the  procoagulant  Factors  VII,  X,  and  fibrinogen  occurs,  and  a  fall  in 
anticoagulant antithrombin 111(1999a).
Further evidence that there  is a  hormonal  influence on  coagulation  are the 
changes in coagulation markers observed in postmenopausal women, which 
appear  to  be  at  least  partly  reversible  with  hormone  replacement 
therapy(Sagripanti, Carpi, 1998).
In theory, the male coagulation response should remain fundamentally more 
stable, as the male is not predisposed to such large hormonal fluctuations. 
Conclusion
TEG is a reproducible measure of coagulation over time in male and female 
controls.
I have failed to identify any cyclical changes in coagulation in male or female 
controls using TEG.
104Experimental studies 
Studies in haemostasis following subarachnoid haemorrhage
105Literature review
Subarachnoid haemorrhage (SAH) occurs at all ages but strikes primarily in 
middle age, often with devastating consequences.  It is estimated that about 
40% of patients admitted to hospital die within  1   month and  more than one 
third  of survivors  have  severe  disability(Schievink,  1997).  Even  in  patients 
admitted to  hospital  in a good  clinical grade (WFNS  1   or 2),  approximately 
one third will have a poor outcome(Roos et al., 2000a). SAH accounts for a 
quarter of cerebrovascular deaths(Wardlaw, White, 2000). SAH is due to the 
rupture of an  intracranial  saccular aneurysm  in  about 75% of cases, which 
usually arise from the circle of Willis or a branch artery(Schievink, 1997). 
Several studies have indicated that smoking and hypertension are important 
risk factors for SAH due to aneurysms(Ruigrok et al., 2001). Genetic factors 
may also have a role as more close relatives of aneurysm patients harbour 
intracranial  aneurysms  than  the  background  population(Gaist  et  al.,  2000; 
Teunissen et al., 1996).
Over the last 20-30 years there has been a remarkable improvement in the 
results reported after surgery for ruptured  intracranial aneurysms. Operative 
mortality has fallen from over 20% to less than 5%(Hop et al., 1997; Maurice, 
Kitchen,  1994).  However,  despite  considerable  advances  in  diagnostic, 
surgical  and  anaesthetic  techniques,  and  perioperative  management,  the 
outcome for patients with SAH remains poor, with overall mortality rates of at 
least 25% and  significant morbidity among approximately 50% of survivors. 
When even more detailed outcome assessments of SAH patients have been 
performed  in  structured  studies,  it  is  clear that  very few  patients  return  to 
their level  of premorbid  function  following  the  ictus(Hop  et al.,  1998).  Well
106known  clinical  predictors of mortality at  1,  6  and  12  months following  SAH 
include, the level of consciousness on admission, age (>65 years), presence 
of  comorbid  disease,  such  as  hypertension,  and  neurological  signs  on 
admission(Arboix,  Marti-Vilalta,  1999;  Germanson  et  al.,  1998;  van  Gijn, 
1992; Vermeulen, 1996).
Population based incidence rates for SAH vary from 6-16 per 100000, with 
the  highest  rates  reported  in  Finland  and  Japan(Broderick  et  al.,  1993; 
Kiyohara et al., 1989; Linn et al., 1996; Sarti et al., 1991). The most accurate 
estimate  of the  incidence  in  the  UK  is  9.7  per  100000(Pobereskin,  2001). 
Unlike  other types  of stroke,  the  incidence  of  SAH  has  not  declined  over 
time. The incidence of SAH increases with age (mean age of approximately 
50 years), and is higher in women than in men(lngall et al., 1989).
The  evolution  of  treatment  protocols  for  patients  with  SAH  has  been 
influenced  by  large,  multicentre  prospective,  randomised,  cohort  analyses 
and,  more  recently,  by  multicentre  prospective,  randomised  trials. 
Nevertheless,  several  accepted  treatment  modalities  have  not  been 
substantiated  by  rigorous  clinical  scientific  assessment.  In  many  cases 
specific  treatments  for  SAH  are  not  amenable  to  testing  by  randomised, 
prospective trials because of practical or ethical considerations.
Vasospasm,  as  well  as  rebleeding  poses  a  serious  problem  of  prognostic 
importance in patients with aneurysmal  SAH. Although there are number of 
effective  methods  for  improving  symptomatic  vasospasm  (hypervolaemic 
therapy,  percutaneous  transluminal  angioplasty,  intraarterial  papaverine 
infusion), due to their serious side effects, these methods are not completely 
safe.  Therefore,  a  means  of  predicting  whether  delayed  ischaemic
107neurological  deficits  (DINDs) were  likely to  occur,  would  allow clinicians  to 
identify and intensively treat only those patients at greatest risk of DIND.
One  major  unresolved  controversy  in  the  management  of  ruptured 
intracranial  aneurysms  is  the  timing  of  surgery.  Should  this  be  performed 
early  or  late?  Very  early  surgery  in  good  condition  patients  is  becoming 
widespread. It is argued that this prevents not only rebleeding, but may also 
help prevent ischaemia by enabling the basal cisterns to be cleared of blood, 
thereby reducing the  incidence of vasospasm, and  permitting  postoperative 
hypertensive  treatment  to  aggressively  manage  delayed  cerebral 
ischaemia(Yoshimoto et al.,  1999).  On the other hand,  it is likely that early 
surgery  is  associated  with  a  higher  mortality  and  morbidity  than  surgery 
delayed  until  after the  period  of cerebral  instability following  rupture  of an 
intracranial aneurysm(Kassell et al., 1990a; Maurice, Kitchen, 1994; Maurice- 
Williams, 1987).
Haemostatic  indices  are  relevant  to  this  debate.  Thus,  if  there  are  two 
phases of haemostasis following a SAH; an initial period of hypocoagulability 
followed  by a  second  phase  of hypercoagulability.  In  SAH  if  rebleeding  is 
related to  hypocoagulability, which  can  be  measured  by  bench techniques, 
then  perhaps  pharmacological  manipulation  of  coagulation  could  be 
focussed  on the administration  of antifibrinolytic  agents to those who  have 
not  entered  the  period  of  fibrinolytic  shutdown.  A  reduction  of  the  early 
rebleeding  risk would  allow for delayed  surgery and  significantly impact on 
the outcome of haemorrhage. Conversely,  if the period of hypercoagulability 
can  be correlated to the period when  patients are at greatest risk of DIND, 
then early surgery followed by anticoagulation may impact on the outcome.
108Haemostatic changes and SAH
Although  spontaneous  SAH  has  been  extensively  studied  from  various 
standpoints, few reports have assessed changes in the haemostatic systems 
occurring in association with SAH.
Fujii  et  al(Fujii  et  al.,  1997)  compared  the  serial  changes  in  haemostatic 
systems  after the  clipping  of  ruptured  aneurysms,  and  compared  this  with 
those  seen  after the  clipping  of unruptured  aneurysms  for  a  period  of  30 
days.
Blood cells.  They observed  no change  in the white cell  count,  haematocrit 
and  platelet  count  between  the  2  groups.  The  white  cell  count  gradually 
decreased to within its normal range within  1   month of SAH. The change in 
platelet  count  was  biphasic.  The  initial  decrease  possibly  reflected 
haemodilution  and  consumption  after  surgery,  whereas  the  subsequent 
elevation was thought to represent the physiological response to injury.
Blood  coagulation.  The  change  in  fibrinogen  levels  was  monophasic  and 
very similar in the 2 groups. The plasma level reached a peak on day 3. The 
level of fibrinogen,  a  representative acute phase reactant,  never decreased 
significantly following SAH.
The  plasma  level  of  thrombin-antithrombin  complex,  although  highest  on 
admission  and  gradually decreasing thereafter,  never  returned  to within  its 
normal  range.  The complex levels on  day 3 and  6 were  higher in the  SAH 
group.  Hence, patients with SAH appeared to be in a hypercoagulable state 
within the 1s t month following SAH which was not attributable to the surgery 
itself.
109Fibrinolysis. The change in the plasma level of plasmin-antiplasmin complex 
was biphasic. Although the complex reached  its highest level on day 6 and 
gradually decreased, it did  not return to its normal level. Thus, patients with 
SAH also appear to be in a state of hyperfibrinolysis during the initial month, 
and especially in the 2n d  week following the ictus.
The change  in  D-dimer was  monophasic, with the  plasma  level  reaching  a 
peak after day 3 and gradually decreasing thereafter.  However, the  plasma 
levels of D-dimer were far higher than in the patients who underwent clipping 
of ruptured aneurysms. Because D-dimer is a fragment of cross-linked fibrin 
digested by plasmin, the apparent elevation of D-dimer may be attributable to 
the entry of dissolved subarachnoid clot into the blood circulation with CSF.
In this study, the authors compared the results in patients with, and without a 
DIND,  to  see  if  any  of  the  above  factors  could  be  used  to  predict  the 
development of ischaemia. There was no significant difference in any of the 
haemostatic  parameters  on  day  0.  However,  on  day  3,  that  is,  before  the 
appearance  of  DINDs,  the  plasma  levels  of fibrinogen  and  D-dimer  were 
significantly  higher  in  those  patients  who  subsequently  developed  DINDs 
than in those who did not. The levels of fibrinogen and thrombin-antithrombin 
complex on  day 6,  and the  level  of D-dimer on  day  14  in the  patients with 
DINDs were also significantly higher.
Nina  et  al(Nina  et  al.,  2001)  observed  a  less  clear  association  between 
coagulation and fibrinolytic makers following SAH. They studied 76 patients, 
however,  52 of these were treated with antifibrinolytics and dexamethasone 
which  may  have  altered  the  levels  of  factors  measured.  All  had  blood 
samples were drawn within 24 hours of the SAH.
110In this study PT, APTT and fibrinogen were within normal limits. TAT levels in 
the plasma paralleled the severity of the neurological state, but did not reach 
statistical  significance.  TAT  levels  appeared  to  be  associated  with  clinical 
outcome because  16  patients out of 27  (59%) with  unfavourable outcomes 
displayed  TAT  levels  >20  ng/ml,  as  compared  with  10  patients  out  of  38 
(26%) with favourable outcomes.
Plasma  d-dimer  was  invariably  raised  and  unrelated  to  clinical  grade  at 
admission.  Nevertheless, very high values of d-dimer (>1000 mcg/ml) were 
found in 16 out of 22 patients (73%) with unfavourable outcomes, but in only 
9  patients  out of 38  (24%) with  favourable  ones.  D-dimer showed  a  weak 
association  with  DIND,  whereas  a  stronger association  was  observed  with 
DIND severity.  In this study 14 patients out of 76 (18.4%) developed  DIND, 
which  was  responsible  for  poor outcome  in  10.  In  9  of these  10,  d-dimer 
levels rose above 1000 mcg/ml.
Itoyama  and  colleagues(ltoyama  et al.,  1994)  examined  the  relationship  of 
thrombin-antithrombin (TAT) and  plasmin-0 2 -plasmin inhibitor complex (PIC) 
in  51  patients with  non traumatic SAH.  They  investigated the correlation  of 
these levels with the severity of the disease, the incidence of arterial spasm, 
and the outcome.
The TAT and PIC on admission both showed a positive correlation with Hunt 
and  Hess grade. There was a  less significant correlation  between TAT and 
PIC on admission and Fisher grade. This association was lost between TAT 
and Fisher grade 4.
i nThere was no association between either TAT, or PIC on admission, and the 
occurrence  of  arterial  vasospasm.  However,  a  lower  TAT  or  PIC  on 
admission correlated with improved neurological outcome on discharge.
The authors also evaluated the chronological changes in TAT and PIC levels 
in 44 of the  patients.  The  mean TAT level on  admission was 27.3  +/- 20.5 
ng/ml, and  1   week later 13.0 +/-  10.9 ng/ml. The mean PIC value was 2.50 
+/- 3.11  pg/ml at the time of admission, and 1.09 +/- 0.89 pg/ml 1  week later. 
These differences were significant.
Fujii  et al(Fujii  et al.,  1995) examined  the changes  in  haemostatic systems 
within  24  hours  following  spontaneous  SAH,  and  their  relationship  to 
neurological  grade,  blood  load on  admission  CT and  clinical  outcome.  The 
haematological  factors  examined  were  prothrombin  time  (PT),  activated 
partial  thromboplastin  time  (APTT),  fibrinogen,  antithrombin,  protein  C, 
thrombin-antithrombin complex (TAT), plasminogen,  0 2 -antiplasmin, d-dimer, 
plasmin-antiplasmin  complex  (PAP),  platelet  count,  platelet  sensitivity  and 
white blood cell count (WCC).
Relationship with neurological grade. The levels of WCC, TAT, d-dimer, and 
PAP  significantly  increased  with  neurological  severity,  and  almost all  were 
elevated beyond the normal range. All other parameters were not statistically 
different.  In  addition, the  poor outcome  rate significantly increased with the 
neurological severity.
Relationship  with blood load.  The  levels  of WCC,  TAT,  d-dimer,  and  PAP 
significantly  increased  with  the  amount of subarachnoid  clot.  There  was  a 
significant increase in poor outcome rate as the amount of clot increased.
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significantly  increased  with  the  severity  of  clinical  outcome.  The  other 
parameters,  including  WCC,  did  not  change  in  any  significant  association 
with the severity of clinical outcome.
Relationship  of  TAT  complex  levels  and  clinical  outcome.  There  was  a 
significant difference in the TAT complex levels between patients with good 
and poor outcomes. None of the 61  patients whose TAT was < 50ng/ml had 
a poor outcome.  Furthermore, none of the  18 patients whose complex level 
was  >  250ng/ml  achieved  a  good  outcome.  The  poor  outcome  rate  was 
55.3% in 47 patients whose level was >50 and < 250ng/ml.
This study also had  a cohort of ICH  and  cerebral  infarction  patients whose 
coagulation system was activated far less than following SAH.
The WCC is an acute phase reactant, which increases in response to various 
stimuli  (infection),  therefore  its  increase  does  not  indicate  a  specific 
physiological  response.  On  the other hand  elevations  of TAT,  d-dimer and 
PAP,  demonstrate  the  activation  of  the  blood  coagulation  system,  the 
dissolution  of  blood  clots,  and  the  activation  of  the  fibrinolytic  system 
respectively. Thus, this study demonstrates the activation of the coagulation 
and fibrinolytic systems following SAH and that activation to a greater extent 
appeared to be related to the severity of neurological grade,  CT blood  load 
and  clinical  outcome.  The  authors  concluded  that  the  levels  of  plasma 
coagulation  markers, especially TAT,  may reflect the severity of the clinical 
state of the patients with  SAH,  and  may contribute to predicting the clinical 
outcome in these patients.
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thromboplastin  into  the  circulation  from  the  damaged  brain  inducing  a 
hypercoagulable  and  hyperfibrinolytic  state(ltoyama  et  al.,  1994).  In  the 
acute stage of SAH, various events, such as intimal damage to the cerebral 
vessels, the release of thromboplastin from the damaged brain, the elevation 
of biogenic amines (epinephrine, norepinephrine and serotonin) in the serum, 
which  occurs  in  response  to  stress  and  stasis  in  the  bloodstream,  and/or 
systemic  dehydration,  predispose  to  platelet  hyperactivity  and/or 
hypercoagulation disorders.
Perhaps  the  formation  of  microthrombi  within  the  small  cerebral  vessels, 
associated  with  vasospasm  and  hypercoagulability,  could  predispose  to 
DIND and ischaemic symptoms in these patients.
Antifibrinolytic,  antiplatelet or anticoagulant medication  may be  indicated  to 
improve the cerebral microcirculation.
Haemostatic changes and spontaneous intracerebral haemorrhage
While  impaired  haemostasis  is  a  risk  factor  for  ICH  only  one  report  has 
looked at the immediate effect of ICH on coagulation and fibrinolysis in detail. 
Fujii  and  colleagues(Fujii  et  al.,  2001)  examined  these  makers  in  358 
patients within 6 hours of their ICH.  Underlying vascular abnormalities were 
excluded by angiography.
In ICH patients showing neither, intraventricular extension or SAH, the mean 
values of the haematological parameters examined (TAT, PAP and d-dimer), 
with  the  exception  of  WCC  were  not  significantly  higher  than  in  normal 
controls.  There  was  no  difference  in  haemoglobin  concentration,  platelet 
count, platelet sensitivity, fibrinogen, PT or APTT.
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patients with  intraventricular extension, or SAH,  in addition to the  ICH.  The 
other  haematological  parameters  were  not  changed.  Multiple  logistic 
regression  analysis  revealed  that,  TAT  and  WCC  were  significantly  and 
independently  associated  with  intraventricular  and  SAH.  The  WCC,  TAT, 
PAP  and  d-dimer  levels,  significantly  increased  with  the  amount  of 
intraventricular  and  SAH.  In  patients  with  no  intraventricular  or  SAH,  the 
volume of the ICH was not associated with any of the factors measured.
Thus,  in  ICH  patients, intraventricular or SAH appears more responsible for 
the  systemic  activation  of  haemostatic  systems  than  the  intracerebral 
(intraparenchymal) haemorrhage.
Haemostatic changes and head injury
Coagulation  abnormalities  consistent  with  a  state  of  disseminated 
intravascular  coagulation  (DIC)  have  been  shown  to  occur  as  a  result  of 
acute head injury(Kumura et al.,  1987; Miner et al.,  1982; Olson et al.,  1989; 
Pondaag.W.,  1979;  van  der  Sande  et  al.,  1981).  Moreover,  these  studies 
have demonstrated a correlation between the severity of head injury and the 
degree  of  DIC.  Several  investigators(Kaufman  et  al.,  1980;  Kumura  et  al., 
1987; Olson et al.,  1989;  Ueda et al.,  1985) have shown that the degree of 
brain tissue destruction in head injury, appears to correlate positively with the 
level of fibrin degradation products (FDP) present in the plasma.  Preston et 
al(Preston  et  al.,  1974),  and  Stein  et  al(Stein  et  al.,  1992),  implicated 
microthrombosis  as  a  consequence  of  disseminated  intravascular 
coagulation (DIC), in the ischaemic damage following head injury.
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coagulation abnormalities in 204 patients with acute closed head injury. They 
measured  PT, APTT,  thrombin  clotting time,  fibrinogen,  platelet count,  and 
FDP count within 48 hours of head  injury,  and  calculated  a  DIC score from 
this,  by grading the values 0-3. The DIC score correlated  inversely with the 
GCS.  When  the  GCS  was  fixed,  both  DIC  score  and  FDP  score  were 
independent predictors of poor outcome. The predictive value of haemostatic 
parameters were  more  striking within  specific GCS  subsets.  In  GCS  13-15 
patients  (n=43),  all  11  patients who  had  a  poor outcome  had  moderate  to 
severe FDP scores. In the GCS 6-12 subset (n=142), out of 47 patients who 
had significantly abnormal APTT scores only 2 had good outcome. Of the 35 
patients who did  not have significant abnormal  DIC scores, only 2 had  poor 
outcome.  The  authors  suggested  that  following  head  injury  the  following 
mechanisms might contribute to a state of DIC:
The release of thromboplastins following  parenchymal  injury,  and  activation 
of  the  extrinsic  coagulation  cascade.  Endothelial  damage,  with  platelet 
activation  and  activation  of the  intrinsic  coagulation  cascade.  Intravascular 
thrombosis  resulting  in  depletion  of  platelets  and  coagulation  factors,  and 
finally FDPs acting as anticoagulants and platelet inhibitors.
The  authors  concluded  that,  PT,  APTT  and  thrombin  clotting  time,  were 
insensitive assessments of the state of DIC, as they are not abnormal until a 
significant reduction  in the  number of clotting factors occurs.  They however 
concluded that,  abnormal haemostatic parameters may enhance  prognostic 
ability in subsets of patients with acute head injury, defined by clinical or CT 
predictors.
116Coagulation mechanisms specific to brain injury
The  mechanisms favouring  hypercoagulability  may differ following  different 
forms  of  trauma.  In  addition,  it  appears  likely  that  post  traumatic 
hypercoagulability is a systemic phenomenon(Dahl, 1999).
Thromboplastin.  Although  the  brain  contains  the  highest  concentration  of 
thromboplastin  in  the  human  body(Bjorklid  et  al.,  1977;  Bjorklid,  Storm, 
1977),  and  it  is  speculated  that trauma,  infarction  and  surgery to the  brain 
results  in  the  release  of  tissue  thromboplastin,  and  activation  of  the 
coagulation cascade, there is no direct evidence to support this(Hamilton et 
al., 1994).
Tissue  Factor.  Tissue  factor  (TF)  is  the  primary  cellular  initiator  of  blood 
coagulation  and  the  most potent trigger of blood  coagulation  known  today. 
The adventitia surrounding the major blood vessels, the brain, and the bone 
marrow  are  the  structures  with  high  levels  of  TF(Dahl,  1999).  The 
concentration of TF is reported to be greater in the cortical grey matter than 
in white  matter(del-Zoppo et al.,  1992).  It  is  reported  to  be associated  with 
non capillary microvessels in the cerebral cortex and with the adventitia,  as 
seen in superficial cerebral vessels(Dahl,  1999;  Fujii et al., 2001). Thus, the 
entry  of  blood  into  the  subarachnoid  space  may  cause  a  considerable 
amount  of  TF  release  into  the  systemic  circulation  through  injury  to 
superficial  brain  tissues,  including  superficial  cerebral  arteries,  resulting  in 
systemic haemostatic activation.
Dissolved  clots  in  the  subarachnoid  space  enter the  blood  circulation  with 
CSF to activate the haemostatic systems.  Rapidly increasing  ICP or severe 
meningeal  stimulation  may  induce  systemic  activation  of  haemostatic
117systems  through  unknown  neurogenic  and/or  humoral  mechanisms. 
However, as the volume of ICH  is not related to the amount of haemostatic 
activation, it appears unlikely to be due to a rise in ICP(Fujii et al., 2001). 
Cerebral ischaemic stroke and haemorheology
A  number  of  studies  have  implicated  the  haemostatic  system  in  the 
pathogenesis  of  stroke,  proposing  an  excess  of  coagulation  factors, 
fibrinolytic inhibitors or both(Carter et al.,  1998;  Catto,  Grant,  1995;  Kain  et 
al., 2001a; Kain et al., 2001b).
It  is  well  known  that  patients with  polycythaemia  are  prone to  strokes  and 
transient ischaemic attacks (TIA’s). Thomas et al(Thomas et al.,  1977) found 
that cerebral  blood flow in  38  patients with  a  haematocrit of 0.47-0.53 was 
significantly lower than  in 43  patients with a  lower haematocrit in the  range 
0.36-0.46. They then performed venesection in the higher haematocrit group. 
Blood  flow  increased  in  every  case.  Lowering  the  mean  haematocrit  from 
0.493 to 0.426 raised the mean cerebral blood flow by 50% from 41.4 to 62.1 
ml/100g/min.  The  venesected  patients  were  also  symptomatically  better, 
including  5  patients  with  carotid  territory  TIA’s  and  4  patients  with 
vertebrobasilar TIA’s.
Ischaemic stroke as well as developing in the course of many haematological 
conditions,  may  also  be  its  first  clinical  manifestation.  Arboix  and 
Besses(Arboix,  Besses,  1997)  demonstrated  ischaemic  stroke  to  be  the 
initial  presentation  in  cases  of  essential  thrombocythaemia,  polycythaemia 
vera,  thrombotic  thrombocytopenic  purpura,  IgA  lambda  myeloma,  acute 
lymphoblastic  leukaemia,  Waldenstrom’s  macroglobulinaemia,  chronic 
granulocytic  leukaemia,  protein  C  deficiency  and  IgG  lambda  myeloma.  In
118addition,  cases  of  ischaemia  related  to  antithrombin,  protein  C  and  S 
deficiency  are  well  described.  The  role  of  dysfunction  in  coagulation  and 
fibrinolysis,  platelet  hyperactivity,  erythrocyte  abnormalities, 
myeloproliferative,  or  hyperviscosity  states  underlying  many  diverse 
haematological  disorders  in  the  genesis  of  stroke  is  as  yet  unclear  and 
probably multifactorial.
Polycythaemia vera  and  the forms  of secondary polycythaemia  may cause 
cerebral vascular thrombotic events because of increased red cell mass and 
blood hyperviscosity. The hyperviscosity syndrome has also been described 
in a variety of haematological disorders such as paraproteinaemias, in which 
the presence of monoclonal proteins in the microcirculatory bed accounts for 
cerebral vascular occlusive episodes.
Faber et al(Faber et al.,  1996) identified enhanced red blood cell aggregation 
in  a  series  of  young  stroke  patients  which  was  not  related  to  abnormal 
concentrations  of  fibrinogen,  immunoglobulins,  or  abnormal  haematocrit 
values. They suggested that this was the possible stroke mechanism through 
hyperviscosity.
Other authors  have  demonstrated  platelet activation  in  both  the  acute  and 
convalescent  stage  of  thrombotic  stroke(Meiklejohn  et  al.,  2001).  They 
demonstrated  increased  expression  of  P-selectin  and  fibrinogen  binding. 
Others  have  shown  enhanced  fibrinogen,  vWF  and  plasminogen  activator 
inhibitor  concentrations  in  the  acute  and  recovery  phases  of  ischaemic 
stroke(Catto, Grant, 1995).
119In  summary,  haemostasis  and  stroke  have  been  relatively  understudied, 
particularly in  relation to stroke classification,  predicting risk of disease, and 
clinical outcome, with the results obscured by the acute phase reaction.
In  acute  ischaemic  stroke  the  notion  of  ‘time  is  brain’  has  evolved  in  the 
acute management. Irreversible ischaemic brain damage evolves over hours 
and  reperfusion can rescue tissue that is functionally inactive,  but still viable 
(the  ischaemic  penumbra)(Muir,  2001).  Several  haematorheological 
treatments have evolved as a result of large randomised trials.
Thrombolysis. Thrombolytic drug treatment for acute ischaemic stroke is now 
well  established  in  North  America.  Evidence  for  this  arose  from  large 
randomised  trials(Hacke  et  al.,  1998;  Steiner  et  al.,  1998)  of  which  the 
NINDS rt-PA was pivotal(The National Institute of Neurological disorders and 
Stroke  rt-PA  Study  Stroke  Group,  1995).  This  showed  a  highly  significant 
increase in the proportion of patients making a full neurological recovery from 
stroke  (12%  absolute  risk  reduction,  equating  to  1   extra  patient  fully 
recovered for every 8 treated), with no increase in mortality.
Antiolatelet drugs.  Combined data from 3 trials(Chen  et al.,  2000) involving 
over 40000  patients  indicates that initiation  of aspirin  150-300mg within  48 
hours of stroke:
Prevents early recurrent ischaemic stroke (absolute risk reduction 0.7%) 
Reduces death and disability at 3-6 months (1.3%)
Increases  the  proportion  of  patients  making  a  full  neurological  recovery 
(1.1%)
At  the  expense  of a  small  increase  in  intracranial  (0.2%)  and  extracranial 
(0.4%) haemorrhage risk
120Interestingly,  there  was  no  heterogeneity  of  these  effects  across  any 
subgroup  including  intracerebral  haemorrhage  patients  randomised  before 
CT.
Ancrod.  Treatment  within  3  hours  with  this  snake  venom  derivative  that 
reduces  serum  fibrinogen  concentrations,  significantly  increased  the 
proportion  of  patients  making  full  neurological  recovery  in  a  randomised, 
controlled trial(Sherman et al., 2000).
Heparin.  No significant reduction in death or disability after stroke has been 
found  in  any  trial  of  heparin,  either  in  its  unfractionated  or  low  molecular 
weight preparations commenced within 24-48 hours after stroke onset, even 
in subgroups of patients with atrial fibrillation(Bath et al., 2000). 
Antifibrinolytic drugs and SAH
Patients who survive aneurysmal SAH have a high morbidity and mortality in 
the  following  weeks  due  mainly  to  the  complications  of  rebleeding  and 
cerebral ischaemia. Because rebleeding has been attributed to fibrinolysis of 
the blood clot around the fundus of the aneurysm(Fodstad et al., 1978) there 
is logic in using antifibrinolytic drugs (epsilon aminocaproic acid, tranexamic 
acid) in the prevention of rebleeding.  Plasmin  may be carried to the clot by 
blood  circulating  in  the  aneurysm  or  by  the  CSF  and  leptomeninges 
surrounding it(Fodstad et al., 1978).
Adams et al(Adams et al., 1981) reviewed the antifibrinolytic experience from 
three studies (two randomised studies and one prospective phase IV study), 
which  consistently  showed  a  significant  reduction  in  rebleeding  among 
treated patients compared with control subjects. However, nearly one third of 
these patients were worse at 14 days compared with the time of admission.
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on  the  use  of  antifibrinolytics  in  SAH  and  was  unable  to  form  any  firm 
conclusions or recommendations. In 1984, a multicentre, randomised, double 
blind, placebo controlled study using tranexamic acid showed that rebleeding 
was reduced by more than 60% in the treatment group, but an increased rate 
of  cerebral  infarction  in  these  patients  offset  any  improvement  in  overall 
outcome(Vermeulen  et  al.,  1984).  A  nonrandomised,  control  study 
demonstrated  similar  findings;  a  40%  reduction  in  rebleeding  in  patients 
receiving  antifibrinolytic  therapy  was  offset  by  a  43%  increase  in  focal 
ischaemic deficits(Kassell et al., 1984).
A  more  recent  prospective,  double-blind,  placebo  controlled  study(Roos, 
2000),  randomised  462  patients  and  compared  antifibrinolytics  combined 
with maximal anti-ischaemic therapy. Once again this study confirmed that of 
others in showing a statistically significant reduction  in rebleeding in treated 
patients, but no overall improvement in patient outcome.
Possible  explanations  for  the  increased  rate  of  ischaemic  neurological 
deficits  in  patients  receiving  antifibrinolytic  therapy  include  the  following. 
These agents do not increase the severity of vasospasm but may aggravate 
the  intravascular  sludging,  platelet  fibrin  emboli,  and  microthrombosis  that 
accompany  the  arterial  narrowing.  Another  possibility  is  that  antifibrinolytic 
agents do increase the severity of vasospasm. The severity of vasospasm is 
related to the amount and duration of blood  in the basal cisterns, and  it has 
been  shown that tranexamic acid  prolongs the clearance of blood from the 
subarachnoid space(Fodstad et al., 1981; Kassell et al., 1984).
122To determine if a shorter course (4 days) of antifibrinolytic treatment, before 
the  expected  onset  of  ischaemic  complications  might  reduce  the  rate  of 
rebleeding and yet avoid ischaemic complications, Wijdicks et al studied  119 
patients  prospectively(Wijdicks  et  al.,  1989).  However,  at  3  months  the 
outcome was no different to patients treated with long term tranexamic acid. 
In  addition  the  shorter  duration  of  tranexamic  acid  failed  to  prevent 
rebleeding  significantly,  as  most  second  haemorrhages  occurred  after 
stopping the antifibrinolytic.
The Cochrane review study group examined all randomised, unconfounded, 
controlled  trials  in  which,  after  concealed  allocation,  antifibrinolytic  drugs 
were  compared  in  SAH,  in  an  intention  to  treat  analysis,  with  control 
treatment (open studies) or placebo (blind  studies)(Roos et al.,  1998;  Roos 
et  al.,  2000b).  Eight  trials  met  the  predefined  inclusion  criteria.  These 
included  937  patients  of  whom  476  were  randomised  to  receive 
antifibrinolytic  drugs;  364  received  placebo  treatment  and  97  patients 
received  open  control  treatment.  This  analysis  confirmed  earlier 
investigations  in  showing  that  antifibrinolytic  drugs  showed  no  effect  on 
outcome or death from all causes.  It confirmed  an overall 45%  reduction  in 
rebleeding with their use and no effect on the incidence of hydrocephalus. 
Timing of aneurysm surgery
Without operative intervention or antifibrinolytic treatment about 30% of SAH 
patients  have  a  rebleed  within  1   month  of the  initial  ictus(Locksley,  1966). 
Only 20% of patients who rebleed survive at 3 months and most have severe 
brain damage(Hijdra et al., 1987).
123The  international  study  on  the  timing  of  aneurysm  surgery(Kassell  et  al., 
1990a;  Kassell  et  al.,  1990b)  analysed  management  comparison  in  3521 
patients, of whom 83% underwent surgical  repair of the ruptured aneurysm. 
Timing  of  surgery  after  SAH  was  significantly  related  to  the  incidence  of 
preoperative rebleeding (0 to 3 days; 5.7%, 4 to 6 days; 9.4%, 7 to 10 days; 
12.7%,  11  to 14 days; 13.9%,  15 to 32 days; 21.5%). Postoperative bleeding 
did  not  differ among  time  intervals  (1.6%  overall).  However,  there  was  no 
significant difference in overall outcome if surgery was performed early (0-3 
days) or late (11-14 days). Outcome was worse if surgery was performed  in 
the  7-10  day  post-bleed  period.  Surgical  results  were  better  for  patients 
operated  on  after  10  days.  Overall,  early  surgery  was  neither  more 
hazardous nor beneficial than delayed  surgery.  The authors concluded that 
the  postoperative  risk  following  early  surgery  is  equivalent  to  the  risk  of 
rebleeding and vasospasm in patients waiting for delayed surgery.
Even  in  modem  units aiming  at early aneurysm  surgery this  is  achieved  in 
only  55%  of  patients  within  3  days(Roos  et  al.,  1997).  In  this  study, 
rebleeding  was  still  the  most  common  cause  of  morbidity  and  mortality  in 
SAH  patients.  However,  the  most  commonly  occurring  complication  was 
cerebral ischaemia(Roos et al., 2000a).
Cerebral vasospasm following SAH
Cerebral  vasospasm  remains  a  devastating  medical  complication  affecting 
30-70%  of  survivors  of  aneurysmal  SAH(AI  Yamany,  Wallace,  1999). 
Cerebral vasospasm  is the delayed  narrowing of large capacitance arteries 
at  the  base  of the  brain  after  SAH,  often  associated  with  radiographic  or 
cerebral blood flow evidence of diminished perfusion in the distal territory of
124the affected artery. Angiographic vasospasm has a typical temporal course, 
with onset 3 to 5 days after the haemorrhage, maximal narrowing at 5 to  14 
days, and gradual resolution over 2 to 4 weeks(Heros et al.,  1983).  In about 
one half of cases, vasospasm is manifested by the occurrence of a delayed 
ischaemic  neurological  deficit  (DIND),  which  may  resolve  or  progress  to 
cerebral  infarction.  In  contemporary  series,  15%  to  20%  of  such  patients 
suffer stroke  or die from  vasospasm  despite  maximal  therapy(Haley et  al., 
1992;  Longstreth  et  al.,  1993).  The  DIND  associated  with  symptomatic 
vasospasm  usually  appears  shortly  after  the  onset  of  angiographic 
vasospasm with the acute or subacute development of focal or generalised 
symptoms or signs(Heros et al.,  1983;  Kassell et al.,  1985).  Progression to 
cerebral  infarction  occurs  in  approximately  50%  of  symptomatic  cases; 
recovery without deficit  in  the  remaining  individuals  may occur despite  the 
persistence of angiographic vasospasm(Heros et al., 1983).
In  1987,  the  cooperative  aneurysm  study  reported  an  incidence  of 
angiographic vasospasm of more than 50%, with symptomatic vasospasm in 
32% of patients(Adams et al.,  1987; Awad et al.,  1987).  In a comprehensive 
review,  Dorsch(Dorsch,  1995)  reported  that  despite  treatment  with 
nimodipine,  only  51%  of  patients  with  a  DIND  due  to  vasospasm  made  a 
good neurological recovery.
If  vasospasm  decreases  cerebral  blood  flow  below  35ml/100g/min,  brain 
tissue  pH  will  decrease,  and  severe  acidosis  is  associated  with  neuronal 
injury.
While areas of cerebral infarction are often related to the major arteries and 
changes suggestive of infarction can often be seen on CT imaging following
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a relatively normal CT scan and yet patients with obvious ischaemic areas on 
imaging  will  appear  clinically  unaffected  by  such  an  event.  Neil-Dwyer  et 
al(Neil et al., 1994) studied the cortical and hypothalamic changes in 53 SAH 
patients who had died. Cortical ischaemic changes were present diffusely in 
78% of SAH patients studied. There was no clear relationship between either 
the  presence  of  large  vessel  vasospasm  or  the  amount  of  subarachnoid 
blood,  and  the  observed  cerebral  ischaemia.  Hypothalamic  ischaemia  was 
observed  in  50%  of  the  post  modems  studied.  Ischaemic  changes  were 
more  common  in  patients  with  a  fluctuating  blood  pressure,  however  the 
mechanisms  producing  the  ischaemia  were  not  postulated  by the  authors. 
However,  they  did  localise  the  anatomical  area  to  the  cerebral 
microcirculation.  They  suggested  that  the  extensive  distribution  of  lesions 
might  help  explain  some  of  the  neurological  sequelae  following  SAH, 
especially with  regard  to  psychosocial  and  cognitive  problems.  In  particular 
the  lack  of  drive,  loss  of  concentration,  memory  deficits  and  lethargy 
frequently reported.
In  a  recent  study  analysing  the  prognostic  factors  associated  with  the 
occurrence of cerebral vasospasm after SAH, in a singular population of 244 
patients  treated  either  by  endovascular  coils  or  conventional  surgical 
treatment(Charpentier et al., 1999). An age < 50 years, WFNS clinical grades 
<  2,  and  hyperglycaemia  were  independently  and  significantly  associated 
with the occurrence of cerebral vasospasm.  In contrast,  no relationship was 
found with the type of treatment. The 6 month risk of neurological sequelae
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increased with treatment complications and secondary brain insults. 
Interestingly,  MR and perfusion studies have shown cerebral oedema in the 
areas  of  cortex  corresponding  to  vasospastic  cerebral  vessels,  with  the 
relative blood volume significantly higher in the oedematous regions of poor, 
compared  to  good  grade  patients(Rowe  et  al.,  1998).  This  suggests  a 
compensatory  dilatation  of  the  capillary  bed  in  response  to  proximal 
vasospasm.  However,  the  microcirculatory  changes,  especially  whether 
vessels  dilate  or  not  during  vasospasm,  are  controversial  and  still 
uncertain(Ohkuma et al., 2000).
Ohkuma  and  colleagues(Ohkuma  et  al.,  2000)  showed  that  severe 
angiographic  vasospasm  was  statistically  correlated  with  reduced  regional 
cerebral blood flow and prolonged peripheral cerebral circulation time. They 
suggested  that  the  prolonged  peripheral  cerebral  circulation  time  resulted 
from  microcirculatory  changes  producing  cerebral  ischaemia  during 
vasospasm.  These  results  suggest  that  impaired  autoregulatory 
vasodilatation or decreased  luminal  calibre in the  intraparenchymal vessels 
may  play  a  part  in  the  ischaemia  induced  by  cerebral  vasospasm.  These 
authors  suggested  that,  the  therapy  for  cerebral  vasospasm  should  be 
reconsidered  by taking  into  account the  microcirculatory  changes.  Induced 
hypertension and  hypervolaemia might improve regional cerebral blood flow 
by  affecting  small  vessels  with  increased  resistance.  The  effectiveness  of 
calcium  channel  blockers,  despite  the  absence  of  apparent  effect  on 
angiographic  vasospasm  may  partially  depend  on  dilating  the  contractile 
arterioles. The intraarterial injection of papaverine may have an influence on
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arteries.
Mechanisms of cerebral vasospasm
Sustained narrowing of large cerebral vessels remains a major complication 
after aneurysmal SAH.  Despite intensive research, its pathogenesis is still a 
matter  of  debate,  and  adequate  pharmacotherapy  has  been  elusive.  The 
absence  of adequate therapy  continues  to  motivate  preclinical  and  clinical 
studies.  Other complicating findings  are that,  vasospasm  is  not necessarily 
associated  with  SAH  following traumatic head  injury,  that the timescale for 
maximal  vasospasm  seems  different  in  traumatic  SAH,  and  it  appears  to 
rarely produce a clinical deterioration  in  head  injured  patients(Zubkov et al., 
2000).
While cerebral vasospasm is more common following aneurysmal rather than 
traumatic  SAH,  there  have  been  more  recent  reports  of it  occurring  rarely 
after cranial base tumour resection(Bejjani et al.,  1999). A large tumour size, 
the  need  for  preoperative  embolisation  indicating  increased  tumour 
vascularity,  prolonged  operative  time  reflecting  an  increased  intraoperative 
blood loss, preoperative vessel encasement and narrowing, correlated with a 
higher  incidence  of  postoperative  vasospasm.  This  angiographically 
demonstrated  vasospasm  responded  well  to  hypertensive,  hypervolaemic 
and haemodilutional therapy and early use of transluminal angioplasty. 
Evidence has accumulated that blood products and their oxygen free radical 
lipid  peroxidation, may play an important role in the both arterial vasospasm 
and  ischaemic  cell  death.  Intimal  proliferation,  inflammation  and  fibrosis  of
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Yamany, Wallace, 1999).
Another  possible  explanation  of the  occurrence  of vasospasm  may  be  the 
role of surgical  mechanical  manipulation(Miyaoka et al.,  1993;  Murayama et 
al.,  1997).  In  addition,  rather  than  the  presence  of  erythrocytes,  both 
clinical(Brouwers  et  al.,  1992)  and  experimental(Shishido  et  al.,  1994) 
studies  have  argued  in  favour  of  vascular  and  systemic  reactions  to  the 
rupture of an artery.
Glyceryl nonivamide (GLNVA) is a potent vasorelaxant.  It mediates its effect 
by  opening  vascular  potassium  channels  via  a  calcitonin  gene  related 
peptide  pathway.  Lin  and  colleagues(Lin  et  al.,  2001)  demonstrated  in  a 
rabbit  model  of  SAH,  that  intrathecal  GLNVA  had  a  dose  dependent 
protective effect on vascular spasm in the basilar artery. Another potassium 
channel  opener  cromakalim,  has  been  shown  to  topically  relax  vessels 
undergoing  spasm  after  SAH  in  the  same  model(Zuccarello  et  al.,  1996). 
Because of toxic side effects, neither of these compounds has been tested in 
man.
Delayed  cerebral  vasospasm  remains  an  unpredictable  and  inadequately 
treated  complication  of  aneurysmal  SAH.  Despite  intensive  research,  its 
pathogenesis is still a matter of debate, and adequate pharmacotherapy has 
been elusive.
Suzuki et al(Suzuki et al.,  2000) noted that an  increase  in the endothelin  1  
concentration from cisternal CSF appeared to precede the onset of cerebral 
vasospasm.  Endothelin  1   (ET-1)  is  a  potent  vasoactive  21  amino  acid 
peptide that  is a  member of a  large family of endothelins  (1,2  and  3).  The
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modulate  hormone  production,  cell  proliferation  and  vasomotor  tone. 
Endothelin  1   has  been  identified  in  animal  models  as  a  powerful 
vasoconstrictor.  Endothelin  1   has  been  implicated  in  a  number  of 
pathological  processes  characterised  by  vasoconstriction,  and  also  in 
angiogenesis(Dawas et al., 1999).
However,  Nishizawa  and  colleagues(Nishizawa  et  al.,  2000)  recently 
demonstrated,  using  a two-haemorrhage  canine  model,  that although  ET-1 
initiated the development of vasospasm through a protein kinase C activation 
in vascular smooth  muscle cells,  its value returned to  normal within  7 days 
and thus, ET-1  did not appear to contribute to the maintenance of prolonged 
vasospasm.
Fassbender  et  al(Fassbender  et  al.,  2001)  studied  the  effects  of  the 
inflammatory  cytokines  IL-1 p,  IL-6  and  TNF-a,  in  the  blood  and  CSF 
following  aneurysmal  SAH  and  the  mean  CBF  measured  by  transcranial 
doppler.  In 20  patients they measured these values longitudinally over time 
at 1, 2, 3, 5, 7, 9 and  11  days following SAH, and compared the values with 
20  control  subjects.  All  inflammatory  markers  were  dramatically  increased 
following  SAH.  The  CSF  concentration  of  IL-6  was  increased  10,000  fold. 
Longitudinal  analysis  showed  a  subacute  response  for  cytokines,  peaking 
between days 5 and 9 and declining thereafter. In SAH, concentrations of IL- 
1p and  IL-6 were significantly lower in plasma than CSF,  perhaps indicating 
the  intrathecal  origin  of these  mediators.  The  mean  CBF  increased  during 
the  study period,  peaking  between  days  7  and  11  when  values  reached  a 
plateau.  Interestingly, the changes in cerebral blood flow paralleled those of
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slightly  preceded  those  of  the  haemodynamic  abnormalities,  peaking 
between days 5 and 9.  Those  patients with  higher CBFs  (>210 cm/s) were 
associated with significantly increased CSF concentrations of IL-1p, IL-6 and 
TNF-a compared to those patients with lower CBF (<210 cm/s).
This study showed that release of IL-1p, IL-6 and TNF-a in the subarachnoid 
space of patients with SAH, is associated with the development of increased 
CBF  in  the  basal  cerebral  arteries,  suggesting  a  role  of  excessive 
subarachnoid  inflammatory  host  response  in  the  haemodynamic 
complications of SAH.
The  pathophysiological  importance  of  compartmentalised  cytokine  release 
following  SAH  may  also  explain  the  severe  vasospasm  in  experimental 
subarachnoid  inflammation(Peterson  et  al.,  1990)  or  in  bacterial 
meningitis(Fassbender  et  al.,  1996).  Both  conditions  are  characterised  by 
massive cytokine  release(Fassbender et al.,  1996),  but also  by an  obvious 
absence  of  erythrocytes  or  platelets  that  are  considered  key  cells  in  the 
pathophysiology of vasospasm following SAH.
The  triggers  for  the  pronounced  inflammatory  host  response  in  the 
subarachnoid  space following SAH  are unknown.  One mechanism could  be 
complement  activation,  a  strong  inflammatory  stimulus,  by  osmotically 
induced  disruption  of erythrocytes.  This  is  suggested  by in  vitro findings of 
complement mediated haemolysis of erythrocytes in subarachnoid blood clot 
or by raised CSF concentrations of complement factors in SAH(Fassbender 
et al., 2001).
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vasospasm  in  several  ways.  Once  in  the  subarachnoid  space,  these 
mediators could easily access the smooth muscle cells of basal arteries from 
their adventitial surface. This is possible because the surface of pial cerebral 
arteries,  is  exceptionally,  not  confined  by  collagen  or fibroblasts,  but  is  in 
direct  contact with  the  nourishing  CSF.  At the  smooth  muscle  cells,  these 
mediators  could  directly  cause  vasospasm,  although  the  effects  of 
inflammatory cytokines are  still  controversial.  Cytokines  may also  modulate 
vessel tone in an indirect manner,  by inducing synthesis of vasoconstrictors 
such  as  ET-1,  or  by  induction  of  the  adhesion  molecule  expression 
responsible for focal leukocyte recruitment.
Haemostatic  systems  seem  to  have  a  close  relationship  with  delayed 
vasospasm following SAH. Although  its mechanism remains controversial,  it 
is well  known that the severity of vasospasm  increases with the amount of 
residual  clot(lnagawa  et  al.,  1990;  Zabramski  et  al.,  1991).  Vasospasm  is 
accompanied  by  damage  to  the  endothelium,  resulting  in  exposure  of the 
subendothelial  connective tissue.  Platelets  adhere to the  connective tissue 
via the interaction between von Willebrand factor and glycoprotein  lb on the 
platelet surface,  are  activated,  and  are  aggregated  with  each  other via  the 
interaction  between  fibrinogen  and  glycoprotein  I lb/ll la.  The  aggregation  of 
platelets  results  in the generation  of thrombin,  which  converts fibrinogen to 
fibrin,  and  subsequently  a  thrombus  is  precipitated  on  the  damaged 
endothelium.  It  is  conceivable  that  this  thrombus  may  have  a  close 
relationship to the appearance of DINDs.
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who  presented  with  hydrocephalus  on  initial  CT  imaging.  The  authors 
speculated  that  in  these  patients,  the  clearance  of  subarachnoid  clot  was 
delayed because of a disturbance of CSF flow. They suggested that the rise 
in  D-dimer on day 3 following the ictus, could  reflect the amount of residual 
subarachnoid  clot, that is the clot that could  not be  removed  at surgery,  or 
cleared with the flow of CSF.
Fibrinogen  plays  an  important  role  in  the  platelet  aggregation  and  plasma 
viscosity. The increased level of fibrinogen itself may be a risk factor for the 
appearance of DINDs. Thus, hypervolaemic therapy for vasospasm  may be 
effective  in  decreasing  fibrinogen  levels,  by  reducing  platelet  aggregation 
and plasma viscosity.
The  high  level  thrombin-antithrombin  complex  in  the  patients  with  DINDs 
may  indicate  the  precipitation  of  thrombus  on  the  damaged  endothelium. 
Hence, from a haemostatic standpoint it may be useful for the prevention of 
DIND to remove the subarachnoid clot extensively as soon as possible and 
initiate  prophylactic  therapy,  such  as  hypervolaemic  and/or  mild 
anticoagulation therapy, such as low dose heparin administration.
The  effects  of the  heterogeneity of human  vascular endothelium  may also 
play  a  part  in  the  localisation  of  vasospasm.  Although  endothelial  cells 
throughout  the  vasculature  share  basic  structural  and  functional 
characteristics,  marked  differences  exist  in  their  morphology  and  growth 
characteristics.  Vascular endothelial  cells  release  biologically active  agents 
such  as  nitric  oxide  and  prostacyclin  which  are  powerful  vasodilators,  and 
endothelin-1,  a  potent  vasoconstrictor.  The  balance  between  dilators  and
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vascular  tone.  It  is  known  that  the  cerebral  endothelium  differs  from 
peripheral or omental endothelium in its cell proliferation rate, rate of protein 
synthesis, as well as in its response to various agonists such as a-thrombin, 
vasoactive  intestinal  peptide,  endothelin-1 (Thorin  et al.,  1997).  Peltonen  et 
al(Peltonen et al.,  1997) concluded that endothelial dysfunction was causing 
coagulation cascade activation, and that this subsequently led to DIND. The 
endothelial  cells  produce  many  components  of  the  haemostatic  system 
including vWF and tPA.
Treatment of cerebral vasospasm
The  strategies  developed  in  the  management  of  vasospasm  include  the 
following.  Preventative measures:  (a) preoperative management in the form 
of early surgery and the use of calcium antagonists;  (b) intraoperative such 
as  clot  removal  and/or  clot  lysis  using  fibrinolytic  agents  and  minimal 
manipulation  of  blood  vessels;  (c)  postoperative  management  including 
hypervolaemia  and  haemodilution.  Curative  measures:  (a)  hypertension, 
hypervolaemia  and  haemodilution  (triple  H);  (b)  intra-arterial  vasodilators 
(pharmacological); (c) transluminal angioplasty (mechanical dilation). Despite 
all the available measures to prevent and/or treat aneurysmal  SAH  induced 
vasospasm,  it  remains  a  clinical  challenge  for  neurosurgeons,  intensivists, 
and neuroradiologists(AI Yamany, Wallace, 1999; Fandino et al., 1999). 
Several reports from uncontrolled studies, described the resolution of deficits 
from  vasospasm  following  the  elevation  of  blood  pressure,  volume 
expansion,  and  haemodilution,  with  improved  outcome  of  vasospasm 
compared  with  historical  controls(Awad  et  al.,  1987;  Kassell  et  al.,  1982;
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hypertension/hypervolaemia/haemodilution  (HHH)  has  not  been 
demonstrated  in  controlled  trials,  and  studies  of  cerebral  blood  flow  after 
initiation  of therapy  have  been  equivocal(Fandino  et  al.,  1999).  In  addition 
studies  have  not  been  performed  to  determine  which  component  of  this 
therapy (haemodilution  versus  hypervolaemia versus  hypertension)  is  most 
important.  Only  a  proportion  of  the  patients  with  vasospasm  respond  to 
H/H/H  therapy,  with  stroke  and  death  rates  from  vasospasm  approaching 
15% in the series with the best outcome.
Initiation of H/H/H therapy is associated with significant risk, including cardiac 
failure,  electrolyte  abnormalities,  cerebral  oedema,  bleeding  abnormalities, 
and  rupture  of an  unsecured  aneurysm.  An  uncontrolled  series  suggested 
that  therapy  might  be  more  effective  if  initiated  prophylactically  before  the 
onset of symptoms (preferably after clipping of the aneurysm). Treatment is 
usually continued beyond the period of risk for vasospasm or until abatement 
of vasospasm by clinical or transcranial Doppler parameters.
In  patients  with  severe  resistant  symptomatic  vasospasm  unresponsive  to 
HHH  therapy,  nimodipine or angioplasty,  there  have  been  some  promising 
results  with  barbiturate  coma(Finfer  et  al.,  1999).  Barbiturates  are  said  to 
exert  their  protective  effect  by  decreasing  cerebral  oxygen  consumption, 
altering regional blood flow and decreasing intracranial pressure.
Haley et al(Haley et al.,  1997) conducted a study on 902  patients with SAH 
into the effect of tirilazad,  a  non-glucocorticoid  21-amino steroid, which  is a 
potent inhibitor of oxygen free radical induced lipid peroxidation that lacks the 
side effects of glucocorticoids. Oxygen free radical induced lipid peroxidation
135is thought to be a possible factor in the development of vasospasm following 
SAH.  The  study  showed  that  the  incidence  of  vasospasm,  proportion  of 
patients receiving angioplasty and the outcome at 3 months was the same in 
treatment and control groups.
Papaverine is a benzylisoquinoline opium alkaloid that dilates spastic vessels 
with  a half-life of 0.8 hours. The effectiveness of intra-arterial  papaverine  in 
the  treatment  of  cerebral  vasospasm  has  not  been  demonstrated  in  a 
randomised  clinical trial(Polin  et al.,  1998).  However,  an  uncontrolled  study 
by Fandino et al(Fandino et al., 1999), showed improvement in angiographic 
vasospasm  and  doppler  measured  mean  flow  velocities  in  the  main 
intracranial vessels using a combined protocol and percutaneous angioplasty 
and intraarterial papaverine infusion. This study in 30 patients with refractive 
vasospasm showed that mean flow velocity decreased significantly from 135 
+/- 48 cm/s to 87 +/- 32 cm/s in the MCA and  110 +/- 37 cm/s to 84 +/- 30 
cm/s in the ACA. Early clinical improvement was observed in 73% of patients 
following  treatment  and  was  significantly  associated  with  a  good  outcome 
(GOS 4-5).
The effects of volume expansion therapy have not been studied adequately 
in patients with aneurysmal SAH. At present, there is no sound evidence for 
or against the use of volume expansion therapy in  patients with aneurysmal 
SAH(Feigin et al., 2000).
Calcium-channel antagonists
In prospective, randomised trials, oral Nimodipine reduced poor outcome due 
to  vasospasm  in  all  grades  of  patients(Allen  et  al.,  1983).  However,  the
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treatment, and vessel calibre on angiography was unaffected.
Pickard  et  al(Pickard  et  al.,  1998)  conducted  a  trial  in  a  randomised, 
prospective, double-blind population of 199 patients in which nimodipine was 
given orally in a dose of 60mg every 4  hours, started within 4 days of SAH 
and continued for 21  days in survivors. The result of the trial was an overall 
34% reduction in cerebral infarction and a 40% reduction in poor outcome. In 
addition,  there  was  a  36%  death  or  severe  disability  rate  in  the  placebo 
group, compared to 17% in the treatment group, and 83% good recovery and 
moderate disability in the nimodipine group, compared to a 64%  rate in the 
placebo  group.  These  differences  were  significant  both  clinically  and 
statistically.
The action of nimodipine was initially believed to  be vasodilatation  but now 
many  scientists  believe  that  the  calcium  antagonising  effect  of  nimodipine 
may be the protecting factor against delayed ischaemia(AI Yamany, Wallace, 
1999).
Transluminal angioplasty
Zubkov first reported the use of angioplasty for the treatment of vasospasm 
in 1984(Zubkov et al., 1984). As with cerebral vasospasm, the mechanism by 
which angioplasty works is not understood. Angioplasty may be effective by 
disrupting  the  extracellular  matrix  in  the  vessel,  which  maintains  the 
narrowed state. In patients with vasospasm who clinically deteriorate despite 
maximal  medical  therapy,  the  judicious  and  aggressive  use  of  timely 
percutaneous  balloon  angioplasty  in  experienced  hands  can  improve  short 
term  outcomes(Eskridge  et  al.,  1998).  In  this  retrospective,  uncontrolled
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4% died immediately following the procedure, and 2% deteriorated, 33% did 
not improve.  It was found that the longer the vessel was in spasm the more 
difficult it was to perform angioplasty.
Angioplasty  is  not  without  risk.  Vessel  rupture  can  occur,  and  therefore, 
should  not  be  performed  distal  to  the  genu  of  the  MCA,  beyond  the  A1 
segment of the  anterior cerebral  artery,  or  beyond  the  P1  segment of the 
posterior cerebral artery.
The  effects  of  transluminal  angioplasty  have  been  summarised  as  a 
significant  improvement  in  60%-80%  of  patients,  often  within  hours  after 
dilatation,  and  normal  angiographic  calibre  in  nearly  all  cases,  without 
recurrent vasospasm(Eskridge et al.,  1998).  Evidence of improved  cerebral 
blood  flow  by  TCD  or  single  photon  emission  CT  correlated  with  clinical 
improvement.  The  complication  rate  (rupture  of  vessels  or  unsecured 
aneurysm)  is  approximately  5%.  These  benefits,  and  that  of  intra-arterial 
papaverine(Kassell  et al.,  1992)  have  not  been  demonstrated  in  controlled 
clinical trials.
Blood load and vasospasm
Delayed  ischaemic  neurological  deficits  (DIND)  due  to  cerebral  artery 
vasospasm  is  one  of  the  major  complications  that  cause  poor  clinical 
outcome after aneurysmal SAH(Kassell et al.,  1990a).  It is reported that the 
severity  of  neurological  deficits  from  spasm  correlates  with  the  amount  of 
basal  subarachnoid  blood  on  the  admission  CT  scan(Allen  et  al.,  1983; 
Fisher et  al.,  1980;  Kasuya  et  al.,  1998).  Fisher  et  al(Fisher  et  al.,  1980) 
stated that when  subarachnoid  blood  was  not detected  on the  CT scan,  or
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However, in the presence of subarachnoid blood clots larger than 5 x 3  mm, 
of layers of blood 1mm or more thick in fissures and vertical cisterns, severe 
spasm  followed  almost  invariably.  They  noted  an  almost  exact 
correspondence between the site of major subarachnoid  blood  clot and the 
location  of  severe  spasm.  They  suggested  that  blood  clots  are  especially 
spasmogenic when they lie along or in contact with the major arteries of the 
circle of Willis, particularly the proximal 9 to 10cm of the anterior and middle 
cerebral arteries.
Jurus-Dziedzic et al(Jarus-Dziedzic et al., 2000) concluded in a study of 127 
aneurysmal  SAH  patients that the blood  load  as measured  by Fisher grade 
was significantly correlated with cerebral  blood flow velocity measurements 
using transcranial doppler. These authors found that during the first 21  days 
following SAH the highest flow velocities were observed  in the Fisher grade 
III  and  II  patients.  Lower values were  found  in  patients  with  massive  SAH 
(group  IV) and the  lowest flow velocities were  recorded  in group  I  patients, 
that is those without SAH on the original CT scan.  In addition the number of 
days  for  which  the  mean  flow  velocity  in  the  middle  cerebral  artery  was 
>120cm/s was statically correlated with  blood  load on  CT imaging  (I,  II  and 
III).  In  all  patients  the  greatest  difference  in  mean  flow  velocity 
measurements were observed  between the 9th  and  14th  day following  SAH. 
The  authors  suggest that the  apparent failure  to  demonstrate  a  consistent 
trend with  regard to the grade IV patients could  be explained  by raised  ICP 
and thus decreased cerebral blood flow in these patients. Similar findings of 
increased  ischaemic deficit and  increased  doppler flow velocities were also
139observed by Grosset et al(Grosset et al., 1994) in relation to increased blood 
load.  Once again  however,  Fisher grade  IV patients were not in  agreement 
with this trend.  The authors suggest that this  may be explained  by the fact 
that intracerebral and intraventricular blood can be present without significant 
volumes of subarachnoid blood.
Fujii  et  al  found  no  significant  relationship  between  the  severity  of 
subarachnoid  clot  and  the  levels  of  fibrinogen,  D-Dimer,  and  thrombin- 
antithrombin complex following SAH(Fujii et al., 1997).
However, because heavy CT blood load also correlates with other prognostic 
indicators  such  as,  poor  condition  on  admission,  coexistent  hypertension, 
age and surgery, the causative relationship between  blood  load  and overall 
clinical outcome is complex(Grosset et al., 1994).
Clot removal and fibrinolytics
Clinical  and  experimental  evidence  has  related  the  severity  of  cerebral 
vasospasm  to  the  volume  and  duration  of  perivascular  thrombosis  in  the 
subarachnoid  space(Tanaka  et  al.,  1998).  Experimental  work  with  clot 
placement  models  of vasospasm  shows  that  vasospasm  is  related  to  the 
length  of  time  arteries  are  in  contact  with  clot(Handa  et  al.,  1987). 
Kasuya(Kasuya et al., 1998) reported that the patients showing a slower rate 
of clearance of subarachnoid blood from the basal cisterns had a higher rate 
of  infarction,  and  higher  CSF  levels  of  fibrinopeptide  A.  Removal  of 
fibrinopeptides  from  the  fibrinogen  molecule  by  thrombin  allows  the  fibrin 
monomers formed  to  undergo  polymerisation  through  the  production  of an 
insoluble  fibrin  network.  Thrombin  is  also  a  potent  inducer  of  platelet 
aggregation and secretion. This cascade reaction occurs in the subarachnoid
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firm fibrin  network entrapping the  red  cells  in  the  subarachnoid  space  and 
influences  the  persistence  of  the  blood  clot  in  the  subarachnoid 
cistems(Kasuya  et  al.,  1998).  This  concept  led  to  the  practice  of  early 
surgery  to  ensure  extensive  clot  removal  to  reduce  the  incidence  and 
severity of vasospasm(Hosoda  et al.,  1999;  Suzuki  et al.,  1979).  However, 
no controlled  study has demonstrated the effectiveness of this technique  in 
reducing  vasospasm,  and  other authors  have found  no  significant effect of 
clot  removal  by  surgery(lnagawa  et  al.,  1990).  Lysis  of  subarachnoid 
thrombus by intracisternal recombinant tissue plasminogen activator is under 
investigation.
Kodama  et al(Kodama  et al.,  2000)  reported  the  use  of cisternal  irrigation 
therapy.  In their technique urokinase was used to dissolve residual clot, and 
ascorbic acid is added to degenerate oxyhaemoglobin, one of the strongest 
spasmogenic  substances,  into  haem-like  products  which  are  non- 
spasmogenic. They studied the efficacy of this technique in 217 patients with 
Fisher  grade  3  SAH.  They  reported  an  extremely  low  incidence  of 
symptomatic vasospasm  in  this  cohort of 2.8%,  with  only 0.9%  developing 
clinical sequelae.
Findlay  et  al(Findlay  et  al.,  1995)  reported  the  results  of  100  patients 
randomised  using  a  single  intraoperative  dose  of  recombinant  tPA.  The 
results  did  not  show  a  significant  difference  in  the  overall  degree  of 
angiographic  vasospasm,  yet  there  was  a  consistent  trend  toward  lesser 
degrees of vasospasm  in the tPA group with  no or mild  spasm  in  68% and
141severe  spasm  in  15%,  compared  to  42%  with  no  or  mild  vasospasm  and 
23% severe vasospasm in the placebo group.
Hosoda and colleagues(Hosoda et al., 1999) examined 32 SAH patients with 
anterior  communicating  artery  aneurysms,  and  symmetrical  cisternal 
subarachnoid blood, who had a unilateral pterional approach within 3 days of 
the ictus. Cerebral blood flow was determined in these patients using single 
photon  emission  tomography  (SPECT)  and  related  to  angiographic 
vasospasm and blood load on CT imaging. The regional cerebral blood flow 
(CBF)  showed  a  continuous  fall  during  the  first  4  weeks  after  the  ictus, 
followed  by  improvement.  A significant association  between  a  decrease  of 
cisternal  blood  after surgery, with the degree of local vasospasm and  local 
CBF values during the spasm  stage, was observed  in the  interhemispheric 
cisterns, A2 and medial frontal cortex, but not in the sylvian fissure or insular 
cisterns,  M1  or  M2,  and  frontal  watershed  and  temporal  cortex.  However, 
they also observed  a significant reduction  in  regional  CBF  in the vicinity of 
the surgical route that continued up to  1   month following surgery. They thus 
concluded that, direct clot removal with early surgery is effective with respect 
to  vasospasm  and  CBF  reduction.  However,  this  potential  improvement  in 
CBF with clot removal is masked by brain retraction and oedema, sacrifice of 
veins,  mechanical  manipulation  of  the  subarachnoid  vessels,  and 
intraoperative  induced  hypotension,  which  affects  cerebral  blood  flow 
adversely at the operative site.
A similar reduction  in  CBF on the operated  side  in  anterior communicating 
artery aneurysms was observed by Yoshimoto and colleagues(Yoshimoto et
142al.,  1999),  however  they  failed  to  demonstrate  any  improvement  in 
vasospasm associated with extensive subarachnoid clot removal at surgery. 
Coil embolisation and vasospasm
Surgery during the  period  of maximal  vasospasm  (4 to  12) days  has  been 
traditionally regarded as less suitable, particularly in patients of higher clinical 
grade.  Surgery is therefore often performed early (before) or late (after) the 
‘spasm  period’(Tomer et al.,  1990).  This  is  largely due to the  International 
Cooperative  Study on  the  timing  of aneurysm  surgery  suggesting  that the 
operative  results  depended  on  the  time  interval  between  treatment  and 
SAH(Kassell et al.,  1990a). Early surgery reduced the risk of rebleeding, but 
technical results were better when surgery was delayed until at least 10 days 
after  SAH.  Overall  the  advantages  of  delayed  surgery  were  negated  by 
rebleeding  during  the  preoperative  period.  Therefore,  6  month  outcomes 
after early surgery were equivalent to those after delayed surgery. The least 
favourable surgical results were associated with surgery performed between 
days  7  and  10  after  the  ictus,  that  is,  during  the  period  of  greatest 
susceptibility to vasospasm.
Endovascular  treatment  with  Guglielmi  detachable  coils  (GDC)  is  an 
alternative  treatment  for  acutely  ruptured  aneurysms  that  is  now  well 
established(Fernandez  et  al.,  1994;  Vinuela  et  al.,  1997).  In  contrast  to 
surgical clipping, the endovascular procedure does not allow removal of the 
subarachnoid  clot.  Murayama  et  al(Murayama  et  al.,  1997)  measured  the 
incidence of symptomatic vasospasm  after early endovascular treatment of 
acutely ruptured aneurysms in 69 patients with Hunt and Hess clinical grades 
between  I  and  III.  The  23%  incidence  of  cerebral  vasospasm  was
143comparable with surgical series. In a series of 37 patients(Yalamanchili et al., 
1998),  preliminary  data  has  suggested  that  the  frequency  of  cerebral 
vasospasm  may  be  reduced  in  those  treated  by  endovascular  therapy 
compared with those treated by direct surgical clipping. Recently, it has been 
shown in univariate analysis that the vasospasm related ischaemic infarction 
rate  was  higher with  endovascular treatment versus  surgery(Gruber et  al., 
1998).  Charpentier  et  al’s(Charpentier  et  al.,  1999)  recent  study  in  244 
patients treated  either by surgery or endovascular means did  not show any 
significant difference in mortality, morbidity or the incidence of vasospasm in 
either of the treatment arms.
A  recent  report(Wikholm  et al.,  2000)  has  suggested  that the  incidence  of 
ischaemic  complications  is  unaffected  when  coil  embolisation  is  performed 
outside or within the period of maximal spasm. However, this compares only 
a  small  number of clinical  events.  Baltsavias  et  al(Baltsavias  et  al.,  2000) 
reported  on  a  group  of  327  patients  consecutively  treated  with  coil 
embolisation  following  aneurysmal  SAH.  They  concluded  that  the  interval 
between  endovascular  treatment  and  SAH  did  not  affect  periprocedural 
morbidity rates or 6 month outcomes. They suggested that coil embolisation 
should be performed as early as possible to prevent rebleeding.
The metabolic response to trauma.
A  series  of  metabolic,  water,  electrolyte  and  endocrine  changes  occur 
following trauma, sepsis, or surgical operations. These may be divided into 4 
phases.
In the injury phase, tissue catabolism occurs.
144At  the  ‘turning  point’,  the  Na+   and  K+   balance  reverses  before  protein 
anabolism begins.
During protein anabolism, lean tissue mass is regained.
During fat anabolism, body weight is regained 
An alternative nomenclature is that:
A  shock  or ebb  phase  lasts  1-2  days.  Metabolic  rate,  temperature,  and 
cardiac output are reduced.  Catecholamines, glucose,  lactate and free fatty 
acids  are  increased  and  insulin  secretion  is  reduced,  the  patient  is  in  a 
negative nitrogen balance.
Flow phase occurs from the third day onwards. Metabolic rate, temperature, 
cardiac output and insulin secretion are increased. Catecholamines, glucose 
and lactate are slightly increased or normal, and free fatty acids are low. The 
nitrogen balance becomes positive.
After  an  injury  involving  tissue  damage,  the  body  mounts  a  series  of 
responses  which  are  relatively  constant  irrespective  of  the  nature  of  the 
insult.  The  magnitude  of  the  response  though  is  variable.  The  principal 
events which produce signals to initiate this response are fluid loss, afferent 
sensory nerve output and circulating mediators.
The  proteins that increase are often  referred to as the acute phase  plasma 
proteins. C-reactive protein, alphai-acid glycoprotein, alpha-i-antitrypsin, and 
fibrinogen  are  the  best  known  examples.  There  is  evidence  to  support 
interleukin I as the mediator of the acute phase protein response.
Those  proteins  that  decrease  are  albumin,  transferrin,  prealbumin  and 
retinol-binding  protein.  The  concentration  of plasma  proteins  can  decrease 
as  a  result  of  a  fall  in  the  rate  of  synthesis,  increased  consumption,  by
145dilution  in  the  intravascular  compartment  or  by  loss  of  protein  into 
extravascular  spaces.  The  last  mentioned  is  probably  the  most  important. 
Increased  vascular  permeability  is  caused  by  the  chemical  mediators, 
histamine and bradykinin, released from the site of injury.
Surgical procedures and coagulation
The development of a  hypocoagulable state as a  consequence of massive 
blood  loss  and  transfusion  is  well  established(Hewson  et  al.,  1985).  This 
dilutional coagulopathy occurs after large volume blood loss.  However, if the 
volume lost is only small to moderate, and if no transfusion is performed, the 
changes in coagulation have not been well studied(Ng, Lo, 1996b).
An  in  vitro  study  by  Heather  et  al.  was  the  first  to  report  that  a 
hypercoagulable,  in  contrast  to  a  hypocoagulable  state  could  develop  in 
association with mild to moderate haemodilution(Heather et al.,  1980).  More 
recent  in  vivo  studies  have  confirmed  these  findings(Gibbs  et  al.,  1994; 
Tuman et al.,  1987). However, Sharma failed to observe any change in TEG 
variables in pregnant women given a bolus of Ringers lactate(Sharma et al., 
1997).
Tuman  et al(Tuman  et al.,  1987) observed the effects of progressive  blood 
loss on coagulation as measured  by TEG. They demonstrated that patients 
tended  to  become  hypocoagulable  after  induction  of  general  anaesthesia, 
when compared to their pre-anaesthetic state. This finding was reflected by a 
prolongation of R and  K values, with  a diminution of angle and  MA values. 
However, with moderate blood loss (10-15% estimated blood volume) and at 
the end of the operation TEG parameters were hypercoagulable compared to 
the post-anaesthesia values.
146However,  evidence  exists  that  a  hypercoagulable  state  will  develop  as  a 
result  of  the  stress  of  surgery  per  se(Barrer,  Ellison,  1977;  Gibbs  et  al., 
1992). The effects of stress, tissue trauma, pain, endogenous catecholamine 
levels and anaesthesia on global coagulation status are poorly understood. It 
has been suggested that catecholamine  release has a stimulatory effect on 
platelet aggregation. These factors undoubtedly act as confounding variables 
in the development of a hypercoagulable state following a surgical procedure 
or  serious  illness.  From  an  evolutionary  perspective,  activation  of 
haemostatic  systems  could  be  considered  a  normal  response  following 
surgical aggression, and aimed at preventing excessive bleeding(Arcelus et 
al., 1995).
Proposed  mechanisms  have  included  deficiency of protein  C  or protein  S, 
high levels of plasminogen activator inhibitor, acute dilution of antithrombin III 
and  consumption  of  antithrombin  lll(Nachman,  Silverstein,  1993). 
Physiological  concentrations of epinephrine appear to sensitise  platelets to 
other agonists such as ADP.  Epinephrine activates platelets in vivo.  Platelet 
volume is increased, thromboxane B2formation is enhanced, platelet release 
is  stimulated,  and  platelet aggregation  is enhanced(Hjemdahl  et al.,  1994). 
Epinephrine  and  norepinephrine  enhance  the  fibrinogen  binding  and  P- 
selectin expression of platelets in the  presence of the agonist ADP,  both  in 
vivo and  in vitro.  These  platelet responses to agonist stimulation  indicate a 
prothrombotic potential for sympathoadrenal activation  in  humans(Hjemdahl 
et al., 1994).
Increased  levels of renin, angiotensin, and  catecholamines are likely during 
progressive  blood  loss.  Platelet  adhesiveness  increases  significantly  after
147angiotensin  as  well  as  catecholamine  administration(Barrer,  Ellison,  1977; 
Rubegni et al., 1969a). The stress of surgery leads to the release of catabolic 
hormones, such as cortisol and catecholamines, and local cytokines(1999b). 
It  is  likely  that  surgical  stress,  tissue  trauma  (with  release  of  tissue 
thromboplastin),  and  elevations  in  serum  catecholamine  levels  offset  any 
hypocoagulable  tendency  resulting  from  haemodilution  and  loss  of 
coagulation  factors  during  progressive  blood  loss(Rubegni  et  al.,  1969b; 
Spagnaetal., 1971; Tuman et al., 1987).
Vasopressin (AVP) is concerned physiologically in the maintenance of water 
balance.  However,  during  periods  of  stress  such  as  profound  nausea, 
surgical  operation,  or  hypotension,  plasma  concentrations  can  transiently 
rise.  The  physiological  consequences  of this  are  not  entirely  understood. 
Grant et al(Grant et al., 1985) have shown in vivo though that this increase is 
accompanied by a dose response increase in factor VIII and an  increase in 
plasminogen  activator.  In  addition,  AVP  stimulates  blood  platelets  to 
aggregate.  Grant  et  al(Grant  et  al.,  1986)  observed  a  similar  response  in 
apomorphine induced nausea in control subjects.
A  mild  to  moderate  degree  of  surgical  blood  loss  (10-15%)  with 
haemodilution  is  associated  with  the  development  of  hypercoagulability  as 
measured  by TEG.  No evidence of hypercoagulability was observed  at one 
hour  into  the  operation  in  the  absence  of  bleeding(Ng,  Lo,  1996b).  These 
authors suggested that the hypercoagulability was unlikely to  be due to the 
stress of anaesthesia of tissue trauma per se,  as no hypercoagulability was 
demonstrated unless a degree of haemodilution was also observed one hour 
into the surgical procedure. Another interesting observation of this study was
148that the degree of hypercoagulability as measured by TEG variables, did not 
progress  significantly when  the  haemoglobin  fell  from  90%  to  85%  of the 
preoperative level. This might suggest that a dilutional hypocoagulable state 
was evolving  as  blood  loss  progressed,  counteracting the  hypercoagulable 
state.
Gibbs et al documented the development of hypercoagulable TEG indices in 
the first 3 days following  abdominal  aortic surgery(Gibbs et al.,  1994).  The 
progressively hypercoagulable state demonstrated with TEG in the first week 
following  open  abdominal  surgery  has  been  shown  to  be  reversible  with 
heparin and dextran(Arcelus et al., 1995).
However, Benzon et al observed no difference in preoperative, intraoperative 
and  24  hour  postoperative  TEG  tracings  in  120  patients  undergoing 
abdominal and pelvic surgery(Benzon et al., 1994).
Many factors  affect the  observed  changes  occurring  in  coagulation  during 
surgery.  These  include  case  mix,  use  and  degree  of  systemic  cooling, 
operative  times,  time  of day  and  level  of personnel  involved(Spiess  et  al.,
1995).
It  is  important  to  determine  the  extent  and  time  course  of  postoperative 
hypercoagulability  in  this group of patients.  Only then  will  it  be  possible to 
decide whether clinical trials of antithrombotic therapy are warranted.
It  is  well  established  that  both  vasopressin  and  adrenaline  affect  the 
regulation  of both  clotting factors  and  platelets(Grant et al.,  1988).  Studies 
have  indicated  a  temporal  relationship  between  increased  plasma 
concentrations  of vasopressin  and  von  Willebrand  factor (vWF)  and  factor 
VIII.C  in  cardiac  surgical  patients(Kuitunen  et  al.,  1993).  Large  molecular
149weight multimers of vWF act as glue to overcome high shear forces between 
circulating  platelets  and  collagen  exposed  by  endothelial  injury.  In  the 
perioperative  period,  influences that can  raise the concentrations of clotting 
factors  include  elevated  levels  of  catecholamines,  tissue  necrosis  factor, 
interleukin-1, and arginine vasopressin
On the humoral side during trauma or intraoperative stress, the complement 
system is activated via the alternative pathway. Complement activation plays 
an  important  role  in  shock  producing  inflammatory  mediators  because  of 
anaphylatoxin formation  (C3a,  C4a and  C5a). The physiological  importance 
of this  has  focused  on  polymorphonuclear  neutrophils  (PMNs)  in  terms  of 
adhesiveness, aggregation and degranulation.  However, an additional effect 
of complement activation is the secretion of potent proinflammatory cytokines 
such  as,  tumour necrosis factor (TNF) and  interleukin  1   (IL-1),  and  platelet 
activating  factor  (PAF)  by  macrophages.  The  membrane  attack  complex 
(C5b-C9)  can  release  secondary  mediators,  such  as  prostaglandin  E2 
(PGE2),  leukotrienes,  and  thromboxane,  which  are  all  important  in  the 
inflammatory process(Schlag,  Redl,  1996).  It has  been  suggested  by some 
authors  that  the  measurement  of  these  complement  components  can  be 
used to predict the outcome from severe injury(Schlag, Redl,  1996). With the 
release of the  mediators  mentioned  above,  cell  damage  is  produced which 
that  results  in  a  generalised  inflammatory  response  with  primary  organ 
damage.  Leukocytes  and  the  complement  system  are  triggers  during  the 
earliest  phase  of  severe  trauma  or  intraoperative  stress,  which  leads  to 
activation of the complex cascade systems with the release of further tissue- 
toxic mediators.
150During the earliest phase of trauma, adhesion  proteins are also involved  (P 
and  L-selectin),  that  are  responsible  for  the  adherence  of  PMNs  to 
endothelial  cells.  The  latter  results  in  damage  to  the  endothelial  cell 
membrane, caused by the release of oxygen radicals and proteases.
During  trauma  there  is  early  activation  of the  coagulation  system  and  the 
release of thrombin via intrinsic and extrinsic pathways. Thrombin stimulates 
the  endothelial  cells followed  by the  expression  of adherence  proteins  (P- 
selectin).  Thrombin  also  cleaves  fibrinogen  to  fibrin  monomers,  forming  a 
fibrin  clot  by  polymerisation.  These  coagulation  changes  have  been 
associated with the development of acute  lung failure, which occurs  by the 
deposition  of  fibrin  in  the  alveolar  space(Schlag,  Redl,  1985).  This  fibrin 
formation is caused mainly by the transudation of plasma proteins due to the 
increase in permeability in the capillary region of the lung.
Activation of coagulation via the extrinsic pathway is initiated via factor VII  in 
the  presence  of  tissue  factor.  Tissue  factor  is  present  in  many  tissues, 
including brain, monocytes, endothelium and the alveolar interstitial space.  It 
has  been  suggested  that fibrin  deposition  in  connection  with  depression  of 
fibrinolytic  activity,  is  the  basis  for  the  formation  of  alveolar  air  block, 
atelectasis,  and  disturbances  in the ventilation/perfusion  ratio(Schlag,  Redl,
1996).
The procoagulant stage is also important in the pathological  mechanisms in 
the development of disseminated  intravascular coagulation, which  results in 
fibrin  deposition  in  the  microvascular  system  and  can  be  responsible  for 
further organ damage.
151Platelet activating  factor (PAF)  is  expressed  rapidly  by the  endothelial  cell 
during  shock  in  response  to  various  stimuli  (thrombin,  histamine  and 
leukotrienes).  This  may also  be  responsible  for the  earliest  adherence  of 
PMNs  to  endothelial  cells  (in  addition  to  P-selectin) via  PAF  receptors.  In 
addition to the cytokines (IL-1  and TNF) this may initiate tissue damage and 
increase membrane permeability.
Galster  et  al(Galster  et  al.,  2000)  have  shown  that  coagulation  and 
fibrinolysis  are  significantly  enhanced  up  to  14  days  following  orthopaedic 
and abdominal surgery by measuring fibrin monomers and d-dimers. 
Coagulation changes and Neurosurgery
Goh et al. used TEG to investigate intraoperative and first day postoperative 
changes  in  neurosurgical  patients  undergoing  large  tumour  resections 
(>4cm) in 50 patients(Goh et al.,  1997).  They observed the generation of a 
hypercoagulable state even in the intraoperative sample (though  not in MA) 
and  suggested  that  this  was  related  to  the  release  of  thromboplastic 
substances  from  the  injured  brain.  They  also  demonstrated  a  significant 
reduction  in  PT  and  APPT  on  the  first  postoperative  day.  This  group 
suggested that there was evidence of reduced activation of coagulation and 
increased  fibrinolysis  in  those  patients  who  subsequently  suffered  an 
intracranial  haematoma  following  surgery  compared  with  the  non- 
haematoma group.
Palmer(Palmer  et  al.,  1995)  reports  the  use  of  TEG  to  identify 
hyperfibrinolysis  in  a  case  report  of  a  brain  tumour  resection  and  its 
successful  treatment  with  aprotinin.  The  demonstration  of  intraoperative
152fibrinolysis  by  TEG  was  paralleled  by  an  increase  in  tPA  in  the  jugular 
venous samples.
Tsujiguchi  and  colleagues(Tsujiguchi  et al.,  1998)  report the  use of TEG  in 
examining  the  effect  of  local  anaesthetic  infiltration  prior to  scalp  incision. 
They  demonstrated  that  hypercoagulation  in  TEG  indices  was  observed 
following  the  incision,  but that this  could  be  prevented  by the  prior  use  of 
bupivacaine.
Fujii  et  al(Fujii  et  al.,  1994)  performed  haemostatic  studies  on  8  patients 
undergoing clipping of unruptured intracranial aneurysms in order to assess 
the  influence of intracranial  surgery  itself.  They collected  blood  before  and 
after  induction  of  anaesthesia,  immediately  after  surgery,  6,  12,  24  hours 
and, 2, 3, 5, and 7 days after surgery.
Anaesthesia.  No difference was observed  in any test performed  before and 
after induction of anaesthesia.
Blood  coagulation  system.  The  PT  was  significantly  prolonged  for  2  days 
after surgery compared with baseline value. There was no change in APTT. 
Antithrombin  III  activity gradually decreased after surgery,  reaching its nadir 
2 days after surgery (87.3% of baseline),  but soon  returned to the baseline 
value.  The  fibrinogen  level  started  to  increase  12  hours  after  surgery, 
reached  its highest level 2 or 3 days after surgery (191% of baseline),  and 
decreased  gradually  thereafter.  However,  its  value  remained  significantly 
higher than the baseline study until the end of the study. The TAT level rose 
significantly  immediately  after  surgery,  then  gradually  diminished,  and 
returned  to  the  normal  range.  Its  level,  however,  remained  significantly 
higher than the baseline value until the end of the study.
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lowest level  24  hours  after surgery  (77.3%),  and  then  gradually  increased, 
becoming  significantly  higher than  the  baseline  value.  On  the  other  hand, 
there  was  no  significant  change  in  a2-antiplasmin  activity  for  3  days  after 
surgery,  however,  significant  increases  (116.5%)  were  observed  5  and  7 
days  postoperatively.  The  PAP  level  became  considerably  elevated 
immediately after surgery and,  after rapidly returning to  baseline,  began  to 
rise  again  3  days  after surgery,  significantly exceeding  the  baseline  value. 
The  D-dimer  and  FDP  levels  rose  significantly  immediately  after  surgery, 
reaching a peak at 6 hours, then gradually decreased to their lowest value 2 
days  after surgery,  and  subsequently  increased  to  a  higher  level  than  the 
initial peak. Their level remained considerably higher than  baseline until the 
end  of the study.  Both  tPA and  PAI-1  levels  increased  significantly  initially 
after surgery, then rapidly decreased and reached baseline values within 24 
hours  of surgery.  No  significant elevations  of tPA and  PAI-1  followed  their 
initial increase.
Platelet  system.  The  platelet  count  increased  slightly  immediately  after 
surgery,  then  gradually  decreased,  reaching  its  nadir 2  days  after surgery 
(81%),  after which  it  rapidly  increased  to  become  significantly  higher than 
baseline.  Both  p-thromboglobulin  and  platelet  factor  4  levels  rose 
significantly  immediately  after  surgery,  rapidly  decreased,  and  returned  to 
baseline  levels  within  24  hours.  They  then  gradually  increased  again, 
becoming significantly higher 7 days after surgery.
154Fibronectin. The fibronectin level gradually decreased after surgery, reached 
its  lowest  level  (71.8%)  24  hours  after  surgery,  and  returned  to  baseline 
within 5 days.
Blood cell counts. The white  blood  cell count (WCC) significantly increased 
immediately  after  surgery,  peaked  at  6  hours  (247%),  then  gradually 
decreased  reaching  baseline  at  5  days.  Although  the  red  cell  count, 
haemoglobin,  and  haematocrit  value  did  not  change  immediately  after 
surgery, they gradually decreased,  reaching their nadir 3 days after surgery 
(80%,  77.3%  and  76.3%),  and  remained  significantly  lower  than  baseline 
values until the end of the study.
The  above  study  provides good  reference data  as  most other neurological 
illness  e.g.  stroke,  brain tumours or trauma,  would  already  be expected  to 
have a haemostatic abnormality before surgery.
The  haematocrit  gradually  decreased  by  23.7%  probably  as  a  result  of 
haemodilution  with  intravenous  fluids.  It  is  generally  accepted  that  the 
concentration  of  platelets,  fibrinogen,  antithrombin  III,  0 2 -antiplasmin,  and 
plasminogen,  change  in  parallel  with  the  fall  in  haematocrit  after 
haemodilution(Fujii  et  al.,  1994).  Thus,  haematocrit  is  an  important 
parameter in assessing changes in haemostatic systems.
Heesen  et  al(Heesen  et  al.,  1997a)  evaluated  the  changes  in  coagulation 
and fibrinolysis in  15 patients undergoing elective brain tumour resection via 
a craniotomy, who were not treated with heparin. They observed a significant 
increase  in TAT at  1   hour,  with  a  maximum  3  hours after the  beginning  of 
surgery.  Returning to baseline on the first postoperative day. A similar time 
course  for  F1  and  2  (also  indicating  coagulation  activation)  was  also
155observed.  These  authors  suggested  that  the  dramatic  increase  in  TAT, 
compared  with  the  observations  of  Fujii(Fujii  et  al.,  1994)  in  aneurysm 
patients, could possibly be explained with the release of thromboplastin from 
the operative site were more brain tissue was transgressed  in  brain tumour 
resection.  D-dimer (activation of fibrinolysis) increased throughout the study 
period  and  was  at  a  maximum  on  the  first  postoperative  day.  Heesen  et 
al(Heesen et al., 1997a) also measured PT and APPT at each time point and 
failed to observe a significant change in these coagulation tests.
It  is  well  known  that  increases  in  the  concentration  of  many  haemostatic 
substances  are  observed  shortly  after  chemical,  inflammatory,  or  physical 
stimulation,  i.e.  the  acute  phase  reaction,  mainly  due to the  interaction  of 
cytokines.  The  acute  phase  reaction  must  be  considered  in  evaluating 
postoperative changes in haemostatic systems.
Iberti and colleagues(lberti et al.,  1994) examined coagulation changes in 20 
neurosurgical  patients  undergoing  brain  tumour  (mostly  benign)  resection. 
Factor  VIII,  IX,  vWF  and  AVP  were  significant  increased  at  the  end  of 
surgery  and  postoperatively.  Bleeding  times  and  APPT  were  significant 
shortened  from  the  time  of  incision,  intra  and  postoperatively.  Serum 
osmolality was  significantly elevated  in  the  neurosurgical  patients from  the 
time of incision. Both factor VIII and vWF are known to be stimulated by AVP 
and increased to the same extent. However, this group of patients were fluid 
restricted  and  haemoconcentrated.  It is  possible that these  measures were 
responsible for the reduction in bleeding times and APPT.
Goobie  et  al.  have  suggested  that  hypercoagulation  occurs  in  children 
undergoing  resective  brain  procedures.  In  25  children  they  suggested  that
156TEG demonstrated hypercoagulation was proportional to the amount of brain 
resected,  perhaps  related  to  thromboplastin  release  from  injured 
brain(Goobie et al., 1999).
The effects of anaesthetic agents on coagulation
There is little evidence in this field.  However, some studies have shown that 
TEG variables tend to have a more hypercoagulable profile when comparing 
general with  regional anaesthesia for the same surgical  procedure, such  as 
caesarean  section(Sharma,  Philip,  1997).  This  study  showed  accelerated 
clot  formation  but  no  change  in  final  clot  strength.  However,  Gibbs  et  al 
showed  no  difference  in  general  compared  with  general  plus  regional 
anaesthetic for abdominal aortic surgery(Gibbs et al., 1994).
Tuman  et  al(Tuman  et  al.,  1987)  demonstrated  patients  to  become 
hypocoagulable after induction of general anaesthesia compared to their pre­
anaesthetic state using TEG variables. The authors suggested that, this may 
be explained by a decreased level of stress and lower serum catecholamine 
levels,  than  compared  to  the  unanaesthetised  preoperative  state. 
Additionally,  some  general  anaesthetics  have  been  shown  to  have  direct 
effects on blood coagulation, especially platelet function. Propofol appears to 
have  little effect on  coagulation  but significantly  increases fibrinolysis when 
assessed in vitro with TEG analysis(Kohro et al., 1999).
The effects of intravenous fluids on coagulation
The crystalloid versus colloid debate continues as to which fluid provides the 
best means of fluid resuscitation(Alderson et al., 2000;  Hillman et al.,  1997). 
There  is extremely strong evidence that the different crystalloid  and  colloid 
solutions  used  for  intravenous  fluid  replacement  have  very  definite  and
157repeatable effects  on  coagulation  and  fibrinolysis.  A full  discussion  on  this 
topic can be found in experimental study 6.
Gender differences and haemostasis
Profound differences in haemostatic responses at rest and  in  response to a 
specific systemic stress  have  been  reported  as a direct result of gender.  A 
full discussion of this topic can be found in control study 2.
Immobilisation
Patients with SAH are confined to strict bed rest following the ictus, and for 
some  considerable time following  treatment.  During  immobilisation  there  is 
venous stasis due to a lack of the calf muscle pump effect as well as venous 
stagnation in intra-abdominal organs(lnci et al., 1995).
Risk factors for thrombosis
Virchow  postulated  3 groups of causes of thrombosis;  reduced  blood  flow, 
changes  in  the  vessel  wall,  and  changes  in  blood  composition(Virchow, 
1856).  However,  clinically  thrombosis  is  multifactorial  with  genetic, 
environmental and behavioural risk factors(Rosendaal, 1999)(Table 20).
Deep vein thrombosis  (DVT) and  pulmonary embolus (PE) are appreciable 
causes  of  morbidity  and  mortality  in  surgical  patients(Bynke  et  al.,  1987; 
Iberti  et  al.,  1994;  Lazio,  Simard,  1999).  Those  patients  undergoing 
neurosurgery constitute one of the  high  risk groups for the development of 
venous thromboembolism(Hamilton  et al.,  1994;  Inci  et al.,  1995;  Stephens 
et  al.,  1995).  Factors  responsible  for  this  include  long  operative  times, 
release  of  brain  thromboplastic  substances  during  surgery,  prolonged 
postoperative  bed  rest  or  immobile  limbs  due  to  neurological  deficit,  high
158dose glucocorticoid treatment and dehydrating osmotic treatment(Frim et al., 
1992).
Deep  vein  thrombosis  (DVT)  in  the  calf  veins  of  patients  undergoing 
neurosurgery  was  estimated  at  an  incidence  of  19-50%(Agnelli,  1999),  as 
measured by radiolabelled fibrinogen testing. Clinically evident DVT occurred 
in  2.3%  of  523  patients  admitted  to  a  combined  neurology-neurosurgery 
service,  1.8% of these patients developed pulmonary embolus diagnosed by 
lung  scan  and  angiography(Agnelli  et  al.,  1998).  Mortality  from  pulmonary 
embolus  ranges from 9 to  50%(Macdonald  et al.,  1999).  The safety of low 
dose  subcutaneous  heparin  for  DVT  prophylaxis  in  a  broad  range  of 
neurosurgical  procedures  has  been demonstrated (Agnelli  et al.,  1998;  Frim 
et  al.,  1992;  Hamilton  et  al.,  1994;  Macdonald  et  al.,  1999),  but  not  its 
effectiveness.  The  safety  of  the  newer,  more  effective  direct  thrombin 
inhibitors, such as recombinant hirudin(Eriksson et al.,  1996; Eriksson et al.,
1997)  has not been shown in a neurosurgical population.
Other prothrombotic conditions
Factor V Leiden mutation, or hereditary resistance to activated protein C has 
a prevalence of 5% in white persons, with some geographical variation, but is 
virtually absent in Asian and African populations(Dahlback et al.,  1993; Rees 
et al.,  1995). The  presence of other well  recognised  prothrombotic defects, 
such  as  protein  C,  protein  S  and  antithrombin,  have  a  much  lower 
prevalence(Vandenbroucke et al., 2001). These defects all  increase the risk 
of thrombosis  and  have  been  shown  to  be  additive  to  the  risk  of the  oral 
contraceptive pill and HRT in females.
159High  levels  of factor VIII  are  linked  to  blood  groups  other than  O,  which 
accounts in part for the observation that having a blood group other than O, 
increases the risk of venous thrombosis by a factor of about 1.6 in general, 
and by a factor of 3.3 among users of oral contraceptives(Jick et al., 1969).
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Age Antithrombin defeciency Hyperhomocysteinaemia
Previous thrombosis Protein C deficiency Increased factor VIII
Immobilisation Protein S deficiency APC resistance
Major surgery Factor V Leiden
Malignancy Prothrombin 20210A
Oral contraceptives 
Hormone replacement therapy 
Antiphospholipid syndrome 
Myeloproliferative disorders 
Polycythaemia vera
Dysfibrinogenaemia
Table 20. Risk factors for venous thrombosis
161Experimental study 1  
Serial changes in standard haematological and coagulation indices
following SAH
Introduction
A standard full blood count generates a series of haematological indices. The 
Haemoglobin concentration (Hb) is a measure of the amount of this protein 
molecule, specialised to carry oxygen, in a fixed volume of blood. The 
haematocrit (Hct) or packed cell volume is a measure of the volume of the 
cells in a fixed volume of blood. The red cell count (RCC), white cell count 
(WCC), and platelet count (pit), are a measure of the number of red cells, 
white cells, and platelets respectively, in a litre of blood in that individual 
(Table 21).
The prothrombin time (PT) measures the extrinsic system (factor VII) as well 
as factors common to both systems (factors X, V, prothrombin and 
fibrinogen). Tissue thromboplastin (brain extract) and calcium are added to 
plasma. The normal time for clotting is 10-14 seconds. The international 
normalised ratio (INR) is the ratio of the PT to a control PT expressed as a 
fraction. The activated partial thromboplastin time (APTT) measures the 
intrinsic system factors VIII, IX, XI and XII in addition to factors common to 
both systems. Three substances; phospholipid, a surface activator (e.g. 
kaolin), and calcium are added to plasma. The normal time for clotting is 35- 
45 seconds.
162Male  Female
Hb (g/dl)
Hct (PCV) (I/I) 
RCC (x 1012/l) 
WCC (x 10P/I) 
Pit (x 1 CP/I)
PT (s)
APPT (s)
14.0-17.7  12.2-15.2 
0.42 - 0.53  0.36 - 0.45 
4.5-6.0  3.9-5.1 
4.0-11.0 
150 - 400 
10 -1 4  
35 -  45
Table 21. Reference ranges of normal haematological and coagulation 
parameters.
163Methods
This  was  a  prospective,  observational  study  on  67  consecutive  patients 
admitted  with  a  primary  diagnosis  of  SAH  to  the  National  Hospital  for 
Neurology  and  Neurosurgery,  London,  UK,  from  January  2000.  The 
diagnosis  of  SAH  was  confirmed  by  CT,  lumbar  puncture  or  cerebral 
angiography.
There  were  24  males,  median  age  47.5  years  (25-75)  and  43  females, 
median  age  53  years  (23-80)  (Figure  23).  Women  were  preferentially 
represented  in  this  sample  (1.8:1).  Using  the  World  Federation  of 
Neurosurgeons system for grading the admission of SAH patients (Appendix 
I), 37 of the patients were grade 1,11  grade 2, 4 grade 3, 10 grade 4, and 5 
grade  5  (Figure  24  and  Table 22).  The  cause  of the  SAH  was  a  ruptured 
cerebral  aneurysm  in  56  patients,  an  arteriovenous  malformation  in  2,  the 
angiogram was negative in 6, and the cause was undetermined in 3 patients. 
Blood  was  taken  via  a  standardised  technique,  previously  described  in 
control  study  1   for  venous  sampling.  Arterial  sampling  was  performed 
through  a  heparinised  arterial  line.  The  technique  involved  removing  the 
dead space from the line prior to sampling. In this way heparin contamination 
of the sample is avoided.
The  day  of  ictus  (Day  0)  was  taken  to  be  the  day  of  onset  of  severe 
symptoms  (e.g.  headache,  neck  pain,  neurological  deficit,  confusion, 
collapse). Blood was taken at 4 time periods (<48hours, 4-5, 9-10 and  15-16 
days) following the ictus depending on the day of hospital admission, and on 
regular intervals during the hospital stay.  If admission was not within one of 
the time periods above, a sample was taken on the day of admission to the
164National  Hospital.  In  addition,  a  sample  was  taken  at  3  months  from  the 
ictus.  The  time  periods  were  chosen  to  reflect  the  practicality  of  referral 
speed  to  a tertiary hospital,  the  most frequently documented  onset time of 
cerebral vasospasm  (4-9days),  and the first routine outpatient appointment 
following discharge (3 months).
A standard protocol of 3 litres of normal saline, 60mg of nimodipine every 4 
hours for 21  days and simple codeine based  analgesia was followed for all 
patients.
Studies on  haemostasis are often difficult to analyse because of wide inter­
patient  variability  and  a  wide  range  of  normal  values(Chalkiadis,  Gibbs,
1996).  In this study, we have attempted to reduce inter-patient variability by 
collecting control (3 month) and test samples from the same patient i.e. each 
patient is effectively acting as their own control.
At each  time  point a  4  ml  EDTA Vacutainer ™  (Ref.  367839)  sample  was 
taken  for a  FBC  (Hb,  RCC,  WCC,  Pit  and  Hct),  and  a  Vacutainer™  (Ref. 
367914) 0.105M (3.2%) buffered sodium citrate tube for PT, INR, and APTT. 
Arterial sampling
Previous control studies have shown no statistical difference in TEG analysis 
performed  on  arterial  and  venous  samples  from  the  same  patient 
sequentially(Spiess et al., 1987).
In addition, to exclude any contamination effect from the heparinised arterial 
line,  we  compared  the  citrated  sample  collected  after  removing  the  dead 
space  using  Heparinase  modified  TEG  and  the  unaltered  sample,  tested 
sequentially  through  two  channels.  The  technique  of  heparinase  modified 
TEG  removes the effect of any  heparin  present,  and  allows the  underlying
165coagulation pattern to be observed. The output of the two channels can then 
be  compared  and  the  effect  of  any  heparin  present  can  be  assessed. 
Previous studies have shown that heparinase reverses the effect of heparin, 
but has no direct effect on the TEG  profile(Gibbs,  Bell,  1998; Tuman et al., 
1994).  We  observed  no  difference  between  the  unaltered  citrated  sample 
and  the  heparinase  modified  test,  showing  that  there  was  no  heparin 
contamination of the sample. Thus, the technique used to remove the dead 
space from the line was effective. Moreover, our control data had shown that 
there was no systematic difference between the two TEG channels. 
Anaesthetic  and  fluid  replacement  protocol  for  patients  undergoing 
intracranial surgery
Patients  received  fentanyl  (3-4  micrograms/Kg),  propofol  (3  mg/Kg)  and 
atracurium  (0.5  mg/Kg)  on  induction.  Maintenance  consisted  of ventilation 
with 50% oxygen and air, with 0-2% sevoflurane and  a remifentanil infusion 
as  required  to  maintain  blood  pressure  at  preoperative  levels.  All  patients 
received  1   mg/Kg  of morphine  at the end  of anaesthesia for postoperative 
pain,  and  bolus doses intravenously as  required.  Regular paracetamol  (1  g 
every 6 hours) commenced 6 hours postoperatively.
Intraoperative fluids consisted of 1.5-2 litres of normal saline, with gelofusine 
to maintain a CVP of 10-12 mm Hg.
Thromboembolism prophylaxis
All SAH patients had graduated  pressure TED® stockings for the duration of 
their inpatient hospital  stay.  In  addition,  intermittent external  pneumatic calf 
compression  was  used  intraoperatively  in  all  surgically  treated
166patients(Bynke et al., 1987). No aspirin or subcutaneous heparin prophylaxis 
was given to any patient.
Corticosteroids
Corticosteroids  are  often  administered  preoperatively  to  neurosurgical 
patients.  It has been suggested that hypercoagulability secondary to steroid 
treatment  may  act  synergistically  to  precipitate  intravascular  coagulation. 
This  condition  can  also  increase  the  tendency to  thromboembolism(lnci  et 
al., 1995).
No  corticosteroids  were  given  to  any  patient  in  the  study  as  part  of  the 
routine management of cerebral swelling and oedema.
Exclusions
Patients with  a  known  coagulation  disorder,  on  anticoagulation  medication, 
taking the oral  contraceptive  pill,  or in  whom  the  day of ictus  could  not  be 
accurately  stated,  were  excluded.  Any  patient  with  a  history  of  trauma 
precipitating  the  event  was  excluded.  Pregnant  and  paediatric  (<16  yrs) 
patients were also excluded.
Ethical approval
All  studies  were  approved  by  the  joint  medical  ethics  committee  of  the 
Institute  of  Neurology  and  University  College  Hospitals  Trust  (Ref.  No. 
99/N037).
Consent
All  patients  or  their  relatives  provided  informed  consent  for  the  study 
(Appendix IV).
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Figure 23. Scatter plot of the age distribution in SAH patients showing 
mean and 95% confidence intervals.WFNS Grade
□ 1  m2  m3 D 4  ■ 5
56%
Figure 24. Pie chart demonstrating the percentage of SAH patients in 
the study admitted in each WFNS grade.
16937 3 25
10 22 10
5 16 19
10 22 2
5 N/R 11
4
Table 22. Summary table of admission and discharge grades for SAH 
patients.
World Federation of Neurosurgeons Grade (WFNS) -  Appendix I
Fisher grade -  Appendix II
Glasgow outcome score (GOS) -  Appendix V
N//R -  not relevant
170Statistical analysis
The first analysis involves a comparison of the 3-month measurement of PT, 
APTT, WCC, Hb, RCC, Hct, and pits, with the first ever measurement 
following the SAH, if that measurement was within 7 days of the ictus. This 
analysis compared the results of 34 patients. A paired t-test and Wilcoxon 
signed rank tests, were used to compare these measurements.
The mean rate of change of PT, INR, APTT, WCC, Hb, RCC, Hct, and pits 
was calculated over the first 21 days following SAH in each of the 67 
patients. The average slopes of each variable were then compared using 
firstly a one-sample t-test, and then subsequently a Wilcoxon signed rank 
test. The latter test was chosen on statistical advice as not all the data was 
normally distributed, and the signed rank test is more robust in this regard. 
For some of the t-tests the log of the value has been taken prior to analysis. 
This is because t-tests assume a normal distribution in the data, and taking 
logs means that the assumption of normality holds more closely. The log has 
no effect on the Wilcoxon signed rank test, which returns the same result, 
whether or not logs are used.
A p value p<0.05 was taken to be significant.
Results
The results show that there were differences in some of the tests depending 
on whether the measurement was taken soon after the SAH, or 3 months 
later. In the coagulation tests, there was a statistically significant difference in 
the PT which was shortened initially following the SAH compared to the tests 
performed at 3 months. There was no difference in the value for APTT (Table 
23, and Figures 25 and 26). Even though PT was shortened, both means lay
171comfortably within the reference range. The mean after the SAH was 11.13 
seconds, and 3 months later it was 12.81  seconds.
It can be seen from Table 25, and Figures 25 and 26, that there is no change 
in PT, INR or APTT in the first 21  days following the ictus, and that all means 
lie within the standard reference ranges.
There are statistically significant differences in WCC, RCC and Hct, between 
the first and 3 month values. The WCC rises acutely initially after the SAH, 
and then remains elevated but does not change over the next 21  days 
(Tables 24 and 26, and Figure 27). The mean WCC value changes from 
11.94 to 7.32 (x 109 /I) from the first to the 3 month assessment.
The RCC falls acutely and then continues to fall at a statistically significant 
rate of 0.005 x 1012 /l/day for the first 21 days following the ictus (Tables 24 
and 26, and Figure 28). The Hct also falls acutely and then continues to fall 
at a statistically significant rate of 0.005 l/l/day for the first 21  days (Tables 24 
and 26, and Figure 30).
Although the haemoglobin concentration is lower following the SAH than at 3 
months, this does not reach statistical significance. However, Hb does fall 
significantly over the first 21 days at a rate of 0.17 g/dl/day (Tables 24 and 
26, and Figure 29).
The platelet count shows an interesting change. There is no statistically 
significant difference between the first and 3 month value (Table 24). 
However, it can be seen from Figure 31, that the platelet count appears to 
fall initially, and then rises acutely up to 21  days at a rate of 14.15 x 109/l/day 
(Table 26 and Figure 32).
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2.41 0.02 2.55 0.024 <0.0001 <0.0001
3.35 0.125 3.36 0.822 0.49 0.4
Table 23. PT and APTT comparing the first assessment following the 
SAH with the value in the same 34 patients 3 months later.
P values are shown using a paired t-test, and Wilcoxon rank sum tests.
1732.48 0.31 1.99 0.28 <0.0001 <0.0001
■
4.37 0.57 4.66 0.56 0.002 0.003
13.27 1.76 13.76 1.33 0.21 0.06
0.39 0.05 0.42 0.04 0.01 0.003
244.9 82.42 250.82 69.63 0.43 0.11
Table 24. WCC, RCC, Hb, Hct, and Pits comparing the first 
measurement made following the SAH with the value in the same 34 
patients 3 months later.
P values are shown using a paired t-test, and Wilcoxon rank sum tests.
1740.0033 0.016 (-) 0.0005 to 0.0072
-0.00002 0.015 (-) 0.003 to 0.003
0.0019 0.031 (-) 0.006 to 0.010
0.0033 0.002 0.09 0.32
-0.00002 0.002 0.99 0.19
0.0019 0.004 0.64 0.41
Table 25. The mean rate of change per day of PT, INR and APTT, in the 
first 21  days following SAH.
SD = Standard deviation 
SE = Standard error
P values are shown using a single sample t-test, and Wilcoxon rank sum 
tests.
175(-) 0.0015 0.035 (-) 0.01 to 0.007
(-) 0.053 0.073 (-) 0.07 to (-) 0.036
(-) 0.171 0.233 (-) 0.23 to (-) 0.12
(-) 0.005 0.007 (-) 0.006 to (-) 0.003
14.15 12.53 11.23 to 17.07
0.004 0.64
O
C
D
(-) 0.053 0.008 <0.0001 <0.0001
(-) 0.171 0.027 <0.0001 <0.0001
(-) 0.005 0.0008 <0.0001 <0.0001
14.15 1.47 <0.0001 <0.0001
Table 26. The mean rate of change per day of WCC, RCC, Hb, Hct and 
Pits, in the first 21  days following SAH.
SD = Standard deviation 
SE = Standard error
P values are shown using a single sample t-test, and Wilcoxon rank sum 
tests.
176PT
Figure 25. Scatter plot of prothrombin time (PT) for each of the first four 
weeks following SAH (1-4).
The mean PT value at 3 months is shown at time period 5 on the x-axis.
The mean and 95% confidence limits are also shown for each time period.
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Figure 26. Scatter plot of activated partial thromboplastin time (APTT) 
for each of the first four weeks following SAH (1-4).
The mean APTT value at 3 months is shown at time period 5 on the x-axis. 
The mean and 95% confidence limits are also shown for each time period.
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Figure 27. Scatter plot of white cell count (WCC) for each of the first 
four weeks following SAH (1-4).
The mean WCC value at 3 months is shown at time period 5 on the x-axis. 
The mean and 95% confidence limits are also shown for each time period.
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Figure 28. Scatter plot of red cell count (RCC) for each of the first four 
weeks following SAH (1-4).
The mean RCC value at 3 months is shown at time period 5 on the x-axis. 
The mean and 95% confidence limits are also shown for each time period.
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Figure 29. Scatter plot of haemoglobin concentration (Hb) for each of 
the first four weeks following SAH (1-4).
The mean Hb value at 3 months is shown at time period 5 on the x-axis. 
The mean and 95% confidence limits are also shown for each time period.
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Figure 30. Scatter plot of haematocrit (Hct) for each of the first four 
weeks following SAH (1-4).
The mean Hct value at 3 months is shown at time period 5 on the x-axis. 
The mean and 95% confidence limits are also shown for each time period.
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Figure 31. Scatter plots of the change in platelet count (Pits) in each 
patient following a SAH.
The 3-month reading for each patient is shown to the left of the X-axis. It can 
be seen that there is a trend for an initial fall after the ictus, followed by a 
significant rise.
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Figure 32. Scatter plot of platelet count (Pits) for each of the first four 
weeks following SAH (1-4).
The mean Pit value at 3 months is shown at time period 5 on the x-axis. 
The mean and 95% confidence limits are also shown for each time period.
184Experimental study 2 
Serial changes in haemostasis using thromboelastography following
subarachnoid haemorrhage 
Hypothesis
'Following SAH there is an undefined period of increased coagulation 
which if present could predispose to ischaemic stroke’ 
Introduction
Thromboelastography  (TEG)  provides  a  comprehensive  documentation  of 
the overall clotting process, from the formation of the first fibrin strands to clot 
dissolution,  thus  time-profiling  the  viscoelastic  properties  of the  blood  clot. 
TEG has never previously been used to investigate haemostasis in SAH.
In SAH,  if rebleeding  is related to hypocoagulability which can  be measured 
by  bench  techniques,  then  pharmacological  manipulation  of  coagulation 
could  be  focussed  on  the  administration  of antifibrinolytic  agents  to  those 
who have not entered the  period of fibrinolytic shutdown. A reduction of the 
early rebleeding risk would allow for delayed surgery and significantly impact 
on  the  outcome  of  haemorrhage.  Conversely,  if  the  period  of 
hypercoagulability  can  be  correlated  to  the  period  when  patients  are  at 
greatest  risk  of  DIND,  then  early  surgery  followed  by  anticoagulation  may 
impact on the outcome.
Methods
As for experimental study 1.
A 3.6ml volume of venous or arterial blood was sampled through a 19-gauge 
needle,  into  a  Vacutainer™  (Ref  367914)  0.105M  (3.2%)  buffered  sodium 
citrate test tube.  Blood  was taken  via  a  standardised technique,  previously
185described  in  control  study  1   for  venous  sampling.  Arterial  sampling  was 
performed through a heparinised arterial line.
A TEG profile performed at 37°C was obtained at each time point.
Statistical analysis
We  have  looked  at  time  trends  in  6  different  TEG  variables,  namely,  R 
(secs),  K (secs),  Angle (deg),  MA (mm), tMA (secs),  and  G  (dyn/cm2).  The 
first analysis  involves  a  comparison  of the  3  month  measurement, with  the 
first ever TEG measurement following the SAH, in the 40 patients in which a 
3  month  measurement was  available.  A  paired  t-test and  Wilcoxon  signed 
rank  tests,  were  used  to  compare  these  measurements.  The  Wilcoxon 
signed rank test was used in addition because some of the data for tMA and 
G was not normally distributed.
The next analysis involved calculating the rate of change of each of the TEG 
variables  over  time  for  the  first  21  days  following  the  SAH.  This  was 
calculated  by  regressing  each  clotting  parameter  in  turn  on  the  time  since 
SAH, for each individual separately. A single sample t-test was used to see if 
the mean rates of change differed significantly from zero. A significance level 
of p<0.05 was taken.
Results
The  results  show  that  there  were  differences  in  all  the  TEG  parameters 
(excluding R), depending on whether the measurement was taken soon after 
the SAH, or 3 months following the SAH (Table 27 and Figures 33 to 38).
The  R time was  unchanged  (Figure  33).  However, there was a  statistically 
significant  reduction  in  K  time  and  tMA  (Figures  34  and  37).  There  was  a 
statistically significant increase in Angle, MA and G (Figures 35, 36 and 38).
186The  mean  rate  of change  of each  of the TEG  parameters over the first 21 
days  following  the  SAH  is  shown  in  Table  28.  The  table  also  shows  the 
standard  deviation  of the  mean  rate  of  change,  and  the  95%  confidence 
interval of the mean rates of change, averaged across all individuals.
It can be seen that again there is no change in R time over the first 21  days 
(Figure  33).  However,  the  mean  K time  is decreasing  by 3.22  seconds/day 
(Figure  34).  The Angle  is  increasing  by 0.74  degrees/day (Figure  35).  The 
MA  is  increasing  by  0.78  mm/day  (Figure  36).  The  tMA  is  decreasing  by 
26.70 seconds/day (Figure 37).  Finally, G  is increasing by 524 dyn/cm2/day 
(Figure 38).  In  Figures 33 to 38, the mean and 95% confidence intervals for 
the mean are demonstrated for the fourth week following the SAH. This is to 
give an  impression of the trend  in these variables over a  longer time scale. 
However,  because there are  much fewer data  points at this time, they have 
not been included in the statistics of the rate of change in the TEG variables, 
which has been confined to the first 21  days.
It  can  be  observed  that  for  each  TEG  variable,  except  R  time,  the  data 
demonstrates a tendency for an increasing hypercoagulable state for the first 
21  days following SAH.
There was no evidence of an age trend in any of the rates of change (p>0.2 
in all cases).
1870.0007 0.0004
0.0004 0.0003
0.0002
1240
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Table 27. Summary statistics of comparison of TEG variables between 
the first ever and 3 month measurements in 40 SAH patients.
For all variables except R time, a tendency to hypercoagulation is found 
immediately following the SAH.
1880.38 30.75 - 6.90 to 7.65 0.41
-3.22 12.35 -6.14 to-0.29 0.001
0.74 2.00 0.27 to 1.21 <0.0001
0.78 0.87 0.57 to 0.98 <0.0001
- 26.70 66.85 -42.52 to-10.8 0.0001
524 573 388 to 659 <0.0001
Table 28. Mean rate of change of each of the TEG variables over the 
first 21  days following the SAH.
The table also shows the standard deviation of the mean rate of change and 
the 95% confidence interval on the mean rate of change for each parameter.
189R time (secs)
Figure 33. Scatter plot of the mean R times for each of the first four 
weeks following SAH (1-4).
The mean R time for 3 months is shown at time period 5 on the x-axis.
The mean and 95% confidence limits are also shown for each time period.
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Figure 34. Scatter plot of the mean K times for each of the first four 
weeks following SAH (1-4).
The mean K time for 3 months is shown at time period 5 on the x-axis.
The mean and 95% confidence limits are also shown for each time period.
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Figure 35. Scatter plot of the mean Angle for each of the first four 
weeks following SAH (1-4).
The mean Angle for 3 months is shown at time period 5 on the x-axis.
The mean and 95% confidence limits are also shown for each time period.
192MA (mm)
Figure 36. Scatter plot of the maximum amplitude (MA mm) for each of 
the first four weeks following SAH (1-4).
The mean MA for 3 months is shown at time period 5 on the x-axis.
The mean and 95% confidence limits are also shown for each time period.
193tMA (secs)
Figure 37. Scatter plot of the time to maximum amplitude (tMA secs) for 
each of the first four weeks following SAH (1-4).
The mean tMA for 3 months is shown at time period 5 on the x-axis.
The mean and 95% confidence limits are also shown for each time period.
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Figure 38. Scatter plot of shear elastic modulus strength G (dyn/cm2) 
for each of the first four weeks following SAH (1-4).
The mean G at 3 months is shown at time period 5 on the x-axis.
The mean and 95% confidence limits are also shown for each time period.
195Experimental study 3 
Serial changes in plasma coagulation and fibrinolytic markers following
subarachnoid haemorrhage
Introduction
Thrombin-antithrombin  III  complex  (TAT)  and  prothrombin  fragment  1+2 
(F1+2) are markers of activation of the coagulation system. Thrombin results 
from  the  proteolysis  of  prothrombin  by  factor  Xa  into  thrombin  and  the 
fragments  F1  and  2.  Subsequent to  its generation, thrombin  is  inhibited  by 
antithrombin  III,  with  which  it  forms  an  irreversible  stable  complex  (TAT). 
Though the immunochemical determination of prothrombin fragments F1+2 it 
is possible to quantify exactly the amount of thrombin formed.
D-dimer  and  plasmin-antiplasmin  (PAP)  complex  are  indicators  of 
fibrinolysis.  D-dimer rises after fibrinolysis of cross-linked fibrin. The removal 
of  polymerised  fibrin  from  the  vascular  system  by  proteolytic  degradation 
(fibrinolysis)  is  important for  maintaining  the  haemostatic  balance.  The  key 
enzyme  in  the  system  is  plasmin.  An  elevation  of  plasmin-antiplasmin 
complex in the plasma is caused by an excess of plasmin generation.
During  early  clot  formation,  thrombin  is  activated  cleaving  fibrinopeptides 
from the soluble plasma protein, fibrinogen. Molecular polymerisation occurs 
with  formation  of soluble fibrin which  is then  stabilised  with  covalent cross- 
linking by XII la activity to produce an insoluble fibrin clot. The stabilised fibrin 
network  is  immediately  degraded  by  the  fibrinolytic  enzyme  plasmin 
(fibrinolysis).  Under  normal  physiological  conditions,  plasmin  is  rapidly 
neutralised  by  antiplasmin  within  the  region  of the  clot.  A variety of cross- 
linked  fibrin  degradation  products  are  formed  dependent  on  the  extent  of
196fibrinolysis. The smallest fragment is the plasmin resistant species,  D-dimer. 
Detection of D-dimer indicates the sequence of events: thrombin activation, 
clot formation and subsequent clot lysis.
Fibrinogen  is  converted  to  fibrin  by  the  action  of thrombin  and  is  used  to 
evaluate the source of fibrin clot.  Fibrinogen is measured using a clot-based 
assay.
Methods
As for experimental study 1.
Once the TEG  analysis had  been started, the remaining citrated Vacutainer 
sample  was  centrifuged  at  3000  rpm  for  6  minutes  to  remove  the  cellular 
elements.  The  remaining supernatant was then  removed and divided  into 3 
polypropylene  tubes,  taking  care  not  to  disturb  the  cellular  debris,  and 
contaminate the samples. The plasma was then immediately transferred to a 
refrigerator were  it was frozen  and  stored  at -80°C,  until  batch  analysis  of 
samples at a later date.
Thus, frozen  plasma was obtained from 4 time periods (<48hours, 4-5, 9-10 
and  15-16  days)  following  the  ictus  depending  on  the  day  of  hospital 
admission, and on regular intervals during the hospital stay. If admission was 
not within one of the time periods above, a sample was taken on the day of 
admission  to  the  National  Hospital.  In  addition,  a  sample  was  taken  at  3 
months from the ictus.
Assay techniques
Enzyme  immunoassays  were  used  for  the  determination  of  TAT 
(Enzygnost®  TAT  micro,  Dade  Behring,  Marburg,  Germany),  F1+2 
(Enzygnost®  F  1+2  micro,  Dade  Behring,  Marburg,  Germany),  PAP
197(Enzygnost®  PAP  micro,  Dade  Behring,  Marburg,  Germany)  and  D-dimer 
(Dimertest® GOLD STRIPWELL, AGEN, UK).
TAT,  F1+2  and  PAP are  sandwich  enzyme  immunoassays.  During the first 
incubation  step  the  TAT  (or  F1+2  antigen,  or  PAP)  present  in  the  sample 
binds  to  the  antibodies  against  thrombin  (or  F1+2,  or  PAP),  which  are 
attached to the surface of the microfiltration plate.  Unbound constituents are 
then removed  by washing and,  in a second  reaction,  peroxidase-conjugated 
antibodies  to  human  antithrombin  III  (or  F1+2,  or  PAP)  are  bound  to  free 
antithrombin  III  (or  F1+2,  or  PAP)  determinants.  The  excess  enzyme- 
conjugated antibodies are removed by washing, the bound enzyme activity is 
then  determined.  The  enzymatic  reaction  between  hydrogen  peroxide  and 
chromogen  is  terminated  by  the  addition  of  dilute  sulphuric  acid.  The 
resulting  colour  intensity,  which  is  proportional  to the  concentration  of TAT 
(or F1+2, or PAP), is determined photometrically.
The  monoclonal  antibody  DD-3B6  recognises  D-dimer  and  degradation 
fragments  containing  the  D-dimer  epitope.  This  monoclonal  antibody  is 
covalently  bound  to  microtitre wells.  When  exposed  to  plasma or standard, 
this capture antibody immobilises fragments containing the D-dimer epitope. 
The  EIA  plate  is  then  washed.  Tag  antibody  (DD-1D2),  conjugated  to 
horseradish peroxidase is added and binds to immobilised cross-linked fibrin 
degradation product fragments. Colour is developed by addition of substrate, 
enabling cross-linked fibrin degradation product quantitation.
The Clauss fibrinogen assay was performed on a Sysmex CA-1500 analyser 
against an immunocoagulation reference plasma.
198Statistical analysis
The  first  analysis  involves  a  comparison  of the  3-month  measurement  of 
TAT,  P1  and  2,  D-dimer,  PAP  and  fibrinogen,  with  the  first  ever 
measurement following the  SAH,  if that measurement was within  7  days of 
the  ictus.  This  analysis  compared  the  results of 28  patients.  A paired  t-test 
and Wilcoxon signed rank tests were used to compare these measurements. 
The  mean  rate  of change  of TAT,  P1  and  2,  D-dimer,  PAP  and  fibrinogen 
was  calculated  over  the  first  21  days  following  SAH  in  each  of  the  67 
patients.  The  average  slopes  of  each  variable  were  then  compared  using 
firstly  a  one-sample  t-test,  and  then  subsequently  a  Wilcoxon  signed  rank 
test. The latter test was chosen on statistical advice as not all the data was 
normally distributed, and the signed rank test is more robust in this regard. 
For some of the t-tests the log of the value has been taken prior to analysis. 
This is because t-tests assume a  normal distribution  in the data,  and taking 
logs means that the assumption of normality holds more closely. The log has 
no  effect on  the Wilcoxon  signed  rank test,  which  returns the  same  result, 
whether or not logs are used.
A p value p<0.05 was taken to be significant.
Results
The  results  show  that  there  were  differences  in  the  plasma  assays 
depending on whether the measurement was taken soon after the SAH, or 3 
months  later  (Table  29,  and  Figures  39  to  43).  Statistically  significant 
increases  were  observed  in  TAT  complex,  D-dimers,  PAP  complex  and 
fibrinogen,  soon  after the SAH.  Prothrombin fragments F1+2 did  not initially 
rise so acutely.
199The normal ranges for these assays are:
TAT complex 1.0-4.1  pg/l
Prothrombin fragments 1 +2  0.4 -1.10 nmol/l
D-dimers <120 ng/ml
PAP complex 120-700 pg /I
Fibrinogen (Clauss) 1.5-4.0 g/l
TAT complex. It can be seen from Figure 39, and Tables 29, 30 and 31, that 
the value for TAT  complex  increases acutely following the  SAH.  It remains 
elevated above the normal range for the next 3 weeks.  However, it does not 
increase  progressively over this time,  and  remains elevated,  but static.  It is 
significantly higher in the first week following the SAH than at 3 months.
In  Figures  39 to 43 the values for the fourth week are illustrated to give an 
impression  of  the  wider  time  scale  of  these  changes.  However,  because 
there  are  relatively few data  points  at this time only the first 21  days  have 
been used to calculate the mean changes in each of the variables. 
Prothrombin  fragments  1+2.  These  fragments  do  not  seem  to  rise  as 
acutely, and the value in the first week is not statistically different from that at 
3 months (Figure 40 and Table 29).  However, by the end of the first week, it 
has  risen  above  the  upper  limit  of  normal  for  the  reference  range.  It 
continues to rise at a statistically significant rate of approximately 2% per day 
for the first 21  days following the SAH (Tables 30 and 31).
D-dimers.  These  fibrin  fragments  rise  acutely  following  the  haemorrhage 
above  the  normal  range.  They  are  statistically  significantly  elevated  in  the 
first  week,  compared  with  the  samples  taken  at  3  months  (Figure  41  and 
Table 29). There is no significant trend however,  in its value over the first 21
200days  (Tables  30  and  31),  and  it  appears  to  remain  elevated  but  relatively 
static.  Some  of the  patients,  as with  other  plasma  markers showed  a  very 
dramatic increase.
PAP complex. The value elevated  acutely and was statistically significantly 
different  in  the  first  week  than  at  3  months  (Figure  42  and  Table  29).  It 
showed  a  highly significant increase  in the first 21  days following the  ictus, 
increasing at an average rate of 35.4 pg /l/day (Tables 30 and 31). 
Fibrinogen (Clauss). A similar finding was observed with fibrinogen.  It rose 
acutely  above  the  normal  range,  being  higher  in  the  first week,  than  at  3 
months  (Figure 43 and  Table 29).  There was a  highly significant rise  in the 
first 21  days of 0.2 g/l/day (Tables 30 and 31).
201zzj
1.423 0.668 1.152 0.649 0.029 0.024
-0.033 0.337 -0.0825 0.278 0.44 0.633
4.483 0.742 3.815 0.77 <0.0001 <0.0001
546.36 258.11 396.28 193.71 0.0159 0.022
3.639 1.148 2.892 0.708 0.005 0.007
Table 29. Comparison of the first measurement taken within the first 7 
days, with the 3 month value for TAT, F1+2, d-dimer, PAP and 
fibrinogen.
Mean and standard deviations are given, along with a p value for a paired t- 
test and a Wilcoxon signed rank test.
2020.0198 0.115 (-) 0.01 to 0.05
0.021 0.065 0.004 to 0.038
0.026 0.117 (-) 0.05 to 0.06
35.4 51.81 21.78 to 49.02
0.195 0.21 0.14 to 0.25
Table 30. The mean rate of change per day of TAT, F1+2, d-dimer, PAP 
and fibrinogen, in the first 21  days following SAH.
SD = Standard deviation
203n=67  I
0.0198 0.015 0.187 0.17
0.021 0.008 0.014 0.0004
0.026 0.015 0.09 0.052
35.4 6.8 <0.0001 <0.0001
0.195 0.027 <0.0001 <0.0001
Table 31. Summary statistics of the mean rate of change of each of 
TAT, F1+2, d-dimer, PAP and fibrinogen in the first 21 days following 
SAH.
SE = Standard error of the mean.
P values are given using a one-sample t-test and Wilcoxon signed rank tests.
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Figure 39. Scatter plot of Thrombin-Antithrombin complex (TAT) for 
each of the first four weeks following SAH (1-4).
The mean TAT value at 3 months is shown at time period 5 on the x-axis. 
The mean and 95% confidence limits are also shown for each time period.
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Figure 40. Scatter plot of prothrombin fragments 1   and 2 (F1+2) for 
each of the first four weeks following SAH (1-4).
The mean F1+2 value at 3 months is shown at time period 5 on the x-axis. 
The mean and 95% confidence limits are also shown for each time period.
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Figure 41. Scatter plot of D-dimer for each of the first four weeks 
following SAH (1-4).
The mean D-dimer value at 3 months is shown at time period 5 on the x-axis. 
The mean and 95% confidence limits are also shown for each time period.
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Figure 42. Scatter plot of plasmin-antiplasmin (PAP) for each of the first 
four weeks following SAH (1-4).
The mean PAP value at 3 months is shown at time period 5 on the x-axis. 
The mean and 95% confidence limits are also shown for each time period.
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Figure 43. Scatter plot of fibrinogen for each of the first four weeks 
following SAH (1-4).
The mean fibrinogen value at 3 months is shown at time period 5 on the x- 
axis.
The mean and 95% confidence limits are also shown for each time period.
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209Experimental study 4 
Does intracranial surgery promote hypercoagulation following SAH? 
Introduction
The  previous  studies  have  shown  that  patients  become  increasingly 
hypercoagulable  following  a  SAH.  In  this  study,  we  have  attempted  to 
investigate  if  surgery  during  this  time  has  an  additive  effect  in  terms  of 
increasing  coagulation.  We  hypothesised  that  the  stress  of  surgery,  pain, 
anaesthesia,  and  brain  manipulation,  perhaps  releasing  thromboplastins, 
may  all  have  promoted  further  hypercoagulation,  and  that  this  would  be 
evident in the rate of change of the TEG parameters following surgery. 
Methods
As for experimental study 1.
Of the 67 patients recruited into this study, 43 had intracranial surgery to clip 
+/-wrap  the  aneurysm  responsible  for  the  subarachnoid  bleed,  and  24 
patients did not receive surgery.
There  is  no  routine  policy  as  to  when  intracranial  surgery  should  be 
performed  on  SAH  patients at the  National  Hospital.  In  general,  patients  in 
good  grade,  with  no  complicating  factors,  following  discussion  with  the 
neuroradiologists  to  assess  if  embolisation  is  more  appropriate,  will  have 
surgery performed  on the  next routinely available operating  list.  Surgery for 
intracranial aneurysms rarely occurs out of normal working hours. Thus, the 
day on which surgery takes place following the SAH is not the same in each 
operated  patient.  The  mean  day on  which  surgery took place following  the 
SAH in this study was 7.7 days (SD 5.12).
210Of  the  43  patients  who  had  intracranial  surgery,  31  had  at  least  2 
postoperative TEG  recordings  distant from the time of surgery (>48  hours) 
but within 21  days following the SAH, and  12 had less than 2 postoperative 
recordings  during  this  time  period.  The  preoperative  reading  and  the  2 
postoperative  readings were used to calculate a trend  in the TEG variables 
for the operated patients. Thus, these trends were calculated on 31  patients. 
Since the  operated  group did  not  include very early times, their trends are 
compared with those calculated for the non operated patients between day 7 
and 21 following the SAH.
Of  the  24  patients  who  did  not  receive  surgery,  7  were  managed 
conservatively,  6  had  suffered  an  angiogram  negative  SAH,  6  had 
undergone coil embolisation of their aneurysm, and 5 had died.
Details  of  the  timing  of  serial  TEG  analysis  have  already  been  given  in 
experimental  study  1.  However,  30 operative  cases also  had TEG  analysis 
performed  on  induction  of anaesthesia,  90  minutes following  ‘knife to skin’, 
and 24 hours following surgery.
Statistical analysis
The first analysis performed was to compare the changes in TEG parameters 
around  the  time  of  surgery  in  30  patients.  The  TEG  variables  were  first 
compared on induction with 90 minutes intraoperatively, then intraoperatively 
with postoperatively, then finally on induction with postoperatively.  Since not 
all of the data was normally distributed a p value has been calculated  using 
Wilcoxon signed rank tests.
A comparison using a Mann Whitney U test was made between the very first 
reading  performed  in  the  non  operated  and  operated  patients.  This was to
211ensure  that  the  groups  were  similar  prior to  surgery,  and  in  particular the 
surgical group had not been selected from the ‘better’ patients.
Then a comparison of the trends i.e. the rate of change of the TEG variables 
per day, was made between the non operated and operated patients using a 
two-sample  t-test  with  equal  variance  and  two-sample  Wilcoxon  rank-sum 
(Mann  Whitney)  test.  The  standard  deviation,  standard  error,  and  95% 
confidence  intervals  on  the  mean  rate  of change  of the TEG  variables  are 
also given.
A p<0.05 was taken as significant.
Results
The first analysis  involved  comparing the TEG variables around the time of 
surgery  in  30  patients  (Table  32).  Because  of the  number  of  significance 
tests caution  is  needed  in  interpreting these findings.  In total  18 tests  have 
been  performed,  and  with  a  p  value  <0.05,  by  random  chance  we  would 
expect one value to be significant.  In addition some of the TEG variables are 
very  closely  related.  Since  no  test  produced  a  strongly  significant  result, 
there is no strong evidence of any particular change.  Between the induction 
of  anaesthesia  and  24  hours  later,  both  MA  and  G  have  increased  with 
borderline  significance.  Most  of  the  change  in  these  variables  has  taken 
place between the intraoperative value and the postoperative test.
When  comparing  the  first  TEG  profile  in  the  non  operated  and  operated 
groups  (Table  33),  it can  be seen that there were  no statistically significant 
differences  between  any  of the  TEG  variables,  suggesting  that the  groups 
were  well  matched  prior to  surgery.  Indeed  the  means for each  variable  in 
the surgical  group are on the  hypercoagulable side compared with the non-
212surgically treated group. Thus, in terms of their coagulation profiles, the ‘best’ 
patients have not been selected out for surgery.
A comparison of the rate of change of the TEG variables per day,  up to 21 
days  following  the  SAH,  between  the  non  surgical  and  surgically  treated 
patients,  shows  that  the  mean  rate  of  change  for  K,  Angle,  MA  and  G  is 
toward the  more  hypercoagulable  in  the  surgically treated  group.  However, 
this does not reach statistical significance for any variable (Tables 34 and 35 
and Figures 44 to 46).
213Immediately  prior  During operation 
to operation
W ithin one day post 
operation
p-value for 
comparing 
prior and 
during
p-salue tor 
comparing 
during and 
after
p-salue Tor 
comparing 
prior and 
after
W ilcoson 
signed rank 
test
Wilcoxon 
signed rank 
test
W ilcoxon 
signed rank 
test
K
(seconds)
K
(seconds) 
Angle 
(degrees) 
M \
(mm)
I NI  \  
(seconds) 
< ;
(dsn cm*)
0.044 0.032
0.099
0.088
0.019
11300 11800 13000 0.012 0.084
0.303 0.307 0.084
Table 32. The changes in TEG variables (R, K, Angle, MA and G) around 
the time of surgery.
SD = Standard deviation 
Prior = On induction.
During = 90 minutes following ‘knife to skin’.
After = 24 hours following surgery.
214503 95 478 103 0.22
112 35.6 101 30.9 0.18
65 7.19 67.3 5.89 0.15
63.5 6.03 65.3 5.66 0.43
1470 300 1300 273 0.37
9150 2930 9830 2680 0.43
Table 33. Comparison of the first TEG profile performed in the non- 
surgically and surgically treated patients.
SD = Standard deviation
215515.5 22.5 468.4 - 562.6 461.5 20.3 420.4 - 502.6
93.7 6.86 79.3-108 85.4 5.68 73.9-96.9
69.3 1.4 66.4 - 72.2 71 1.06 68.8-73.1
68.6 1.63 65.1 - 72 69.8 1.05 67.7-71.9
1202.5 73.5 1048.7-1356.3 1289.9 56.8 1174.8-1405
11928 1088.7 9649.2-14206.7 12497 777.8 10921.3-14073.1
Table 34. Comparison of the mean, standard error (SE), and 95% 
confidence intervals (Cl), for each TEG variable, in the non-operated 
and operated patients.
216-3.36 19.9 2.56 45.6 0.24 0.1
-1.13 6.03 -2.68 17.2 0.63 0.38
0288 1.2 0.689 2.72 0.69 0.38
0.38 1.41 0.565 1.146 0.63 0.51
-28.2 56.7 -34.9 81.8 0.66 0.36
238 839 483 894 0.32 0.67
Table 35. A comparison of the rate of change of each TEG variable per 
day following surgery, with those patients who did not have surgery, 
for the first 21  days following the SAH.
SD = Standard deviation.
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Figure 44. Scatter plot of TEG Angle values for operated and non- 
operated patients
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Figure 45. Scatter plot of TEG MA values for operated and non-operated 
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Figure 46. Scatter plot of TEG G values for operated and non-operated 
patients
220Experimental study 5 
Correlation of Fisher grade, gender and age with thromboelastography 
following subarachnoid haemorrhage
Introduction
Delayed  ischaemic  neurological  deficits  (DIND)  due  to  cerebral  artery 
vasospasm  are  one  of  the  major  complications  that  cause  poor  clinical 
outcome  after  aneurysmal  SAH(Kassell  et  al.,  1990a).  As  has  been 
discussed earlier, the severity of neurological deficits from spasm correlates 
with  the  amount  of  basal  subarachnoid  blood  on  the  admission  CT 
scan(Allen  et al.,  1983;  Fisher et al.,  1980;  Kasuya  et al.,  1998).  Fisher et 
al(Fisher et al.,  1980) stated that when subarachnoid blood was not detected 
on the CT scan, or was distributed diffusely,  severe vasospasm was almost 
never encountered.  However,  in  the  presence  of subarachnoid  blood  clots 
larger than  5 x 3   mm,  of layers of blood  1mm or more thick in the fissures 
and  vertical  cisterns,  severe  spasm  followed  almost  invariably.  They  noted 
an  almost  exact  correspondence  between  the  site  of  major  subarachnoid 
blood clot and the location of severe spasm. They suggested that blood clots 
are especially spasmogenic when they lie along or in contact with the major 
arteries  of  the  circle  of  Willis,  particularly  the  proximal  9  to  10cm  of  the 
anterior and middle cerebral arteries.
Fisher et al(Fisher et al.,  1980) classified  the  subarachnoid  blood  found  on 
CT imaging into four grades: Grade  1, no blood detected; Grade 2, a diffuse 
deposition or thin layer, with all vertical layers less than 1   mm thick; Grade 3, 
localised  clots and/or vertical layers of blood greater than  1mm thick;  Grade
2214, diffuse or no subarachnoid  blood,  but with intracerebral or intraventricular 
clots (Appendix VIII).
Jurus-Dziedzic et al(Jarus-Dziedzic et al., 2000) concluded in a study of 127 
aneurysmal  SAH  patients that the  blood  load  as measured  by Fisher grade 
was  significantly correlated  with  cerebral  blood flow velocity measurements 
using transcranial doppler. These authors found that during the first 21  days 
following  SAH the highest flow velocities were observed  in the Fisher grade 
III  and  II  patients.  Lower values  were  found  in  patients  with  massive  SAH 
(group  IV) and  the  lowest flow velocities were  recorded  in group  I  patients, 
that is those without SAH on the original CT scan.  In addition the number of 
days  for  which  the  mean  flow  velocity  in  the  middle  cerebral  artery  was 
>120cm/s was statically correlated with  blood  load  on  CT imaging  (I,  II  and 
III).  In  all  patients  the  greatest  difference  in  mean  flow  velocity 
measurements were observed  between the 9th  and  14th  day following  SAH. 
The  authors  suggest  that  the  apparent  failure  to  demonstrate  consistent 
trend with  regard to the grade  IV patients could  be explained  by raised  ICP 
and thus decreased cerebral  blood flow in these patients. Similar findings of 
increased  ischaemic deficit and  increased  doppler flow velocities were also 
observed by Grosset et al(Grosset et al.,  1994) in relation to increased blood 
load.  Once again  however,  Fisher grade  IV patients were  not in  agreement 
with  this  trend.  The  authors  suggest that this  may be explained  by the fact 
that intracerebral and intraventricular blood can be present without significant 
volumes of subarachnoid blood.
Fujii  et  al  found  no  significant  relationship  between  the  severity  of 
subarachnoid  clot  and  the  levels  of  fibrinogen,  D-Dimer,  and  thrombin-
222antithrombin complex following SAH(Fujii et al.,  1997). Though in a previous 
study(Fujii  et al.,  1995),  they  had  suggested that the  level of TAT,  D-dimer 
and  PAP  complexes,  were  all  increased  with  the  severity  of  neurological 
status, Fisher grade, and severity of clinical outcome.
However, because heavy CT blood load also correlates with other prognostic 
indicators  such  as,  poor  condition  on  admission,  coexistent  hypertension, 
age and  surgery, the causative  relationship  between  blood  load  and overall 
clinical outcome is complex(Grosset et al., 1994).
In  this  study  we  investigate  whether  haemostatic  parameters  (measured 
using  TEG),  reflect  the  severity  of  CT  findings  of  SAH  (measured  using 
Fisher grade).  If this  is the  case,  then  TEG  may be a  useful  clinical tool  in 
predicting prognosis, and monitoring treatment strategies.
In  addition,  after  observing  differences  in  TEG  parameters  in  a  control 
population  with  respect  to  gender,  but  not  age  (control  study  2),  we  have 
investigated  the  effect  of  these  variables  on  the  haemostatic  response 
following SAH.
223Methods
As for experimental study 1.
Four of the  patients  in  clinical  study  1   did  not  have  a  CT  scan  performed. 
Thus,  this  is  a  prospective  observational  study  in  63  consecutive  patients 
admitted  to  the  NHNN  with  a  primary  diagnosis  of  SAH  confirmed  by  CT 
imaging.
There were 22 males (mean age 50.5 years, SD 15.9) and 41 females (mean 
age  53.4  years,  SD  13.8).  The  cause  of  SAH  was  a  ruptured  cerebral 
aneurysm in 54 patients, an arteriovenous malformation in 2, the angiogram 
was negative in 5, and no angiogram was performed in 2 patients.
Fisher grading of the CT scans was undertaken by myself and independently 
by a consultant neurosurgeon  (Mr.  Neil  D.  Kitchen).  All admission  CT brain 
scans were analysed.
There were 3  Fisher grade  1   patients, 22 grade 2,  16 grade 3 and 22 grade 
4. The first regression analysis showed that there was no difference in TEG 
variables  when  divided  into  4  groups  by  Fisher  grade.  However,  because 
there were  only 3  patients  in  Fisher grade  1,  doubts were  raised  as to the 
significance  of these  findings.  Therefore,  it was  decided  to  group  patients 
before the regression analysis.
Group 1   ‘Good’ grade (Fisher 1   and 2)
Group 2  ‘Poor’ grade (Fisher 3 and 4)
The mean value of the TEG variables R, K, Angle, MA and G were taken for 
the first  14 days following the SAH.  These were compared  in turn with age, 
gender and group, to establish if any correlation existed.
224Statistical analysis
To  compare  for differences,  the  mean  TEG  value  in  the first  14  days was 
regressed in turn for age, gender and group.
A p-value of <0.05 was taken as significant.
Results
The  results  demonstrate  that  for  the  TEG  parameter  R,  there  was  no 
statistically  significant  difference  due  to  group  (F(3,62)=0.88;p>0.05),  age 
(F(3,62)=0.88;p>0.05)  or gender  (F(3,62)=0.88;p>0.05)  (Tables  36,  41  and 
42,  Figure 47).  The  regression  analysis  of K also  showed  a  non-significant 
result  for  group  (F(3,62)=5.07;p>0.05),  and  age  (F(3,62)=5.07;p>0.05) 
however,  the  analysis  showed  a  significant  effect  of  gender 
(F(3,62)=5.07;p<0.01)  (Tables  37,  41  and  43,  and  Figure  48).  Regression 
analysis  of  Angle  also  showed  that  there  was  no  statistically  significant 
difference due to group (F(3,62)=5.84;p>0.05) or age (F(3,62)=5.84;p>0.05) 
but again  gender effects were  found  (F(3,62)=5.84;p<0.01)  (Tables  38  and 
41).
Regression analysis of TEG parameters MA and G also showed no statistical 
difference  due  to  group  (MA:  F(3,62)=3.71;p>0.05  and  G:
F(3,62)=3.65;p>0.05),  and  age  for  G:  F(3,62)=3.65;p>0.05).  There  was  a 
significant  effect  for  age  identified  in  MA:  F(3,62)=3.71;p<0.05.  However, 
both  MA  and  G  showed  a  statistical  difference  due  to  gender  (MA: 
F(3,62)=3.71 ;p<0.05 and G: F(3,62)=3.65;p<0.05) (Tables 39, 40, 41  and 44, 
and Figure 49).
Thus, in summary no association was established between any TEG variable 
and  Fisher grade as represented  by group.  Only MA showed an association
225with  age,  and this was only weakly significant.  However, the TEG variables 
K,  Angle  MA  and  G  in  the first  14  days following  a  SAH  were  significantly 
associated with gender.  In each case the mean value for the female variable 
was hypercoagulable compared to the male value (Table 41, and Figures 48 
and 49).
226Regression Statistics
Multiple R 0.21
R Square 0.04
Adjusted R -0.01
Square
Standard Error 74.63
Observations 63
ANOVA
df ss MS F Significance F
Regression 3 14739.15 4913.05 0.88 0.46
Residual 59 328576.77 5569.09
Total 62 343315.92
Coefficients Standard
Error
tStat P-value Lower 95% Upper
95%
Intercept 444.12 52.52 8.46 9.28E-12 339.04 549.21
age 0.08 0.66 0.12 0.90 -1.24 1.40
Group -2.29 19.44 -0.12 0.91 -41.19 36.62
sex 32.44 19.98 1.62 0.11 -7.53 72.41
Table 36 Analysis of the effects of group, gender and age on the TEG 
parameter R following SAH.
Using p<0.05 to determine significance, regression analysis of R for effects 
of group, gender and age revealed that neither group, gender or age 
produced a significant effect on R (p>0.05).
227Regression Statistics
Multiple R 0.45
R Square 0.20
Adjusted R 0.16
Square
Standard Error 23.43
Observations 63
ANOVA
_______________ df_______SS____________ MS__________ F______Significance F
Regression  3  8351.08  2783.69  5.07  0.003
Residual  59  32392.61  549.03
Total  62  40743.69
Coefficients Standard
Error
tStat P-value Lower 95% Upper
95%
Intercept 80.51 16.49 4.88 8.347E-06 47.51 113.50
age -0.37 0.21 -1.78 0.08 -0.78 0.05
Group 5.51 6.11 0.90 0.37 -6.71 17.72
sex 19.29 6.27 3.08 0.003 6.74 31.84
Table 37. Analysis of the effects of group, gender and age on the TEG 
parameter K following SAH.
Using p<0.05 to determine significance, regression analysis of K for effects 
of group, gender and age revealed that neither group nor age produced a 
significant effect on K (p>0.05).
There was a significant effect of gender on K (p<0.01).
228Regression Statistics
Multiple R 0.48
R Square 0.23
Adjusted R 0.19
Square
Standard Error 4.62
Observations 63
ANOVA
df SS MS F Significance F
Regression 3 373.79 124.60 5.85 0.001
Residual 59 1256.83 21.30
Total 62 1630.62
Coefficients Standard
Error
tStat P-value Lower 95% Upper
95%
Intercept 71.59 3.25 22.04 3.624E-30 65.09 78.09
age 0.08 0.04 1.87 0.07 -0.01 0.16
Group -0.88 1.20 -0.73 0.47 -3.29 1.53
sex -4.19 1.24 -3.39 0.001 -6.67 -1.72
Table 38. Analysis of the effects of group, gender and age on the TEG 
parameter Angle following SAH.
Using p<0.05 to determine significance, regression analysis of Angle for 
effects of group, gender and age revealed that neither group nor age 
produced a significant effect on Angle (p>0.05).
There was a significant effect of gender on Angle (p<0.01).
229Regression Statistics
Multiple R 0.40
R Square 0.16
Adjusted R 0.12
Square
Standard Error 5.70
Observations 63
ANOVA
df SS MS F Significance F
Regression 3 361.72 120.57 3.71 0.02
Residual 59 1915.77 32.47
Total 62 2277.49
Coefficients Standard
Error
tStat P-value Lower
95%
Upper 95%
Intercept 67.15 4.01 16.75 4.345E-24 59.13 75.18
age 0.11 0.05 2.18 0.03 0.01 0.21
Group -0.45 1.48 -0.30 0.76 -3.42 2.52
sex -3.44 1.53 -2.25 0.03 -6.49 -0.39
Table 39. Analysis of the effects of group, gender and age on the TEG 
parameter MA following SAH.
Using p<0.05 to determine significance, regression analysis of MA for effects 
of group, gender and age revealed that group had no significant effect on 
(p>0.05).
There was a significant effect of gender and age on MA (p<0.05).
230Regression Statistics
Multiple R 0.34
R Square 0.16
Adjusted R 0.11
Square
Standard Error 3250.91
Observations 63
ANOVA
df SS MS F Significance F
Regression 3 115631576 38543859 3.65 0.02
Residual 59 623538279 10568445
Total 62 739169856
Coefficients Standard
Error
tStat P-value Lower 95% Upper
95%
Intercept 11637.73 2287.75 5.08 3.966E-06 7059.96 16215.5
age 54.433114 28.75 1.89 0.06 -3.09 111.95
Group -105.93 847.03 -0.13 0.90 -1800.85 1588.98
sex -2159.44 870.16 -2.48 0.02 -3900.64 -418.25
Table 40. Analysis of the effects of group, gender and age on the TEG 
parameter G following SAH.
Using p<0.05 to determine significance, regression analysis of G for effects 
of group, gender and age revealed that neither group nor age produced a 
significant effect on G (p>0.05).
There was a significant effect of gender on G (p<0.01).
231477.3 71.6 509.2 76.7 0.88 0.109
58.7 21.9 109.7 26.9 5.07 0.003
70.1 4.5 65.6 5.1 5.85 0.001
68.9 6.2 65.1 5 3.71 0.03
12219 3723.3 9889.6 2256.9 3.65 0.02
Table 41. Summary of the regression analysis for gender for the TEG 
variables taken within the first 14 days following SAH.
SD = Standard Deviation.
232680
630
580
530
480
430
380
330
280
All Females Males
Mean  Standard  Confidence
________________________________ Deviation_______ Interval
All  488.47  74.41  18.38
Females  477.32  71.62  21.92
Males  509.25  76.71  32.05
Figure 47. Scatter diagram of R for males and females following SAH.
There was no significant difference between males and females for TEG 
parameter R (p>0.05).
Table 42. Summary table of R for males and females following SAH.
The table shows the mean, SD and Cl for All subjects, female subjects and 
male subjects for TEG variable R.
233150
130
110
90
70
50
All Females Males
Mean  Standard  Confidence
_________________________________Deviation_______ Interval
All  96.07  25.64  6.33
Females  88.73  21.94  6.72
Males  109.75  26.87  11.23
Figure 48. Scatter diagram of K for males and females following SAH.
There was a significant difference between males and females for TEG 
parameter K (p<0.01).
Table 43. Summary table of K for males and females following SAH.
The table shows the mean, SD and Cl for All subjects, female subjects and 
male subjects for TEG variable K.
23425000
20000
CM
15000
10000
5000  J
All Female Male
Mean  Standard  Confidence
_________________________________Deviation_______ Interval
All  11405.63  3452.84  852.62
Females  12219.13  3723.25  1139.67
Males  9889.56  2256.90  943.08
Figure 49. Scatter diagram of G for males and females following SAH.
There was a significant difference between males and females for TEG 
parameter G (p<0.05).
Table 44. Summary table of G for males and females following SAH.
The table shows the mean, SD and Cl for All subjects, female subjects and 
male subjects for TEG variable G.
235Discussion
The  study  population  of  sequential  SAH  patients  shows  the  known 
preponderance of this condition in females (1.8:1.0). The median age of SAH 
was similar between the sexes, with males presenting at a slightly earlier age 
(47.5 Vs 53 yrs).
The WFNS breakdown of the study population reflects the nature of a tertiary 
referral  population,  with  this  condition,  in  the  United  Kingdom  at this  time. 
The  study  population  conforms  to  the  recognised  teaching,  that 
approximately  10%  of  cases  of  SAH  have  negative  findings  on  cerebral 
angiography.  The  vast  majority of the  study cohort  (83.6%)  had  suffered  a 
SAH secondary to the rupture of an intracranial cerebral aneurysm.
In  the  studies,  I  have  taken  serial  measurements  of  haemostatic  and 
haematological  variables around the time  period when  it is  recognised that, 
the  symptoms  of vasospasm  present  most frequently  (5-12  days  following 
SAH).  Because  of  wide  variations  of  haematological  variables  in  control 
populations,  I  have  taken  a  distant  sample  (3  months),  in  the  studied 
patients.  In  this  way  each  patient  is  effectively  acting  as  his  or  her  own 
control.  The assumption  being that if the  patient was well enough to attend 
the outpatient department at this time, any acute changes in haematological 
variables  as  a  result  of the  SAH,  should  have  returned,  or be  returning  to 
normal for that patient.
Unfortunately,  because of delays  in  presentation, diagnosis,  and transfer of 
patients,  it was  not always  possible to get a  sample within 48  hours of the 
ictus.  In addition, not all patients have presented to the outpatient clinic, for a 
3-month  sample.  This  can  be  explained  by  death,  or  severe  disability  in
236some  of  the  study  cohort,  and  some  patients  chose  for  geographical 
reasons, to be followed up at other units.
By  using  a  standard  method  of  sample  collection,  handling,  and  TEG 
analysis  throughout  the  control  and  clinical  studies,  I  have  reduced  the 
chances  of the  observed  changes  in  haemostasis,  being  due  to  technical 
error.  My  own  and  others  studies  have  demonstrated,  that  the  results 
obtained by TEG analysis are comparable with standard venous and arterial 
sampling(Spiess et al., 1987).
By excluding patients with known coagulopathies, I have attempted to ensure 
that  I  am  observing  the  systemic  changes  as  a  result  of the  SAH  and  its 
treatment,  and  not changes related to an  intrinsic problem with haemostasis 
specific  to  particular  individuals.  SAH  patients  were  not  given  heparin, 
aspirin, other non-steroidal anti-inflammatory medications, or corticosteroids, 
which may have interfered with the haemostatic process during the study.
The TEG  data  shows evidence of increased coagulation following the ictus, 
when  compared  to the  value  3  months  later in the  same  patient.  All  of the 
TEG variables show a hypercoagulable change (K, Angle,  MA, tMA and G), 
except  R.  This  is  an  interesting  finding,  as  the  R  time  is  said  to  provide 
information analogous to that of the routine coagulation tests PT and APPT, 
as  it is the time  until the first fibrin  strands start to form. This suggests that 
these  differences  would  not  have  been  found  using  such  tests.  Thus,  the 
data  provides  evidence  of  an  increased  rate  of fibrin  build  up  and  cross- 
linking  (K  and  Angle),  and  increased  strength  and  stability of the final  clot 
(MA  and  G),  following  SAH.  The  final  strength  of  the  clot  is  particularly 
sensitive to platelet number and function, and fibrinogen concentration.
237In  addition,  the  TEG  data  demonstrates  that  there  is  ever  increasing 
hypercoagulability using these markers, over the first 21  days following SAH. 
This  data  is  highly  significant,  and  once  again  the  only  variable  not 
statistically  changed  over  time,  is  the  R  time.  This  suggests  that  the 
haemostatic process takes a similar time to start to form fibrin in all patients, 
however,  once  it  is  initiated,  it forms  more  quickly,  with  more  cross-linking, 
and platelet-fibrinogen binding, during the first 21 days following SAH.
TEG  has  never  previously  been  used  to  investigate  coagulation  in  SAH. 
Previous  studies  have  suggested  that  comprehensive  haemostatic  assays 
may predict the severity of aneurysmal SAH and the risk of DIND(Fujii et al., 
1997).  It  has  never  been  previously  suggested  that  patients  become 
increasingly  hypercoagulable  in  the  days  following  a  SAH.  A  state  of 
increased  thrombogenicity may increase the  risk of cerebral  ischaemia  and 
infarction, by increasing the incidence of microembolic events.
It  remains  to  be  established  at  what  point  following  a  SAH,  the  trend  in 
coagulation  changes,  and  procoagulant and fibrinolytic markers start to fall. 
Certainly they have fallen by 3 months.  It can be seen that although there is 
an  increase  in  TEG  coagulation  markers  each  week,  the  trends  appear to 
show a reduction in this increase week by week, up to the fourth week.
The plasma assays show similar findings to the TEG data. There is evidence 
of  initiation  of coagulation  and  fibrinolysis  following  the  ictus.  The  markers 
also  show  that  coagulation  and  fibrinolysis  appears  to  be  increasingly 
triggered  each  day,  for the first 21  days following  a  SAH.  Previously  it  has 
been  suggested that these changes show no overall change in the balance 
between  coagulation  and  fibrinolysis.  An  alternative  explanation  is  that
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being  generated.  When  taken  in  conjunction with the TEG  data,  it appears 
that  the  overall  balance  has  swung  in  favour  of  a  hypercoagulable  and 
procoagulant response following SAH.
The fact that TAT does not appear to increase over time at the same rate as 
the  prothrombin  fragments  F1+2,  is  probably explained  by variability  in  the 
TAT  assay.  Taken  in  conjunction  with  other  tests,  there  appears 
overwhelming  evidence  of  increased  thrombin  generation  in  the  weeks 
following  a  SAH.  A  similar  trend  in  TAT  has  been  observed  by  other 
authors(Fujii et al., 1997; Itoyama et al., 1994).
The  results of the fibrinolytic  markers also  provide evidence of the  balance 
occurring  between the opposing  systems.  The  PAP  increases steadily over 
time, but the D-dimer value, although elevated does not increase at the same 
rate.  This  suggests  increased  fibrinolytic  potential,  but  not  increased 
fibrinolysis.  There are  increasing amounts of plasmin generated,  perhaps in 
response to the  increased  thrombin formation.  However,  one can  postulate 
that  this  is  quickly  mopped  up  by  circulating  antiplasmin  and  inactivated. 
Thus,  there  is  no  increase  in  the  concentration  of  D-dimers,  because  the 
inactivated  plasmin  is  unable  to  break  down  fibrin.  Thus,  the  increased 
plasmin generation is controlled.
Similar  trends  have  been  reported  previously  for  D-dimers  following 
SAH(Fujii et al.,  1995; Fujii et al.,  1997; Nina et al., 2001). However, previous 
studies have reported that the PAP level is highest in the first week, and then 
falls very slowly subsequently(Fujii et al.,  1997;  Itoyama et al.,  1994). These
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medications in some patients.
The  increase  in  fibrinogen  may  reflect  the  acute  phase  response.  The 
increased  availability  of fibrinogen  may  be  one  of the  explanations  of the 
increased  clot  strength  demonstrated  using  TEG  (increased  MA  and  G). 
Certainly the increase in these 3 variables follow a very similar time course. 
The increased fibrinogen concentration would increase plasma viscosity and 
increase  the  thrombotic  potential.  Certainly  an  increased  fibrinogen 
concentration  is  a  well-recognised  epidemiological  marker for an  increased 
rate of myocardial infarction, ischaemic stroke and thrombosis. An increased 
fibrinogen gives an increased propensity for fibrin formation. During the acute 
phase  reaction,  there  is  a  diversion  of  synthesis  away  from  somatic  and 
circulating  proteins such  as albumin,  towards acute phase proteins such as 
C-reactive  protein,  haptoglobin,  caeruloplasmin,  a-1  antitrypsin  and 
fibrinogen.  It would  be  interesting to  investigate if the increase  in fibrinogen 
over  time  following  SAH,  was  similar  in  rate  to  the  increase  of  a  non­
coagulation  based  acute  phase  protein  such  as  caeruloplasmin  or  a-1 
antitrypsin.  In this way I could investigate if other mechanisms specific to the 
coagulation  pathways were  responsible for part of the  increased thrombotic 
potential and not just the acute phase response.
The  routine  coagulation  tests  PT,  INR  and  APTT do  not change over time 
following the SAH, and although there is a difference for the PT between the 
first  and  3  month  reading,  its  value  is  still  comfortably within  the  standard 
reference  range.  It appears  that these  tests are  insensitive to the changes 
observed  in  the  TEG  data,  and  in  the  plasma  assays  of  coagulation  and
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are analogous to the  R time  in the TEG  analysis.  The  R time was the only 
TEG  variable  in  which  no  statistically  significant  change  was  observed 
following  the  haemorrhage.  These  results  provide  further confirmation  that 
PT,  INR  and  APTT  are  insensitive  with  regard  to  detecting 
hypercoagulability. A similar trend in  PT and APTT was observed by Nina et 
al(Nina et al., 2001).
The  results  of  the  haematological  indices  from  the  full  blood  count  are 
extremely interesting.  It appears that the aim of treatment i.e.  haemodilution 
and  hypervolaemia  is  comprehensively  achieved  with  the  fluid  regimen 
employed.  The  haematocrit  falls  from  a  mean  value  of 0.39  I/I  in  the  first 
week,  to  0.32  I/I  in  the  third  week  (0.42  I/I  at  3  months).  The  changes  in 
haemoglobin concentration and  RCC fall in line with this haemodilution. The 
platelet  count  initially falls,  presumably  as  a  result  of haemodilution  or the 
consumption  of  platelets  in  the  arrest  of  haemorrhage,  but then  there  is  a 
secondary  thrombocytosis  and  its  level  rises  acutely for  at  least  21  days. 
This biphasic response in the platelet count following SAH has been reported 
previously(Fujii et al., 1997).
It  is  interesting  to  note  that  despite  powerful  evidence  of  haemodilution 
during the first 21  days following the SAH,  both the fibrinogen concentration 
and the platelet count rise abruptly. Also, despite the effects of haemodilution 
on  the  circulating  clotting  factors  and  their  cofactors,  I  have  observed 
powerful evidence of hypercoagulability in the blood samples taken within 21 
days  of  the  ictus.  The  elevated  changes  observed  in  the  plasma  markers
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had been adjusted for haemodilution.
The acute rise in the WCC is another reflection of the acute phase response 
following  SAH.  Its  initial  rise and  very slow decline over the first month  has 
been observed previously(Fujii et al., 1997).
I  have  investigated  the  effect  of  operative  intervention  on  the  trend  of 
increased coagulability following SAH.  It might be expected that the stress of 
surgery, pain, anaesthesia and the release of thromboplastins from the brain 
substance  would  produce  a  further  increase  in  coagulation  profiles(Barrer, 
Ellison,  1977;  Gibbs et al.,  1992). Any further increase in coagulation would 
predispose to thrombosis, and  potential ischaemic outcome.  In the operative 
study,  I  observed  little  change  in  TEG  parameters  around  the  time  of 
surgery.  These  findings  are  consistent  with  those  of  other  authors 
investigating the changes at similar time periods around open abdominal and 
pelvic surgery in the absence of large volume blood loss(Benzon et al., 1994; 
Ng, Lo,  1996a). The only significant difference found was a small increase in 
MA  and  G,  perhaps  indicating  some  enhancement  of  platelet  function  or 
fibrinogen,  during  this  time.  Goh  et  al(Goh  et  al.,  1997)  observed 
hypercoagulation  in  intra  and  postoperative  TEG  samples  in  neurosurgical 
patients.  The  explanation  for this  difference  is  probably the  extent of brain 
resection and amount of thromboplastin released. The group studied by Goh 
et  al  were  undergoing  brain  tumour  resections.  Tuman  et al(Tuman  et  al., 
1987) observed a statistically significant hypocoagulable change in the TEG 
variables  R,  K,  Angle  and  MA on  induction  of anaesthesia, which  I  did  not 
observe.
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TEG  variables  between  the  surgically  and  non-surgically  treated  patients. 
This  suggests  that  surgery  was  not  additive  to  the  profile  of  increased 
coagulation  observed  in  SAH  patients.  However,  the  trend  was  for  the 
surgical  patients to be more hypercoagulable. This may be explained  by the 
fact  that  the  surgically  treated  group  had  a  more  hypercoagulable  initial 
mean when their first TEG sample was performed.
Thus,  I  have  failed  to  identify  a  difference  between  the  surgical  and  non- 
surgically treated  groups.  However,  an  alternative  explanation  for this  may 
be  in  the  mixture  of the  non-operative  patients.  This group  comprises  both 
the  best  (angiogram  negative)  and  worst  (those  treated  conservatively 
because of their poor condition and prognosis) patients in a SAH population. 
It  may  be  that  if  a  pure  perimesencephalic  haemorrhage  population,  or  a 
grade-matched  embolisation  population,  were  compared  with  the  surgical 
group,  then  a  significant  difference  might  have  been  found.  Due  to  a 
limitation  in  numbers,  these  comparisons  have  not  been  possible  in  this 
study.  It  has  been  suggested  that  the  outcome  following  embolisation  is 
better  than  after  intracranial  surgery  for  cerebral  aneurysms,  and  that  the 
risks  of  ischaemia  are  less.  It  is  only  speculative  at  this  time  how  the 
influence  of  these  treatment  modalities  on  coagulation  might  influence 
patient outcome.
It has been suggested by some authors, that there is an association between 
makers of haemostatic activation following SAH and clinical outcome(Fujii et 
al.,  1995;  Fujii  et  al.,  1997;  Itoyama  et  al.,  1994;  Nina  et  al.,  2001; 
Shibahashi,  Yamaura,  1991).  These  authors  have  attempted  to  correlate
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DIND(Fujii  et ai.,  1997;  Itoyama et al.,  1994;  Nina et al.,  2001;  Shibahashi, 
Yamaura,  1991).  Fisher et al(Fisher et al.,  1980) correlated the incidence of 
DIND  and  subsequent  patient  outcome  following  SAH,  to  the  initial  blood 
load on the CT scan using a four point scale. This finding had been repeated 
in  other studies(Allen  et al.,  1983;  Kasuya  et al.,  1998). They hypothesised 
that,  as the amount of blood  increases on  CT  imaging,  so the  incidence of 
vasospasm and DIND also increases.  In my study, I have tried to bring these 
theories together and  correlate the  blood  load  (measured  by Fisher grade), 
with haemostatic activation (measured using TEG).
I failed to show any statistically significant relationship in the present study. 
However,  the  means  for  each  TEG  variable  did  become  increasingly 
hypercoagulable from  Fisher grades  1   through to 3.  Fisher grade 4 patients 
did  not follow this  trend,  and  had  a  mean  value  roughly  between  those  in 
grade 1   and grade 2 for each TEG variable.
Thus,  it  must  be  asked,  have  I  failed  to  show an  association  because  non 
exists,  or  have  I  failed  to  show  it  because  of  a  problem  with  the  study 
design?  Potential  problems  with  the  study  design  are  firstly  that  I  have 
grouped  the  patients,  and  that  each  grade  was  not  equally  represented.  I 
only  recruited  3  grade  1   patients.  In  addition  I  have  grouped  together the 
grade 3 and 4 patients. There is good evidence that grade 4 patients do not 
always  follow  the  outcome  and  ischaemia  trends  associated  with  Fisher 
grading.  It  has  been  suggested  that  the  presence  of  intracerebral  and 
intraventricular blood  is not as bad as widely distributed subarachnoid blood 
(grades 2 and 3), when it comes to predicting ischaemic outcome(Grosset et
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and 3 patients were separated and compared, the mean values for the grade 
2 patients were hypocoagulable for every TEG variable studied, compared to 
the  grade  3  patients.  However,  this  failed  to  reach  statistical  significance. 
This  suggests  that  a  difference  may  be  present,  but  that  I  have  failed  to 
recruit enough patients to find statistical significance.
The  study  of SAH  patients  has  also  found  further evidence to  support the 
findings  of  Gorton  et  al(Gorton  et  al.,  2000),  that  TEG  can  identify  sex 
differences in coagulation. This is also in agreement with the data acquired in 
my  control  studies  (control  study  2).  The  results  of  the  study  show  that 
females and males differed in their TEG values when sampled within 14 days 
of a  SAH.  As  with  the  control  data  no  difference was observed  for R time. 
This  suggests that the first fibrin  strands are generated  at the  same  rate  in 
males  and  females.  However,  for  all  the  other  variables  studied,  females 
were  more  procoagulant  than  males.  Thus,  following  a  SAH,  females  had 
faster rates of fibrin build-up and cross-linking and enhanced overall final clot 
strength.  These  results  mirrored the control data.  These findings lend  more 
support  to  the  idea  that  males  and  females  differ  in  their  coagulation 
activation and formation. These changes are presumably under some form of 
hormonal influence.  Further discussion of these findings can be found earlier 
in control study 2.  It has not been previously suggested that females may be 
at greater  risk  of thrombosis  and  cerebral  ischaemia following  SAH  due  to 
increased coagulation, but these findings warrant its further investigation.
I  have  not  shown  any  significant  variation  in  the  coagulation  response 
following  SAH  using  TEG  that  is dependent on  the age of the  patient.  It  is
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of  multiple  significance  tests.  This  is  in  agreement  with  our  control  data 
(control study 2).
As  a  consequence  of  the  observational  nature  of  my  data,  it  can  not  be 
excluded that,  part of the associations observed could  be explained  by bias 
and  confounding.  In  these  studies,  patients were  not screened  at entry for 
prothrombotic states.
It  is  interesting  to  speculate  that  the  formation  of  microthrombi  within  the 
small  cerebral  vessels,  associated  with  vasospasm  and  hypercoagulability, 
could  predispose  to  DIND  and  ischaemic  symptoms  in  SAH  patients. 
Potentially  antifibrinolytic,  antiplatelet  or anticoagulant  medications  may  be 
indicated to improve the cerebral  microcirculation at different times following 
the  ictus  and  improve  patient  outcome.  The  role  for TEG  in  directing  this 
management is still to be established.
The  aetiology  of  this  hypercoagulable  change  must  also  remain  highly 
speculative.  It  is  possible  that the  changes  simply  reflect the  acute  phase 
response  to  a  systemic  injury.  Alternatively,  it  may  be  a  response  to  an 
intrinsic  factor  released  by  brain  following  haemorrhage  such  as 
thromboplastin, or blood  breakdown products in the CSF. Another possibility 
is  that  it  is  due  to  factors  specific to  the  cerebral  endothelium.  There  is  a 
focal area of damage to the endothelium at the site of aneurysm rupture, but 
perhaps the histological changes observed in the endothelium of vasospastic 
vessels  also  play  a  significant  part  in  the  activation  of  the  coagulation 
response.  It  must  also  be  considered  whether  the  treatment  protocols 
employed  in  the  management  of  patients  following  SAH,  such  as
246haemodilution  or  bed  rest,  may  also  be  contributing  to  the  observed 
coagulation changes.
Conclusions
One  of  the  difficulties  in  studying  hypercoagulability  is  the  requirement  to 
perform  specific  factor  assays  to  document  its  presence.  This  is  time 
consuming  and  expensive,  with  the  results  taking  several  hours  or  days. 
Thus,  TEG  appears  to  be  a  useful  alternative  to  identify  and  study 
postoperative  hypercoagulability.  The  technique  is  simple  and  inexpensive, 
and  the  results  can  be  obtained  within  one  hour.  Moreover,  TEG  provides 
additional  information  about  platelet  function  and  the  coagulation  process 
that  cannot  be  obtained  from  individual  factor assays  or routine  laboratory 
coagulation  tests.  Individual  factor  assays  are  still  required  however,  to 
detect  specific  clotting  defects  and  to  determine  the  mechanisms  of 
coagulation changes.
Haemodilution is achieved in SAH patients using a fluid protocol of 3 litres of 
normal saline per day.  Haemoglobin,  red cell count and haematocrit fall to a 
similar degree for the first 21  days following a SAH.
Despite  haemodilution,  platelet  count  and  fibrinogen  concentration  rise 
acutely for the first 21  days following a SAH. The platelet count response is 
biphasic.
SAH  patients  are  hypercoagulable  in  the  period  following  a  SAH  when 
compared with blood samples taken 3 months later in the same patient.
SAH  patients  become  increasingly  hypercoagulable  for  the  first  21  days 
following the ictus.
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processes  are  stimulated  following  a  SAH.  However,  coagulation  is 
proportionally stimulated  to  a  greater extent to tip the  balance towards this 
process for the first 21  days following a SAH.
The routine coagulation assays PT, APTT and INR do not change for the first 
21  days following a SAH.
Operative  intervention  in  the  form  of  craniotomy  and  clipping  of  an 
intracerebral  aneurysm  appears  to  produce  little  change  in  the  baseline 
coagulation process following a SAH.
I  have  failed  to  show  an  association  between  haemostatic  activation 
measured using TEG and Fisher grade following SAH.
There  are  differences  in  the  haemostatic  response following  SAH  in  males 
and females. Female patients show hypercoagulation in TEG variables in the 
first 14 days following a SAH compared to male patients.
Age  appears  to  have  little  or  no  effect  on  haemostatic  mechanisms 
measured using TEG following SAH.
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The in vitro effects of haemodilution with crystalloid and colloid 
solutions on coagulation using thromboelastography 
Introduction
Over the last 20-30 years there  has  been  a remarkable improvement in the 
results  reported  after surgery for ruptured  intracranial aneurysms. Operative 
mortality has fallen from over 20% to less than 5%(Hop et al., 1997; Maurice, 
Kitchen,  1994).  However,  despite  considerable  advances  in  diagnostic, 
surgical  and  anaesthetic  techniques,  and  perioperative  management,  the 
outcome for patients with SAH remains poor, with overall mortality rates of at 
least 25%  and  significant morbidity among  approximately 50% of survivors. 
When  more  detailed  outcome  assessments  of  SAH  patients  have  been 
performed  in  structured  studies,  it  is  clear that  very few  patients  return  to 
their level of premorbid function following the ictus(Hop et al., 1998).
Despite  recent  advances  in  diagnosis  and  therapy,  cerebral  ischaemia 
remains  the  greatest treatable  cause  of  morbidity and  mortality  in  patients 
who  survive  the  ictus  and  become  within  the  limits  of  neurosurgical 
care(Mayberg,  1998).
Cerebral  vasospasm  remains  a  devastating  medical  complication  affecting 
30-70%  of  survivors  of  aneurysmal  SAH(AI  Yamany,  Wallace,  1999). 
Cerebral  vasospasm  is the  delayed  narrowing  of large capacitance arteries 
at  the  base  of  the  brain  after  SAH,  often  associated  with  radiographic  or 
cerebral  blood flow evidence of diminished  perfusion  in the distal territory of 
the affected artery.
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delayed  ischaemic  neurological  deficit  (DIND),  which  may  resolve  or 
progress to cerebral  infarction.  In contemporary series,  15% to 20% of such 
patients suffer stroke or die from vasospasm despite maximal therapy(Haley 
et al.,  1992; Longstreth et al.,  1993).  If vasospasm decreases cerebral blood 
flow  below  35ml/100g/min,  brain  tissue  pH  will  decrease,  and  severe 
acidosis is associated with neuronal injury.
A  reduction  in  plasma  volume  following  SAH  may  contribute  to  the 
development  of  cerebral  ischaemia(Hasan  et  al.,  1990).  Therefore,  fluid 
balance management is an essential task(van Gijn, Rinkel, 2001). Avoidance 
of hypotension, hypoxia and hypovolaemia becomes a primary aim.
One  strategy employed  to  prevent  DIND  is  prophylactic volume expansion. 
There is some evidence that this is associated with a reduction in ischaemic 
episodes in the short term following SAH(Rosenwasser et al., 1983), and that 
cerebral  perfusion  can  be  improved  by  a  reduction  in  blood  viscosity 
associated  with  haemodilution(Wood  et  al.,  1984b).  This  may  preserve 
cerebral  blood  flow  and  oxygen  delivery  to  tissues  with  borderline 
viability(Wood et al., 1984a).
Although  moderate  haemodilution  is  thought  to  be  beneficial,  marked 
decreases in haematocrit (below 30%) should be avoided. This is because a 
reduction  in the oxygen carrying capacity of the blood outweighs the benefit 
of  increased  perfusion,  resulting  in  a  decrease  in  cerebral  oxygen 
delivery(Reasoner et al.,  1996).
The  main  determinants  of  blood  viscosity  in  clinical  practice  are  the 
haematocrit  and  shear  rate.  Volume  loading  may  be  accomplished  by
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maintain  the  haematocrit  around  30%.  It  has  become  routine  practice  to 
manage  SAH  patients with  3  litres  of normal  saline every 24  hours,  unless 
there are haemodynamic contraindications.
The  evolution  of  treatment  protocols  for  patients  with  SAH  has  been 
influenced  by  large,  multicentre  prospective,  randomised,  cohort  analyses 
and,  more  recently,  by  multicentre  prospective,  randomised  trials. 
Nevertheless,  several  accepted  treatment  modalities  have  not  been 
substantiated by rigorous clinical scientific assessment.
Several  reports from uncontrolled studies described the resolution of deficits 
from  vasospasm  following  the  elevation  of  blood  pressure,  volume 
expansion,  and  haemodilution,  with  improved  outcome  of  vasospasm 
compared  with  historical  controls(Awad  et  al.,  1987;  Kassell  et  al.,  1982; 
Levy,  Giannotta,  1991;  Muizelaar,  Becker,  1986;  Origitano  et  al.,  1990). 
However,  the  efficacy  of  hypertension/hypervolaemia/haemodilution  (HHH) 
has not been demonstrated  in controlled trials, and studies of cerebral blood 
flow after initiation of therapy have  been  equivocal(Fandino et al.,  1999).  In 
addition studies have not been  performed to determine which component of 
this  therapy  (haemodilution  versus  hypervolaemia  versus  hypertension)  is 
most  important.  Only  a  proportion  of  patients  with  vasospasm  respond  to 
H/H/H  therapy,  with  stroke  and  death  rates  from  vasospasm  approaching 
15% in the series with the best outcome.
Initiation of H/H/H therapy is associated with significant risk, including cardiac 
failure,  electrolyte  abnormalities,  cerebral  oedema,  bleeding  abnormalities, 
and  rupture  of  an  unsecured  aneurysm(Amin-Hanjani  et  al.,  1999).  An
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prophylactically before the onset of symptoms (preferably after clipping of the 
aneurysm).  Treatment  is  usually  continued  beyond  the  period  of  risk  for 
vasospasm  or  until  abatement  of  vasospasm  by  clinical  or  transcranial 
Doppler parameters.
The effects of volume expansion therapy have  not been studied  properly in 
patients with aneurysmal SAH. At present, there is no sound evidence for or 
against  the  use  of volume  expansion  therapy  in  patients  with  aneurysmal 
SAH(Feigin et al., 2000).
In  acute  ischaemic  stroke  the  notion  of  ‘time  is  brain’  has  evolved  in  the 
acute management.  Irreversible ischaemic brain damage evolves over hours 
and  reperfusion can  rescue tissue that is functionally inactive,  but still viable 
(the ischaemic penumbra)(Muir, 2001).
Despite all the available  measures to  prevent and/or treat aneurysmal  SAH 
induced  vasospasm,  it  remains  a  clinical  challenge  for  neurosurgeons, 
intensivists, and neuroradiologists(AI Yamany, Wallace, 1999; Fandino et al., 
1999).
In  this  prospective,  observational,  in  vitro  study,  we  aim  to  ascertain  if 
haemodilution ‘per se’ may have an intrinsic effect on coagulation, specific to 
the dilutent  itself,  and thus  may be contributing to the observed  changes in 
coagulation following SAH.
Methods
Using opportunity sampling,  blood was taken from 20 volunteer subjects:  10 
male  (mean  age  31.4  yrs  SD  5.1)  and  10  female  (mean  age  30.6  yrs  SD 
10.9).
252Citrated whole blood was sampled from each subject.
Method  of  sampling,  exclusion  criteria,  consent  and  ethical  approval  has 
been described previously in control study 1.
A  3.6  ml  volume  of  blood  was  taken  into  a  ‘blue-capped’  Vacutainer 
polypropylene tube,  containing  0.5  ml  of 3.2%  (0.105M) sodium  citrate  (pH 
7.4)  (Vacutainer™  [Ref  367914]).  The  sample  was  immediately  mixed  by 
gentle inversion of the tube 3 times and left to stand at room temperature for 
30 minutes.
Following this time, 4 plain  polypropylene tubes were taken  into which were 
placed:
Tube 1.  0.952ml  CWB
Tube 2.  0.952ml  CWB + 0.408ml 0.9% NS
Tube 3.  0.952ml  CWB + 0.408ml Gelfusion
Tube 4.  0.952ml  CWB + 0.408ml HES
CWB  =  Citrated  whole  blood,  NS  =  Normal  saline,  HES  =  200000/0.5 
Hyd roxyethylstarch.
Thus, a 30%  haemodilution  had  been achieved  in each of tubes 2, 3 and 4. 
All tubes were gently inverted  3 times to mix the contents,  and  left to stand 
for a further 30 minutes at room temperature.
After this time TEG analysis was performed simultaneously on each of the 4 
tubes,  through  4  separate  TEG  channels  in  series.  This  enabled  a  direct 
comparison  of  the  coagulation  profiles  of  each  of  the  4  tubes  in  the  20 
subjects  studied.  The  method  of  TEG  analysis  has  been  previously 
described.
253This  study compares the  TEG  coagulation  profiles  in  an  undiluted  (control) 
sample (Tube  1), with a 30% crystalloid  haemodilution (Tube 2), and a 30% 
haemodilution of two different colloid solutions (Tubes 3 and 4).
The  advantages  of performing  an  in  vitro  study on  healthy volunteers,  are 
that other factors  which  might  of affected  coagulation  in  SAH  patients  are 
excluded, such as: stress, acute phase reaction, anaesthesia, surgery, blood 
loss and endothelial injury.
Statistical analysis
The mean, standard deviation and 95% confidence intervals were calculated 
for each TEG variable in each of the groups.
To  assess  the  effect  crystalloid  and  colloid  haemodilution  on  coagulation, 
multiple  two-sample  paired  t-tests  were  used  for  comparison  of  TEG 
variables between the different groups (Appendix VII).
Results 
R time
The R time is the TEG variable least affected by haemodilution in this study. 
This is interesting as it is the TEG variable most closely associated with the 
value of the  routine coagulation tests  PT and APPT,  and  stops at the  point 
where  the  first fibrin  strands  start to  form  in  the  clot.  It  can  be  seen  from 
Appendix  VII,  Tables  45  to  49,  and  Figure  50  that  the  only  significant 
differences found in R were associated with the Gelfusion sample which had 
a  significantly  shortened  R  time  compared  to  all  other samples.  This  data 
suggests that the  routine tests  PT and APPT would  not have picked  up the 
differences  in  coagulation  profiles  identified  with  TEG  in  the  following 
sections.
254K time
The  K time was significantly shortened  by haemodilution with  normal  saline 
and  Gelfusion,  and  significantly  lengthened  by  haemodilution  with  HES 
(Appendix VII, Tables 45 to 49, and Figure 51).
Angle
The  Angle  was  significantly  increased  with  Gelfusion  haemodilution,  and 
significantly decreased with HES haemodilution. These differences were also 
observed  in  comparison  to the  normal  saline  sample  (Appendix VII, Tables 
45  to  49,  and  Figure  52).  Although  the  saline  dilution  increased  the  mean 
Angle  compared  to the  undiluted  sample,  this  increase was  not statistically 
significant.
MA
All fluids used to provide haemodilution significantly reduced MA. There was 
a  significantly  greater  reduction  with  HES  than  normal  saline,  and  a 
significantly  greater  reduction  with  normal  saline  then  Gelfusion  (Appendix 
VII, Tables 45 to 49, and Figure 53).
Shear elastic modulus G
All fluids used to provide haemodilution significantly reduced G. There was a 
significantly  greater  reduction  with  HES  than  either  Gelfusion  or  normal 
saline haemodilution (Appendix VII, Tables 45 to 49, and Figure 54).
255R K ANG MA G
Mean 658.9 215.8 47.175 57.025 6643.8
Standard Error 27.406 14.964 1.76899 1.12301 353.22
Median 682 215.5 47 56.5 6494.5
Mode #N/A 145 42.5 56.5 6494.5
Standard Deviation 122.56 66.919 7.91114 5.02225 1579.6
Sample Variance 15022 4478.2 62.5862 25.223 2E+06
Kurtosis -0.267 0.3442 -1.13143 0.55856 1.5313
Skewness -0.436 0.6228 -0.08463 0.48273 1.1892
Range 432 269 27.5 20 6101
Minimum 428 115 33.5 48 4524
Maximum 860 384 61 68 10625
Sum 13178 4316 943.5 1140.5 132875
Count 20 20 20 20 20
Confidence Level(95.0%) 57.361 31.319 3.70253 2.35049 739.29
Table 45. Summary of TEG statistics for the undiluted samples (Tube 
1).
256RNS KNS ANGNS MANS GNS
Mean 667.95 193.75 48.625 51.725 5658.7
Standard Error 30.113 9.1921 1.38168 0.7767 220.16
Median 690.5 183 49.5 51 5526.5
Mode 499 180 41.5 49.5 5526.5
Standard Deviation 134.67 41.108 6.17907 3.47349 984.59
Sample Variance 18136 1689.9 38.1809 12.0651 969424
Kurtosis -0.622 0.4779 -0.17508 -0.06148 -0.5
Skewness 0.2733 0.7351 -0.21787 0.63724 0.6886
Range 481 165 24.5 13 3312
Minimum 467 125 35.5 46.5 4346
Maximum 948 290 60 59.5 7658
Sum 13359 3875 972.5 1034.5 113175
Count 20 20 20 20 20
Confidence Level(95.0%) 63.028 19.239 2.8919 1.62564 460.8
Table 46. Summary of TEG statistics for the samples with a 30% 
haemodilution with 0.9% normal saline (NS)(Tube 2).
257R Gel KGEL ANG
GEL
MA GEL GGEL
Mean 607.85 180.7 54.15 54.15 5904.2
Standard Error 18.967 11.826 1.49345 1.02026 255.89
Median 621.5 175 54.5 53.25 5526.5
Mode 667 180 55.5 51 5204
Standard Deviation 84.822 52.887 6.67891 4.56272 1144.4
Sample Variance 7194.8 2797.1 44.6079 20.8184 1E+06
Kurtosis -0.369 1.7473 1.29271 -0.56333 0.8742
Skewness -0.485 1.2258 -0.46691 0.4066 1.0565
Range 310 215 29 16.5 4365
Minimum 441 100 38 47.5 4524
Maximum 751 315 67 64 8889
Sum 12157 3614 1083 1083 118084
Count 20 20 20 20 20
Confidence Level(95.0%) 39.698 24.752 3.12583 2.13542 535.58
Table 47. Summary of the TEG statistics for the samples diluted 30% by 
Gelfusion (GEL)(Tube 3).
258RHES KHES ANG
HES
MAHES G HES
Mean 679.75 238.4 44.825 47.8 4649.2
Standard Error 27.8 11.59 1.35203 0.87389 164.4
Median 668 237.5 44.75 48 4662
Mode 629 215 43 50.5 5101
Standard Deviation 124.33 51.833 6.04648 3.90816 735.2
Sample Variance 15457 2686.7 36.5599 15.2737 540518
Kurtosis 0.6431 0.8303 0.14535 1.80786 2.2666
Skewness 0.2835 0.7376 0.09766 -0.12562 0.5402
Range 516 205 22.5 18.5 3498
Minimum 423 150 33.5 38.5 3130
Maximum 939 355 56 57 6628
Sum 13595 4768 896.5 956 92983
Count 20 20 20 20 20
Confidence Level(95.0%) 58.186 24.259 2.82984 1.82907 344.08
Table 48. Summary statistics of TEG variables for the samples 30% 
diluted with hydroxyethylstarch (HES)(Tube 4).
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Table 49. Summary of t-tests between TEG variables R, K, Angle (A), 
MA and G for undiluted and diluted samples.
1  = Undiluted citrated whole blood
2 = CWB with a 30% haemodilution with 0.9% normal saline
3 = CWB with a 30% haemodilution with Gelfusion
4 = CWB with a 30% haemodilution with HES
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Figure 50. Scatter plots of R values with means and 95% confidence 
intervals for undiluted and diluted samples.
Wb = Citrated whole blood, ns = Normal saline, gel = Gelfusion, hx = 
Hydroxyethyl starch.
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Figure 51. Scatter plots of K values with means and 95% confidence 
intervals for undiluted and diluted samples.
Wb = Citrated whole blood, ns = Normal saline, gel = Gelfusion, hx = 
Hydroxyethyl starch.
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Figure 52. Scatter plots of Angle values with means and 95% 
confidence intervals for undiluted and diluted samples.
Wb = Citrated whole blood, ns = Normal saline, gel = Gelfusion, hx = 
Hydroxyethyl starch.
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Figure 53. Scatter plots of MA values with means and 95% confidence 
intervals for undiluted and diluted samples.
Wb = Citrated whole blood, ns = Normal saline, gel = Gelfusion, hx = 
Hydroxyethyl starch.
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Figure 54. Scatter plots of G values with means and 95% confidence 
intervals for undiluted and diluted samples.
Wb = Citrated whole blood, ns = Normal saline, gel = Gelfusion, hx = 
Hydroxyethyl starch.
265Discussion
The crystalloid versus colloid debate continues as to which fluid provides the 
best means of fluid resuscitation(Alderson et al., 2000; Hillman et al., 1997). 
Commonly used therapeutic fluids
There are 3  body fluid  spaces:  the  intravascular space (IVS), the interstitial 
space  (ISS)  and  the  intracellular space  (ICS).  A colloid  is considered  as  a 
fluid  with  colloid  osmotic  particles  in  a  concentration  usually  the  same  or 
sometimes  higher than  plasma.  It  is thus transmitted  mainly to the  IVS.  A 
crystalloid  solution  is  an  isotonic  solution,  with  approximately  the  same 
sodium  concentration  as  plasma.  It  is  thus  distributed  mainly  to  the 
extracellular space  (IVS  +  ISS).  Crystalloid  solutions  have become the first 
line fluid for resuscitation in most forms of hypovolaemia.
The  ideal  crystalloid  for  use  in  neurosurgery  is  controversial.  Lactated 
Ringer’s  solution  and  0.9%  normal  saline,  both  have  theoretical 
disadvantages,  but there  is  no  patient outcome data to  advocate one over 
the other. Ringer’s solution is mildly hypoosmolar when compared to plasma, 
whereas  0.9%  normal  saline  has  an  osmolarity  of  308  mOsm/l,  slightly 
greater  than  plasma.  If  large  amounts  of  intravenous  fluids  are  required, 
there  may  be  a  significant decrease  in  osmolarity with  the  use of Ringer’s, 
which might contribute to undesirable cerebral oedema. Thus, some authors 
have suggested that its use be limited in neurosurgical procedures. However, 
experimental animal data has shown a survival advantage after resuscitation 
with  Ringer’s  when  compared  with  normal  saline  following  haemorrhagic 
shock. Also,  large volumes of 0.9%  normal saline has been associated with 
the precipitation of a hyperchloraemic acidosis(Williams, 1998).
266Colloid solutions usually have the same colloid osmotic pressure as plasma. 
They are therefore confined  mainly to the  IVS. They are therefore the most 
efficient  fluid  for  resuscitation  during  hypovolaemia,  and  compared  with 
crystalloids, result in little expansion of the ISS.
Because crystalloids have isotonic concentrations of sodium and  no oncotic 
particles, they are distributed equally throughout the whole extracellular fluid. 
Because the ISS comprises at least two-thirds of the extracellular fluid, most 
crystalloid is distributed to the ISS rather than to the circulating volume.
The ICS is the largest fluid space, containing more than half the body’s total 
water.  It  is  separated  from  the  ISS  by  cell  membranes,  which  allow 
potassium  to  enter  the  cells  while  actively  exporting  sodium.  Thus,  salt 
containing  solutions such  as crystalloids are largely excluded from the  ICS. 
Solutions  such  as  5%  dextrose,  which  are distributed  equally over all  body 
fluid  spaces,  can  be  effectively  used  to  rehydrate  the  cell,  because  the 
majority is distributed to that space(Hillman et al., 1997).
Colloids  are  solutions that contain  natural  (albumin) or synthetic  molecules 
(HES  and  dextran)  that  are  relatively  impermeable  to  the  vascular 
membrane. Albumin (molecular weight 66300 to 69000) is the major plasma 
protein  active  in  osmosis  and  is  responsible for 80%  of the  plasma  colloid 
pressure.  Albumin  has  a  half-life  of  16  hours.  Albumin  may  lower  serum 
ionised calcium producing a negative inotropic effect on the myocardium and 
can cause minor changes in PT and APPT.
HES  is  a  synthetic  colloid  derived  from  corn  starch.  It  consists  of  a 
heterogeneous  group of molecules  ranging  in  molecular weight from  under 
10000 to over 1000000.  Because of the heterogeneity of the HES molecule,
267its pharmacokinetic properties are complex. Its disappearance from the body 
is governed  by the extent of hydroxyethylation, and the molecular weight of 
the starch.  Smaller molecules (<50000) will  be readily excreted  in the urine, 
whereas  the  larger  molecules  will  undergo  enzymatic  degradation  before 
elimination.  The  advantages  of  HES  over  other  synthetic  colloid  solutions 
include a lower incidence of side effects and allergic reactions, stability upon 
prolonged  storage,  immediate  availability,  no  dependence on  human  blood 
donation, no risk of sexually transmitted diseases and lower cost.
Dextran  solutions  are  glucose  polymers  fractionated  to  provide  a  low 
molecular weight and a higher molecular weight product.  Dextran 70 has an 
average molecular weight of 70000. The half-life of these solutions increase 
as the  molecular weight  rises.  Dextrans with  a  molecular weight exceeding 
55000, have a half life exceeding 12 hours.
In  recent  years  there  has  been  increasing  awareness  of the  potential  side 
effects of allogeneic blood  products. With  increasing use of artificial  plasma 
expanders,  their  influence  on  blood  coagulation  may  become  clinically 
relevant.  However,  assessing the influence of various plasma expanders on 
blood coagulation  is difficult because the observed effect may be a result of 
an  intrinsic effect of the  plasma expander molecules in addition to an effect 
of haemodilution on coagulation per se(Egli et al., 1997).
Haemodilution  with  intravenous  fluids  will  decrease  the  concentration  of 
clotting  factors  and  platelets  in  the  blood,  and  intuitively  it  would  be 
anticipated  this  should  induce  some  impairment  of  coagulation.  However, 
these  changes  do  not  result  in  increased  bleeding  unless  the  dilution  is 
profound(Mortier  et  al.,  1997).  It  appears  that  the  reserve  capacity  of the
268coagulation  system  is  so  great,  that  dilution  is  of  no  consequence  unless 
large volumes are used.
In  this  study  we  have  compared  the  effects  on  coagulation  of  a  30% 
haemodilution  in  vitro with  a  crystalloid  0.9%  normal saline,  and two colloid 
solutions Gelfusion and HES 200/0.5.
Experimental and clinical evidence of haemodilution on coagulation
Ruttmann  and  colleagues(Ruttmann  et  al.,  1996)  compared  whole  blood 
TEG  with  samples diluted  by 20% with  0.9%  saline, and  a modified  gelatin 
colloid  solution  (Haemaccel).  The  R  and  K times  were  reduced  relative  to 
control  in  both  diluted  groups.  The  angle  was  increased  in  both  groups 
compared  to  control,  while  MA  was  unchanged  in  the  Haemaccel  diluted 
group.  The  authors  concluded  that  haemodilution  per  se  increases  the 
coagulability of whole blood in vitro, but that saline haemodilution had a more 
profound  effect  on  final  clot  strength.  The  mechanism  by  which 
haemodilution may promote coagulation is far from clear.
When  perioperative  blood  loss  is  replaced  partly  with  plasma  expanders, 
impairment  in  haemostasis  may  be  anticipated(Karoutsos  et  al.,  1999). 
Karoutsos  and  colleagues(Karoutsos et al.,  1999)  investigated  the effect of 
different plasma expanders on  coagulation  measured  immediately following 
total hip replacement. They found that the postoperative TEG of patients who 
received  gelatin  as  a  blood  substitute  showed  significant hypercoagulability 
compared with control tracings and with the albumin and HES groups. In this 
study gelatin affected the onset of the clotting process (R, K, and Angle) but 
not  the  clot  strength  (MA).  A  hypothesis  for this  normal  MA  could  involve 
interaction of fibronectin and gelatin, with clot-incorporated gelatin-fibronectin
269complexes  impeding  polymerisation of fibrin. Although TEG demonstrated a 
state  of  hypercoagulability,  no  significant  change  in  standard  tests  of 
haemostasis was observed.  This  in  vivo  study however,  was compromised 
as each  studied  patient was  also given  the crystalloid  Ringer’s lactate,  and 
some patients received subcutaneous heparin.
In vivo work has demonstrated that not all  intravenous fluid  regimens effect 
TEG  coagulation  profiles  in  the  same  way.  Martin  et  al  showed  that  the 
colloids  Hextend  and  Hexpan  were  hypocoagulable  compared  to  the 
crystalloid Ringers lactate(Gan et al., 1998; Martin et al., 1999).
Kapiotis  et  al(Kapiotis  et  al.,  1994)  used  10  healthy  male  volunteers  to 
investigate  the  in  vivo  infusion  of  500ml  HES  200/0.5  or  500ml  human 
albumin  5%  on  coagulation.  After  a  washout  period  of 4  weeks,  subjects 
crossed  over  to  the  alternate  treatment.  Blood  samples  were  taken 
immediately  before  infusion  and  20,  45,  75,  105,  165,  285,  405,  and  1485 
minutes  after  the  infusion  started.  Haematocrit,  fibrinogen,  APPT,  factor 
VIII:C,  TAT  complex,  D-Dimer,  tPA,  uPA,  PAI,  and  PAP  complex,  were  all 
measured.  Except for factor VIII:C  levels,  which  were  significantly  lower  in 
the  HES  200/0.5  group  (the  albumin  group  showed  no  change),  no  other 
significant  differences  in  the  plasma  levels  were  detected  between  the  2 
groups.
During this study, infusion of albumin and HES caused a significant decrease 
in  haematocrit.  This  had  returned  to  normal  by  1485  minutes.  APPT  was 
significantly  prolonged  until  105  minutes.  TAT  levels  significantly increased 
until  105  minutes.  Fibrinogen  levels  fell  for  the  first  45  minutes,  but  had 
almost returned  to  normal  by  1485  minutes.  D-Dimer levels decreased  until
27045 minutes.  The tPA and  uPA levels were decreased until  105 minutes.  No 
change  in  PAP  levels  was  observed.  Plasma  levels  of  PAI  were  reduced 
significantly in both groups at 165, 285, and 405 minutes.
However, in vitro work by Ruttmann and colleagues(Ruttmann, James, 1999) 
has  shown  that  haemodilution  with  0.9%  saline  increased  coagulability  of 
whole  blood,  as  measured  by TEG variables (not MA). The presence of an 
antiplatelet  agent  (aspirin)  had  no  effect  on  this  observation,  and  they 
concluded  that  the  hypercoagulation  was  not  mediated  via  a  cyclo- 
oxygenase  pathway(Ruttmann,  James,  1999).  These  studies  showed  a 
decrease  in  antithrombin  III  with  both  crystalloid  and  colloid  haemodilution, 
and  increased  platelet aggregation  in  the  crystalloid  group,  suggesting that 
both crystalloid and colloid enhanced the consumption of fibrinogen and that 
saline  increased  the  aggregation  of  platelets.  This  effect  was  maintained 
even  after  the  salt  solutions  were  buffered  to  normal  pH  at  37°C  or  the 
addition  of  a  protein  poor  body  fluid  such  as  cerebrospinal  fluid 
(CSF)(Ruttmann et al.,  1999). They concluded that the electrolyte and acid- 
base  composition  of  the  diluting  fluid  had  no  effect  on  the  observed 
hypercoagulability  that  is  produced  with  crystalloid  haemodilution.  They 
suggested that the trigger must be some aspect related to haemodilution and 
not to any biochemical abnormalities in the diluting fluid.
The results with CSF were extremely interesting and showed a procoagulant 
effect  in  excess  of that expected  through  haemodilution. They suggest that 
the  procoagulant effect of CSF  should  arrest bleeding  into this space  more 
quickly than into other body cavities such as the epidural space.
271In  an  earlier study,  Ruttmann  et  al(Ruttmann  et al.,  1998)  investigated  the 
effects  of  haemodilution  with  either  saline  or  HES  (200/0.5),  on  blood 
coagulation in healthy volunteers in vivo. Standard coagulation tests (packed 
cell volume (PCV),  platelets,  PT, APPT, fibrinogen, antithrombin III, bleeding 
time  and  platelet  aggregation)  and  TEG  were  performed  before  and  after 
administration  of either  1000mls of 0.9%  saline or HES, intravenously over 
30 minutes. Dilution of PCV and platelet concentrations as a result of volume 
load were 9%  in the saline group and  19% in the HES group.  Reductions in 
fibrinogen  (18.6% and 28.8%) and  antithrombin  III  (25.5% and 37.8%) were 
significantly greater than could  be explained  by haemodilution alone in  both 
groups.  Indices of platelet aggregation were significantly enhanced by saline 
dilution,  but  not  by  HES,  which  inhibited  epinephrine  induced  aggregation 
and  prolonged  bleeding  time.  TEG  in  the  saline group showed  significantly 
shortened  R and  K times (24% and 26%  respectively), and  increased angle 
(24%) and  MA (6%).  In this study,  HES haemodilution decreased MA (11%) 
but did not affect other TEG variables. The authors concluded that the overall 
procoagulant  response  of saline  haemodilution  could  possibly be explained 
by  enhancement  of  thrombin  formation.  The  evidence  for  this  being  the 
depletion of circulating antithrombin III  levels below what could be explained 
by haemodilution alone.
The mechanisms by which these effects may occur are unknown.  However, 
it is interesting to observe that there may have been a survival benefit for the 
evolution  of  such  a  mechanism.  One  may  speculate  that  when  internal 
haemodilution  occurs  after  blood  loss,  enhanced  coagulability may  prevent 
further haemorrhage in the wild state, and this could offer a survival benefit.
272To avoid the risks associated with transfusion of homologous blood products 
and  to  limit  the  high  cost  of  albumin  solutions,  artificial  colloid  solutions 
represent  an  alternative  for  intraoperative  blood  loss  replacement.  Mortier 
and  colleagues(Mortier  et  al.,  1997)  tested  the  effect  of  profound 
haemodilution  to  50%  of  various  colloid  solutions  and  compared  them  to 
controls  using  TEG.  In  these  extreme  conditions  gelatin  4%  had  no 
significant  effect,  hydroxyethylstarch  prolonged  K  time  and  reduced  angle 
and  MA,  however  dextran  40  10%  had  the  most  profound  effect,  often 
resulting  in  a  straight  line on  the TEG.  Interestingly there was  a  significant 
shortening  of  the  R  time  in  both  the  gelatin  4%  and  hydroxyethylstarch 
preparations  reflecting  increased  intrinsic  coagulation.  Thus,  although  the 
tendency  of  colloids  is  towards  the  hypocoagulable,  not  all  colloids  act 
equally  and  some  products  produce  contradictory  effects  on  different TEG 
variables  at  50%  dilution.  While  haemodilution  obviously  reduces  the 
concentrations  of  platelets  and  clotting  factors,  it  is  perhaps  the  effect  of 
some  colloids  on  platelet  adhesiveness  and  aggregation  that  is  clinically 
more  significant,  or a  reduction  in  the  cross  linkage  of fibrin(Mortier et  al., 
1997).
Egli  et  al(Egli  et  al.,  1997)  compared  in  vitro,  the  effect  of  haemodilution 
(30% and 60%) with saline 0.9%, HES 200/0.5, gelatin and 5% albumin in 96 
patients  using  TEG.  Haemodilution  with  HES,  gelatin,  albumin  and  saline 
resulted  in a similar decrease in haemoglobin concentration. Compared with 
native  blood,  progressive  haemodilution  with  HES,  gelatin  and  albumin  did 
not  affect  the  R  time,  but  compromised  the  rapidity  of  clot  formation,  as 
manifested by an increase in K and a decrease in angle. With HES, this was
273significant  at  30%  haemodilution;  with  gelatin  and  albumin,  significant 
changes were observed only at 60%  haemodilution. The strength of the clot 
(MA)  was  decreased  by  HES,  gelatin  and  albumin  at  30%  and  60% 
haemodilution. Thus, HES had the most negative effect on K, angle and MA. 
Clot lysis at 30 and 60 minutes was not affected by haemodilution. 
Haemodilution  with  saline  at  30%  reduced  R  and  K  time  and  increased 
angle.  At  60%  haemodilution  all  3  variables  recovered.  MA  was
compromised  at  60%  haemodilution,  and  clot  lysis  at  30  and  60  minutes
showed a progressive decrease with increasing haemodilution.
Dextran 40  has  been  studied  in  vitro.  It  has  been  used  clinically to  prevent 
thromboembolism.  It  binds  to  platelets and  preferentially  to  activated
platelets.  It stimulates platelets and increases fibrinogen binding.  It has been 
hypothesised  that  dextran  40  may  exert  a  beneficial
antiplatelet/antithrombotic  effect  in  vivo  by  inhibiting  the  recruitment  of 
activated platelets to the growing thrombus.
HES  is  a  modified  natural  polymer  of  amylopectin  with  volume  expansion 
properties.  Its  physical  and  chemical  characteristics  are  defined  by  the 
degree of hydroxyethylation, which  is the major determinant of plasma  half- 
life,  and  also  by  its  molecular  weight,  which  determines  colloidal  activity. 
Solutions of native  starches are  unstable and  rapidly hydrolysed  by plasma 
amylases.  With  minimal  substitution  of  hydroxyethyl  radicals  on  glucose 
units,  solution  stability  is  excellent,  but  hydrolysis  is  rapid  and  half-life very 
short.  Kinetics  of elimination  is  improved  by  higher substitution(Treib et al., 
1999).
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be  an  important  characteristic  in  determining  their  effects  on  blood 
coagulation  during  haemodilution.  Jamnicki  et  al(Jamnicki  et  al.,  1998) 
compared  the  effects  of  the  recently  developed  HES  solution  with  a 
molecular weight  of  130kD  (HES  130)  compared  with  the  currently widely 
used  HES 200 kD (HES 200) on  in vitro blood coagulation using TEG. They 
compared  control  samples,  with  0.9%  saline dilution  and  blood  diluted with 
HES 130 and HES 200, to achieve 30% and 60% haemodilution. All samples 
were  celite  activated.  Both  HES  solutions  significantly  compromised  blood 
coagulation,  as  seen  by  an  increase  in  R  and  K  time,  and  a  reduction  in 
angle  and  MA.  There was  no  significant  difference  between  HES  130  and 
HES  200  diluted  blood.  When  analysing  the  intrinsic  HES  effect  by taking 
haemodilution  with  0.9%  normal  saline  into  account,  progressive 
haemodilution  with  both  HES  solutions  resulted  in  an  increasing  clot  lysis. 
Again there was no difference in the HES 130 and HES 200 diluted samples. 
Changes with 60% haemodilution were greater than with 30% haemodilution. 
HES decreases platelet adhesiveness and aggregation, and decreases both 
factor VIIIC  and  factor VIII:RC  levels(Egli  et al.,  1997;  Mortier et al.,  1997; 
Strauss,  1981),  it  is  not  surprising  that  dilution  with  this  colloid  causes 
marked changes in the TEG.
In the presence of HES, faster transformation of fibrinogen to fibrin has been 
shown (Carr, Jr.,  1986; Strauss et al.,  1985). The fibrin was shown to be less 
stable  as  evidenced  by  a  shortened  urokinase-activated  clot  lysis  time 
suggesting enhanced fibrinolysis(Carr,  Jr.,  1986;  Strauss et al.,  1985). Also, 
gelatin  has  been  shown  to  be  incorporated  into developing  blood  clots and
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study  both  succinylated  gelatin  (Gelofusine)  and  3.5%  polygeline  solution 
(Haemaccel)  demonstrated  a  reduction  in  clot  weight  and  shear  elastic 
modulus  strength  as  measured  by TEG.  After clot formation  the  remaining 
serum was negative for fibrinogen and  cross-linked  FDPs, suggesting these 
physical  changes  reflect  an  alteration  in  structure  of  the  coagulum  when 
formed  in the  presence of gelatin  colloids.  This was supported  by scanning 
electron  microscopy. The widespread  mesh  pattern of fibrin strands seen  in 
normal  blood  clot  was  retained  in  0.9%  saline  control,  while  this  reticular 
network was  much  reduced  in  clots  containing  gelatin  colloids.  Gelatin  has 
been shown to bind with fibronectin, and polygeline infusion has been shown 
to decrease plasma fibronectin concentrations in vivo. Mardel et al(Mardel et 
al.,  1996) suggested  that gelatin  based  products  may become  incorporated 
into  developing  clots  and  reduce  the  function  of  fibronectin  in  forming 
covalent  cross-linkages  and  normal  covalent  associations  with  fibrin,  thus 
interfering with polymerisation of fibrin monomers.
Jamnicki’s study(Jamnicki et al.,  1998) found no difference in the coagulation 
effects  induced  by the  different  molecular weight  solutions.  However,  HES 
molecules  are  usually characterised  by their degree of substitution  (defined 
as the average number of hydroxyethyl groups per glucose moiety), and their 
C2 to C6 ratio, which describes the ratio of the hydroxyethyl groups situated 
at the C2 and C6 positions of the glucose molecule, in addition to their mean 
molecular  weight.  These  structural  aspects  of  the  HES  molecule  also 
modulate  the  influence  on  blood  coagulation.  The  greater  the  molecular
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a particular solution may compromise coagulation(Konrad et al., 2000). 
Despite  different  molecular weights  of  130  kD  and  200  kD,  no  coagulation 
difference  was  observed.  An  explanation  may  be  that  the  degree  of 
substitution  was  also  minimally  different  (0.4vs  0.5),  and  more  importantly, 
there was  a  significant difference  in the C2 to C6  ratio.  HES  130/0.4  has a 
higher C2 to  C6  ratio (11.2) than  HES 200/0.5  (5.1).  Because a  high  C2 to 
C6 ratio is associated with  an  exaggerated  blood coagulation compromising 
effect,  it  is  conceivable  that the  effects  of a  lesser  mean  molecular weight 
and a higher C2 to C6 ratio of HES  130/0.4 resulted  in a blood coagulation- 
compromising  potency,  similar to the higher molecular weight but in a lower 
C2 to C6 ratio of HES 200/0.5.
In  this  study  30%  haemodilution  with  0.9%  saline  induced  a  significant 
decrease  in  R  and  MA,  and  a  significant  increase  in  angle.  There was  no 
change  in  K compared  with  native  blood.  LY30 was  unchanged,  and  LY60 
decreased  slightly.  However, 60% haemodilution with 0.9% saline induced a 
significant increase in R and  K, and a significant decrease in angle and MA. 
Both LY30 and LY60 decreased compared with native blood.
Using a different measure of coagulation, the Sonoclot, Konrad et al(Konrad 
et  al.,  2000)  compared  the  effect  of  3  different  molecular  weight  HES 
preparations  (70000,  130000,  200000kD).  At  a  33%  haemodilution  all 
preparations interfered with the early stage of coagulation, expressed as clot 
rate.  All  interfered  with  haematocrit,  fibrinogen,  red  cell  and  platelet  count 
equally.  Interestingly,  HES  130000,  showed  a faster clot formation  rate and 
better clot retraction than the other preparations on the Sonoclot.
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HES 70 kD(Jamnicki et al., 2000). They found that low molecular weight HES 
compromised  blood  coagulation  slightly less than  HES 200 however,  it was 
unclear whether this  was  clinically  relevant.  A  slightly  greater compromise 
with  HES  200 was found  for APPT,  factor VIII,  vWF,  MA and  angle on the 
TEG.  No difference was observed  for PT,  fibrinogen,  platelet count,  and  R, 
K, LY30 and LY60 on the TEG.
In  1980,  Janvrin  et  al(Janvrin  et  al.,  1980)  using  a  technique  called  the 
Biobridge, suggested that blood clotted faster when diluted with saline. They 
studied 60 laparotomy patients, 30 received intravenous fluids before, during 
and following  surgery and  30  did  not.  The  patients given  intravenous fluids 
became  significantly  more  haemodilute  and  hypercoagulable.  A deep  vein 
thrombosis was observed  in 30% of patients given  intravenous fluids and  in 
only  7%  of  those  who  were  not.  The  patients  with  DVT  had  significantly 
shorter  coagulation  times  at  the  end  of  surgery  than  the  patients  without 
DVT.
Using TEG,  Heather et al(Heather et al.,  1980) used this finding to propose 
the  ‘saline  dilution  test’.  They  suggested  that  the  degree  to  which  the 
coagulability of an individual patient’s blood increased by such a dilution, was 
directly related to the patient’s risk of developing a postoperative DVT.
As  part  of  this  study(Heather  et  al.,  1980)  a  preliminary  experiment  was 
carried  out  to  determine  the  dilution  at  which  subsequent  coagulability 
measurements should  be performed.  Freshly drawn whole blood specimens 
from a series of preoperative patients were progressively diluted in 3 stages 
with  increasing volume of normal saline,  and the TEG coagulability index of
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Although  there  was  a  large  variation  between  patients  in  the  percentage 
increase in the coagulability index at comparable dilutions, all samples tested 
showed a maximum coagulability at whole blood concentrations of 75-85% of 
normal, which declined with further dilution.
The authors found that the  mean  percentage increase in coagulability index 
shown after dilution of the blood of those patients subsequently developing a 
DVT was  55  +/-  16%.  The corresponding  increase for patients who did  not 
develop  a  DVT  was  19  +/-  11%.  In  8  of  the  10  patients  whose  index 
increased  by more than  30%  after dilution developed  a  DVT, while  none of 
the remaining  10 whose blood showed an increase in the index of less than 
30% did so. The authors suggested that this test might predict the maximum 
potential coagulation to in vivo haemodilution.
HES  is  an  appealing  alternative  to  plasma  protein  fractions  (PPF)  in  the 
treatment of cerebral vasospasm because it has an extended shelf life, is not 
subject to  shortages  that  may  affect the  supply of blood  products,  may  be 
given to  patients who do  not take  blood  products on  religious grounds,  and 
carries no risk of transmitting blood borne diseases. The risk of anaphylactic 
reactions  is  also  very  small.  Trumble  et al(Trumble  et al.,  1995)  compared 
the use of HES and  PPF in the treatment of acute vasospasm in 26 patients 
following aneurysmal SAH in patients who had undergone surgery to clip the 
identified  aneurysm.  Both colloids were administered at a median  rate of 50 
cc/hour.  Post treatment  PT  was  slightly  above  pre-treatment levels  in  both 
groups, whereas platelet and fibrinogen levels revealed no trend. The APPT
279was found to be significantly elevated  in all  patients who received  HES,  but 
was not significantly altered in patients who received PPF.
HES  serves  as  potent  volume  expander,  with  the  initial  intravascular 
component comparable to the  infused volume. This agent decreases serum 
albumin  and  globulin  in  a dilutional  manner.  In the treatment of vasospasm 
the  literature  has  suggested  the  use  of  various  plasma  substitutes  for 
optimum  haemodynamic  and  haemorheological  effects  in  the  cerebral 
circulation.  Previous  studies  showing  a  reduction  in  infarct  size  and 
increased  cerebral  blood flow with these agents(Kroemer et al.,  1987). The 
aetiology  of  this  improvement  is  unclear,  but  suggested  theories  have 
included  haemodilution,  decreased  plasma  viscosity,  increased  cardiac 
output, or a mild elevation of clotting time. The mild elevation of clotting time 
by HES has been ascribed to the precipitation by HES of factor VIII moieties 
i.e.,  procoagulant  factor  VIII,  von  Willebrand  factor,  and  factor Vlll-related 
ristocetin  cofactor(Baldassarre, Vincent,  1997;  Korttila et al.,  1984;  Trumble 
et  al.,  1995).  This  effect  may  not  be  concentration  dependent.  HES  may 
decrease platelet adhesion both by reducing plasma levels of von Willebrand 
factor  and  by  coating  platelet  membranes.  HES  may  also  facilitate 
thrombolysis.  Coagulopathies  induced  by  HES  are  said  to  be  dose 
dependent  and  are  usually  described  with  doses  exceeding  20 
ml/Kg/d(Baldassarre, Vincent, 1997).
San  Fellippo  and  Suberviola(San  Filippo,  Suberviola,  1987)  reported  a 
patient with  cerebral  vasospasm  who  developed  gingival  bleeding  after  10 
days of HES infusion at a rate of 1000 ml/d.
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have  been  reported  from  the  United  States  where  only  the  slowly 
degradable,  high molecular weight form HES 480/0.7 is available for plasma 
volume  expansion.  These  side  effects  appear  to  avoided  by  the  use  of 
medium or lower molecular weight HES that is easier to degrade(Treib et al., 
1999).
Data  collected  in  vivo  suggests  that,  from  a  rheological  perspective,  highly 
substituted  medium  and  high  molecular  weight  HES  are  less  desirable, 
because  they  increase  plasma  viscosity.  Medium  or  low  molecular weight 
starches  with  a  low  degree  of  substitution  and  a  resulting  low  in  vivo 
molecular  weight,  have  better  rheological  properties(Treib  et  al.,  1999).  It 
must also be  remember that when  selecting a colloid consideration must be 
given  to  its  half  life  of  elimination,  especially  if  side  effects  which  are 
potentially life threatening, are likely to occur.
Baldassarre  et  al(Baldassarre,  Vincent,  1997)  described  a  patient  treated 
with  2500ml  of  HES  (450  kD)  over  3  days  for  the  management  of  acute 
cerebral  vasospasm who developed  a  significant coagulopathy. The  patient 
still  had  a  concentration  of  HES  in  the  blood  2  days  after  discontinuing 
therapy.  In this patient, APPT was prolonged, D-Dimers and fibrinogen were 
normal, and factors VIII, XI and XII significantly reduced.
In the past 2 decades,  haemodilution therapy by plasma expanders such as 
dextrans  and  HES  has  become  important  in  the  treatment  of  ischaemic 
stroke.  Dextrans  have  a  wide  range  of  molecular  weights.  Their  clinical 
efficacy is mainly related to plasma expansion by colloid osmotic activity, to a 
molecular  weight  dependent  influence  on  erythrocyte  aggregation,  and  to
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and this  elimination  process  depends  on  molecular weight.  There  is only a 
minor  and  slow  biotransformation  by  dextranase  in  the  spleen  and 
liver(Kroemer et al., 1987).
In the treatment of ischaemic stroke with  haemodilution  long term  infusions 
are  required,  as  the  microcirculation  of  the  penumbra  is  impaired  over 
several days.  Kroemer et al(Kroemer et al.,  1987) investigated the effects of 
the long term  administration of dextran  and  HES. With dextran, the  plasma 
viscosity  increased  and  was  linearly  correlated  with  the  total  plasma 
concentration. With  HES the plasma viscosity fell and was not related to the 
plasma concentration. The haemodiluting effect,  as indicated by a decrease 
of the  haematocrit,  was  22%  and  16.8% for dextran  and  HES  respectively. 
This  data  suggested  that  there  were  several  advantages  in  using  HES 
compared with dextran in the haemodilution therapy for ischaemic stroke. 
Reasons  for  the  described  differences  might  be  the  different  molecular 
attraction  between  fibrin  molecules  and  the  applied  solution.  Another 
explanation  might  be  changes  in  the  polymerisation  process  of fibrin.  HES 
changes  the  fibrin  fibre  mass:length  ratios  and  clot elastic  modulus,  which 
changes the tensile properties of the clot(Konrad et al., 2000).
Preoperative  normovolaemic  acute  haemodilution  (PNAH)  helps  to  reduce 
blood transfusion  requirements in  patients undergoing major surgery.  PNAH 
reduces  mean  packed  cell  volume  (PCV)  leading  to  a  decrease  in  blood 
viscosity.  This  in  turn  increases  blood  flow,  assuming  that  the  Hagan- 
Poiseuille  equation  is  observed.  The  linear decrease  in  PCV  results  in  an 
exponential improvement in the rheological properties of blood, particularly in
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cardiac output despite the dilutional reduction in blood oxygen capacity. As a 
result of dilution,  blood  lost  during  surgery  contains  plasma  substitute,  but 
fewer cells and plasma elements.
Freyburger  et  al(Freyburger  et  al.,  1996)  investigated  the  rheological 
properties  of commonly  used  plasma  substitutes  in  vivo.  They  studied  40 
patients  undergoing  elective  aortic  reconstruction.  The  patients were given, 
4%  human  albumin  (HA),  3.5%  dextran  40  (Dex 40),  6%  dextran  60  (Dex 
60),  6%  hydroxyethylstarch  200  (HES)  or  modified  fluid  gelatin  (Gel)  to 
achieve PNAH to produce a PCV of 30%.  Mean volumes of more than 1000 
ml were  infused.  Blood  samples were obtained  before infusion,  immediately 
after,  and  1.5  hours  after the  end  of haemodilution.  The following  variables 
were  measured:  PCV,  plasma  viscosity,  whole  blood  viscosity,  and 
erythrocyte  aggregation.  The  5  substitutes  had  very different effects on  red 
blood  cell  aggregation  and  low shear  rate  viscosity at corrected  PCV.  Red 
blood  cell  aggregation was  reduced  in the  presence of HA and  Dex 40,  but 
was  increased  moderately  to  markedly  in  the  presence  of  the  other 
substitutes  in  the  following  order:  HES<Dex  60<Gel.  The  influence  on  the 
rheological conditions on tissue oxygenation was assessed by measuring the 
concentration of lactic acid. This was unchanged after PNAH with HA or Dex 
40, but was increased in the presence of HES, Dex 60 or Gel.
Erythrocyte aggregation tends to occur at very low shear rates encountered 
in the venous circulation, where most thrombi occur. In whole blood,  red cell 
aggregation  results  from  cross  linking  of  cells  via  interactions  of  their 
membranes  with  plasma  fibrinogen,  globulins  and  macromolecules.  An
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properties  of  macromolecules,  where  plasma  substitutes  operate)  and 
repulsive forces  (electrical  charges  on the  red  blood cell  surface and  sheer 
stress).  Erythrocyte  aggregation  is  a  complex  variable  because  of  its 
relationship  with  blood  flow.  Thus,  any  variable  modifying  red  cell 
aggregation  may influence tissue perfusion  by slowing down circulation and 
reducing capillary flow. Dex 60 and Gel facilitate red blood cell aggregation in 
vitro by reducing the electrostatic repulsive forces after adsorption onto cell 
membranes.  HES has a less consistent rheological effect with a decrease in 
low  shear  rate  viscosity  at  corrected  PCV  and  no  change  in  aggregation 
time,  in  spite  of  increased  cohesion  of  the  aggregates(Freyburger  et  al., 
1996).
Turkan  et  al(Turkan  et  al.,  1999)  studied  the  effect  of  a  500ml  6%  HES 
infusion,  in  20  patients  undergoing  elective  abdominal  surgery.  Blood 
samples  were  taken  immediately  before  and  after  the  HES  infusion 
approximately  1   hour  prior  to  surgery.  The  following  variables  were 
assessed:  platelet  count,  PT,  APPT,  fibrinogen,  Factor  VIII  and  platelet 
aggregation.  They  observed  a  decrease  in  fibrinogen  concentration,  an 
increase in APPT, and a decrease in factor VIII activity following the infusion. 
The mean maximum platelet aggregations induced by all aggregating agents 
were decreased significantly.
Stimulation  of fibrinolysis  may  be  caused  by enhanced  systemic fibrinolytic 
activity due to an increase in plasminogen activator, a decrease in PAI, or by 
stimulation of fibrin proteolysis caused by the incorporation of HES into fibrin 
clots, a mechanism reported for dextran (Carlin, Bang, 1980).
284The  degree  of  haemodilution  may  be  crucial  to  the  observed  coagulation 
changes. One might hypothesise, that the anticoagulant activity of blood may 
be  compromised  more  than  the  procoagulant  activity  during  moderate 
haemodilution,  resulting  in  a  hypercoagulable  state.  With  advanced 
haemodilution,  procoagulant activity  may become diluted  and the net result 
at profound haemodilution is compromised blood coagulation.
The  results  of  this  study  are  in  broad  agreement  with  previous  reported 
findings.  Interestingly, there was little observed change in R, suggesting that 
routine  coagulation  studies  such  as  PT  and  APPT  would  have  failed  to 
observe the changes in coagulation found with haemodilution using TEG.
The value for K was shortened and Angle increased for Gelfusion and 0.9% 
normal  saline.  These TEG  variables  are concerned with the kinetics of clot 
development.  They are  indication  of the speed  of fibrin  build  up and  cross- 
linking. To this extent both  Gelfusion  and 0.9%  normal saline haemodilution 
is promoting coagulation, with the greatest changes seen with Gelfusion. 
However,  the  measures  of  clot  strength  MA  and  G  are  reduced  with  both 
Gelfusion  and  0.9%  normal  saline.  Thus,  although  both  promote  fibrin 
formation and cross-linking, it appears that the final structure is not as strong 
as  seen  with  undiluted  citrated  whole  blood.  Final  clot  strength  is  closely 
related  to  fibrinogen  concentration  and  platelet  number  and  function.  As 
discussed,  there  is good  experimental  evidence to explain why this may be 
so. Certainly there is strong evidence that Gelfusion and other gelatin based 
colloids  react with  and  bind  to fibronectin,  thus  being  incorporated  into the 
final clot structure, and thus perhaps weakening it. There is also evidence of 
an antiplatelet effect on both adhesion and aggregation.
285HES  200/0.5  was  found  to  be  profoundly  hypocoagulable  in  all  TEG 
variables except the R time. This may be explained by the fact that HES has 
been  shown  to  decrease  platelet  adhesiveness  and  aggregation,  and 
decrease both factor VIIIC and factor VIII:RC levels.
The  clinical  implications  of these  findings  are  potentially very important as 
our results suggest that infusion of crystalloid solutions, the common practice 
in the management of SAH, may increase the risk of ischaemic or thrombotic 
complications in patients already predisposed to these events. It may be that 
alternate fluid  regimens, or combination  regimens should be sort to optimise 
the  management  in  these  patients  to  prevent  secondary  insult.  In  those 
patients  with  symptoms  of  cerebral  vasospasm  it  may  prove  possible  to 
increase  cerebral  perfusion  and  oxygenation  by  changing  patients 
intravenous fluid protocol to promote a hypocoagulable profile.
In addition, when examining clinical studies relating to coagulation changes, 
one must be aware of the fluid regimens that have been used and be wary of 
cases where normal saline has been used for the control population. 
Conclusions
Haemodilution does alter coagulation measured in vitro using TEG.
HES  induces  a  profound  hypocoagulable  change  in  the  haemostatic 
response as measured by TEG.
Gelfusion  and  0.9%  normal  saline  promote the  kinetics of clot development 
and fibrin formation, but ultimately reduce final clot strength.
The coagulation effects observed are not particular to crystalloids or colloids. 
As  has  been  demonstrated  in  this  study,  the  two  colloids  had  strikingly 
different effects on the coagulation profile following haemodilution.
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whole blood and not just plasma, is extremely valuable in studying the effects 
of intravenous fluids on the haemostatic process.
As coagulation variables are dynamic, especially in the perioperative setting, 
extrapolation of our data to the in vivo effects is difficult.
287Summary of control and experimental studies and directions of future
research
I  have  examined  the  use  of  Thromboelastography  (TEG®)  as  an  in-vitro 
bench  test  in  monitoring  the  haemostatic  process.  TEG®  is  a  near-patient 
test  of  coagulation.  It  is  easy  to  perform,  relatively  inexpensive,  and  can 
provide  information  on  a  patient’s  coagulation  status  within  30  minutes. 
TEG®  can  provide  information  on  both  coagulation  and  fibrinolysis  from  a 
single tracing.
Standard  coagulation  assays  such  as  the  Prothrombin  time  (PT)  and 
activated  partial thromboplastin time (APTT) are plasma tests designed with 
substitutes  for  platelet  surfaces.  Haemostasis  is  a  balance  between  the 
coagulation  system  forming  fibrin  and  the  fibrinolytic  system  breaking  it 
down.  Measuring  isolated  components  of  these  systems  may  ignore  the 
interactive  nature  of  the  process.  In  addition,  quantitatively  measuring  a 
specific factor or protein gives no indication of its function in vivo.  Functional 
activity is also dependent on the presence and activity of activators, inhibitors 
and  cellular  elements.  Clotting  is  a  dynamic  process  which  is  difficult  to 
measure  using  stated  end  points,  which  provide  no  information  about  the 
quality  of  the  clot  or  the  dynamics  of  its  formation.  TEG®  provides  an 
integrated  profile  of  the  whole  haemostatic  process.  TEG®  provides 
additional  valuable  information  which  can  not  be  obtained  readily  from 
routine haematological indices, and is complimentary to them. TEG® appears 
to be particularly useful in detecting hypercoagulable  clinical states. 
Experience  with  TEG®  has  indicated  that  to  get  reproducible  results  all 
aspects of sample handling must be standardised. This must include sample
288collection  (tourniquet/no  tourniquet,  Vacutainer™/glass  tubes),  sample 
handling  (mixing/agitation/storage  temperature),  and  length  of  sample 
storage prior to analysis. Care must be taken to avoid heparin contamination 
from  arterial  lines,  and with the addition of the incorrect volume of blood  to 
citrated  collecting  tubes  or  calcium  chloride  to  the  cup.  If  all  aspects  of 
sample handling are standardised then my control studies indicate that TEG® 
is an extremely reproducible measure of haemostasis. The reproducibility of 
TEG® is at least as good as the more frequently used laboratory coagulation 
profiles.
I  would  encourage  all  departments  using  TEG®  to  generate  their  own 
‘normal’ reference ranges for their sample collection and handling techniques 
and ignore the commercial ranges generated by the manufacturers software, 
which in my experience is extremely sensitive to these forces.
TEG® analysis  in the control  population  studied  showed  a  highly significant 
sex  difference.  For the TEG  parameters  K,  Angle,  MA,  tMA and  G female 
controls  showed  a  hypercoagulable  tendency  when  compared  with  males. 
This  could  not  be  explained  by  pregnancy  or  OCP  use.  Age  appeared  to 
have  no  significant  effect  on  TEG®  analysis.  Similar  sex  differences  in 
coagulation  were  also observed  in  the  SAH  patients  studied.  The  routinely 
performed  coagulation tests such  as  PT,  APTT,  I NR and fibrinogen,  do  not 
have reference ranges for men and women, and we aim to investigate these 
TEG® differences further.
The  experimental  studies  demonstrate  that  measured  by  TEG®,  a 
consecutive  series  of  SAH  patients  became  increasingly  hypercoagulable 
over  time  (maximum  21  days)  following  the  ictus,  despite  haematological
289evidence of haemodilution.  This  prothrombotic tendency had  reversed  by 3 
months. Both PT and APTT were insensitive to this hypercoagulable state. 
Plasma  assays  of  coagulation  and  fibrinolysis  show  that  both  of  these 
processes  are  stimulated  following  a  SAH.  However,  coagulation  is 
proportionally stimulated  to  a  greater extent to tip the  balance towards this 
process for the first 21 days following a SAH.
The  treatment  aim  of  haemodilution  and  hypervolaemia  was 
comprehensively achieved with the fluid regimen employed. The haematocrit 
fell from a mean value of 0.39 I/I in the first week, to 0.32 I/I in the third week 
(0.42 I/I at 3 months). This is paralleled by falls in haemoglobin concentration 
and  red  cell count.  It is interesting to note that despite powerful evidence of 
haemodilution during the first 21  days following the SAH, both the fibrinogen 
concentration and the platelet count rise abruptly. The functional result of this 
is a prothrombotic response.
I  have  investigated  the  effect  of  operative  intervention  on  the  trend  of 
increased coagulability following SAH.  It might be expected that the stress of 
surgery, pain, anaesthesia and the release of thromboplastins from the brain 
substance  would  produce  a  further  increase  in  coagulation  profiles.  Any 
further increase in coagulation would predispose to thrombosis, and potential 
ischaemic outcome.  In the operative study,  I  observed  little change  in TEG 
parameters  around  the time  of surgery.  These findings  are  consistent with 
those  of  other  authors  investigating  the  changes  at  similar  time  periods 
around  open  abdominal  and  pelvic surgery in the absence of large volume 
blood  loss.  I  observed  no  statistically  significant  difference  in  the 
postoperative  trend  in  TEG  variables  between  the  surgically  and  non-
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profile  of  increased  coagulation  observed  in  SAH  patients.  However,  the 
trend was for the surgical patients to be more hypercoagulable. This may be 
explained  by  the  fact  that  the  surgically  treated  group  had  a  more 
hypercoagulable initial mean when their first TEG sample was performed. 
Thus,  I  have  failed  to  identify  a  difference  between  the  surgical  and  non- 
surgically treated  groups.  However,  an  alternative  explanation  for this  may 
be  in  the  mixture of the  non-operative  patients.  This group comprises  both 
the  best  (angiogram  negative)  and  worst  (those  treated  conservatively 
because of their poor condition and prognosis) patients in a SAH population. 
It  may  be  that  if  a  pure  perimesencephalic  haemorrhage  population,  or  a 
grade-matched  embolisation  population,  were  compared  with  the  surgical 
group,  then  a  significant  difference  might  have  been  found.  Due  to  a 
limitation  in  numbers,  these  comparisons  have  not  been  possible  in  this 
study.  It  has  been  suggested  that  the  outcome  following  embolisation  is 
better than  after  intracranial  surgery  for  cerebral  aneurysms,  and  that  the 
risks  of  ischaemia  are  less.  It  is  only  speculative  at  this  time  how  the 
influence  of  these  treatment  modalities  on  coagulation  might  influence 
patient outcome.
It  has  been  suggested  that  there  is  an  association  between  makers  of 
haemostatic  activation  following  SAH  and  clinical  outcome.  In  this  study,  I 
have  tried  to  bring  these  theories  together  and  correlate  the  blood  load 
(measured  by  Fisher  grade),  with  haemostatic  activation  (measured  using 
TEG).  I  failed  to  show any statistically significant  relationship  however,  the 
means for each TEG variable did become increasingly hypercoagulable from
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and  had  a  mean  value  roughly  between  those  in  grade  1   and  grade  2  for 
each  TEG  variable.  We  continue to  recruit SAH  patients to  investigate this 
relationship in more detail and to ensure a statistically significant relationship 
has  not  been  missed  because  each  Fisher  grade  group  was  not  equally 
represented in the initial sample.
The final experimental study investigated  in vitro whether haemodilution ‘per 
se’ has an intrinsic effect on coagulation specific to the dilutent itself and thus 
may be contributing to the observed  changes in coagulation following SAH. 
At a 30% haemodilution HES induced a profound hypocoagulable change in 
the haemostatic response as measured by TEG. Gelfusion and 0.9% normal 
saline  promoted  the  kinetics  of  clot  development  and  fibrin  formation,  but 
ultimately  reduced  final  clot  strength.  TEG  by  providing  evidence  of  the 
dynamics of clot formation, and examining whole blood and not just plasma, 
is  extremely  valuable  in  studying  the  effects  of  intravenous  fluids  on  the 
haemostatic process. These results have now been repeated in vitro on SAH 
patients.  We  now  aim  to  investigate  if  the  coagulation  profiles  of  SAH 
patients can be manipulated in vivo with differing fluid replacement regimens. 
To further  investigate the  gender differences  in  coagulation  we  propose  to 
study TEG® parameters in  pre and  postmenopausal women  not taking  HRT 
and an age matched (postmenopausal) male cohort.  In addition we have an 
ongoing project examining TEG® profiles in different stages of the menstrual 
cycle in subjects taking and not taking the oral contraceptive pill.
We continue to recruit SAH patients following the same protocol employed in 
the experimental studies. We will compare coagulation profiles in a cohort of
292grade-matched  perimesencephalic  (angiogram  negative)  haemorrhage  and 
angiogram  positive patients.  In addition we will compare the post-procedure 
coagulation profiles in grade-matched operative and embolisation cohorts.
We  continue  to  recruit  SAH  patients  to  further  investigate  the  relationship 
between  Fisher grade and  haematological  activation to ensure a significant 
correlation was not missed due to each grade not being equally represented 
in the initial sample population.
To further investigate the effect of intravenous fluid therapy on coagulation in 
SAH patients we propose the following study.
The  in  vivo  effects  of  haemodilution  on  haemostasis  following 
subarachnoid haemorrhage, as measured by thromboelastography. 
Introduction
The  cornerstone  of management  in  patients  presenting  with  a  SAH  is  the 
prevention of delayed ischaemic neurological deficit (DIND). This is achieved 
by  so-called  Triple  -   H”   therapy  i.e.  Hypertension,  Haemodilution  and 
Hypervolaemia.  In  clinical  practice  this  means  large  volumes  of  IV  fluid 
replacement.  Different  clinicians  employ  different  fluid  regimes,  some 
preferring crystalloids, some colloids and some combinations.
The  effect  of  IV  fluids  on  coagulation  have  not  been  widely  investigated, 
mainly due to the fact that the routine employed coagulation studies such as 
PT  and  APTT  are  quite  insensitive.  If  a  particular  colloid  induced  a 
hypercoagulable response following its administration one might assume that 
this could predispose to ischaemic complications in a vasospastic population 
such  as  patients following  SAH.  The  aim  of this  study is to  investigate the
293effects of the various fluids  used  in  normal clinical  practice on whole  blood 
coagulation as measured by TEG.
Methods 
Participants
30  patients  admitted  to  the  National  Hospital  for  Neurology  and 
Neurosurgery with a diagnosis of SAH will be recruited into the study. 
Procedure
It is  normal  practice for SAH  patients to  be  managed with  a  minimum  of 3 
litres  of normal  saline  in  a  24  hour period.  Thus,  this will  be  taken  as  the 
control population. A pre-fluid administration blood sample will be taken from 
each of these  patients and  a control TEG  analysis  performed.  Each  patient 
will then be administered a unit of one of the following routinely used colloid 
solutions (Dextran 40, Hexastarch or Gelofusine) over a one-hour period. On 
completion of this, the patient will be left for a further hour and then a second 
TEG  analysis will  be  performed.  Analysis  of TEG  data will  then take  place 
between the control  sample  and  the  post-fluid  sample,  to assess for the  in 
vivo effect of each  colloid  on  coagulation.  Following  a “wash-out”  period  of 
three  days,  the  procedure  will  be  repeated  with  the  same  colloid  until  the 
patient  no  longer  requires  intravenous fluids.  In  addition  the  trend  in  TEG 
indices  in  control  samples  over the first 21  days following  the  ictus will  be 
calculated and compared between the 3 groups.
Statistical Analysis
All data will be transferred directly to and analysed  using Microsoft Excel. A 
paired t-test will be used to make a comparison between the mean difference 
between TEG parameters for the pre- and post- fluid administration. The next
294analysis involved calculating the rate of change of each of the TEG variables 
over time for the first 21  days following the SAH. This will  be calculated  by 
regressing  each  clotting  parameter in turn on the time since SAH, for each 
individual  separately.  A  single  sample  t-test was  used  to  see  if the  mean 
rates  of change  differed  significantly  from  zero  for the  control  samples.  A 
significance level of p<0.05 was taken.
To further investigate the effect of intracranial surgery and coil embolisation 
on the coagulation profiles of SAH patients we propose the following study. 
Comparison of the procoagulant effects of embolisation and surgery in 
patients with SAH.
Aneurysm  rebleeding  and  delayed  ischaemic  neurological  deficit  (DIND) 
attributable  to  clinical  vasospasm  are  major  causes  of  morbidity  among 
patients  who  survive  the  initial  effects  of  aneurysm  rupture.  The  optimal 
timing of surgery for acutely ruptured aneurysms is still the subject of debate, 
because of the effects of vasospasm, which  most commonly occurs 3 to  10 
days following  the  ictus  and  has  a  detrimental  effect on  patient outcomes. 
The  International  Co-operative  Study  on  the  Timing  of Aneurysm  Surgery 
suggested that results depended on the time interval between treatment and 
subarachnoid  haemorrhage  (SAH)(Kassell  et  al.,  1990a).  Early  surgery 
reduced  the  risk  of  rebleeding,  but  the  technical  results  of  surgery  were 
better  if  surgery  was  delayed  until  at  least  10  days  following  the  SAH. 
However,  overall  the  advantages  of  delayed  surgery  were  negated  by 
rebleeding during the preoperative period.
Background to present research.
295We  hypothesise  that  following  SAH  there  is  an  undefined  period  of 
increasing  hypercoagulability,  which  if  present  would  predispose  to 
ischaemic stroke.
Methods.  We  have  carried  out  a  prospective,  observational  study  in  67 
consecutive patients with a primary diagnosis of SAH. Blood was taken at 4 
time periods (<48hours, 4-5, 9-10 and 15-16 days) following the ictus, and on 
regular  intervals  during  the  hospital  stay.  In  addition  blood  was  sampled  3 
months  from  the  ictus.  At  each  time  point  a  Thromboelastograph  (TEG) 
profile, I NR and  APTT assay was performed.
Of  these  67  patients,  the  cause  of  the  SAH  was  a  ruptured  cerebral 
aneurysm  in  56,  an  AVM  in  2,  the  angiogram  was  negative  in  6,  and  the 
cause was undermined in 3 patients.
Findings.  The  routine  clotting  studies  INR  and  APTT  showed  no  change 
over  time.  TEG  analysis  demonstrated  the  development  of  a  sequentially 
increasing  hypercoagulable  state  in  the first 21  days following  SAH.  There 
were  statistically significant  changes  in  the following  TEG  variables  K time 
(p=0.001),  Angle  (p<0.0001),  MA  (p<0.0001),  tMA  (p=0.0001)  and  G 
(p<0.0001).  Following  the  ictus  the  patients  were  significantly 
hypercoagulable in TEG indices than when sampled at 3 months (p<0.001). 
Interpretation.  There  are  sound  methodological  reasons  to  explain  why 
routine  coagulation  studies  may  not  be  as  sensitive  as  TEG  analysis  in 
identifying  a  hypercoagulable  state.  A  state  of  increased  thrombogenicity 
may increase the risk of cerebral ischaemia and  infarction by increasing the 
incidence of micro-thrombotic events.
296Although  the  risk  of  morbidity  following  surgery  in  the  time  of  maximal 
vasospasm  is  increased,  recent  studies  have  suggested  that  there  is  no 
increased procedural risk with coil embolisation during this time(Baltsavias et 
al., 2000; Wikholm et al., 2000). Why should this be? Is it that surgery further 
increases  the  developing  hypercoagulable  state,  leading  to  ischaemia  and 
stroke.  Perhaps  manipulation  of  the  brain  itself,  causing  release  of 
thromboplastins  during  surgery  is  responsible  for  this.  An  alternative 
explanation  maybe  the  reduced  fluid  requirements  of  patients  undergoing 
embolisation  compared  with  surgical  patients,  or  the  increased  stress 
response  induced  by  surgery.  Intravenous  fluids  are  well  known  to  effect 
coagulation. Or perhaps the use of heparin in coiled patients (something that 
is  impossible  in  surgical  candidates),  negates  the  developing 
hypercoagulable state which we have shown in SAH patients. Thus, reducing 
ischaemic complications and improving patient outcome.
We  propose  a  study  using  TEG  to  compare  coagulation  activation  in  SAH 
patients  undergoing  embolisation  and  surgery  in  grade  and  sex  matched 
populations.
We will study 30 surgical and 30 coiled aneurysmal SAH patients.  Blood will 
be sampled  at <48hours, 4-5,  9-10,  15-16 days and  3  months following the 
ictus.  In  addition  blood  will  be  sampled  on  induction  of the  surgical/coiling 
procedure,  120  minutes  later and  24  hours  later.  Blood  will  be  profiled  for 
FBC, biochemical indices, PT, APTT, Fibrinogen, TEG, TAT, P1+2, D-Dimer, 
and  PAP.  Statistical  analysis will  be  performed  to  examine the coagulation 
changes around these procedures.  In addition the serial coagulation profiles 
of  these  two  groups  will  be  compared.  We  aim  to  investigate  whether
297embolisation  provides  protection  from  ischaemia  by  reducing  activation  of 
coagulation systems.
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WFNS grading of SAH
WFNS grade GCS Motor deficit
1 15 absent
2 14-13 absent
3 14-13 present
4 12-7 present or absent
5 6-3 present or absent
(Drake, 1988)
299Appendix II 
Fisher Grading(Fisher et al., 1980).
Group 1. No blood detected.
Group 2. A diffuse disposition or thin layer with all vertical layers of blood 
(interhemispheric fissure, insular cistern, ambient cistern) less than 1mm 
thick.
Group 3. Localised clots and/or vertical layers of blood 1  mm or greater in 
thickness.
Group 4. Diffuse or no subarachnoid blood, but with intracerebral or 
intraventricular clots.
300Appendix III
Normal TEG ranges
450-690
120-450
36-48
34-46
2575-4259
301Appendix IV
CONSENT BY VOLUNTEER.
INVESTIGATORS:  Mr Andrew McEvoy  FRCS
Mr Neil Kitchen  MD FRCS (SN)
We would like to invite you to take part in a study to determine the factors which 
alter the ability of the blood to clot during brain injury.
Traumatic brain injury and brain haemorrhage (stroke) accounts for a substantial and 
often devastating disease burden in young and middle aged adults.  Because little 
can be done about the initial injury, treatment must be directed towards preventing 
secondary events which themselves lead to further disability.
The aim of the study is to examine which factors cause the blood to clot more 
quickly after this type of brain injury.  Increased blood coagulation leads to further 
stroke and may be reversed with drugs leading to reduced disability and increased 
survival in these patients.
Patients entering the study will have a small additional amount (5mls) of blood taken 
on each routine occasion when blood would normally be taken during their hospital 
stay.  The only occasion when a blood sample will be taken in addition to the 
present routine samples are at 60 days and 90 days following the injury.  This 
volume of blood is replaced within hours of sampling and will not alter the subject’s 
chances of making a good recovery from their illness.
Your participation in the trial is entirely voluntary.  You are free to decline to enter 
or to withdraw from the study at any time without having to give a reason.  If you 
choose not to enter the trial, or to withdraw once entered, this will in no way affect 
your future medical care.  All information regarding your medical records will be 
treated as strictly confidential and will only be used for
Medical purposes.  Your medical records may be inspected by competent authorities 
and properly authorised persons, but if any information is released this will be done 
so in coded form so that confidentiality is strictly maintained.  Participation in this 
study will in no way affect your legal rights.
The two investigators in this study, Mr Andrew McEvoy and Mr N D Kitchen can be 
contacted during working hours via Mr Kitchen’s secretary at the National Hospital 
on   ext  .  In cases of emergency, Mr McEvoy can be contacted 
out of hours via the National Hospital switchboard and aircall pager 24 hours per 
day.
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INVESTIGATORS:  Mr Andrew McEvoy FRCS
Mr Neil Kitchen MD FRCS (SN)
We would like to invite you to take part in a study to determine the factors which 
alter the ability of the blood to clot during brain injury.
Traumatic brain injury and brain haemorrhage (stroke) accounts for a substantial and 
often devastating disease burden in young and middle aged adults.  Because little 
can be done about the initial injury, treatment must be directed towards preventing 
secondary events which themselves lead to further disability.
The aim of the study is to examine which factors cause the blood to clot more 
quickly after this type of brain injury.  Increased blood coagulation leads to further 
stroke and may be reversed with drugs leading to reduced disability and increased 
survival in these patients.
Patients entering the study will have a small additional amount (5mls) of blood taken 
on each routine occasion when blood would normally be taken during their hospital 
stay.  The only occasion when a blood sample will be taken in addition to the 
present routine samples are at 60 days and 90 days following the injury.  This 
volume of blood is replaced within hours of sampling and will not alter the subject’s 
chances of making a good recovery from their illness.
You are free to agree to your relative being entered or to withdraw them from the 
study at any time without having to give a reason.  If you choose not to enter your 
relative into the trial, or to withdraw them once entered, this will in no way affect 
their future medical care.  Your relative will be informed of his/her involvement in 
the study, and your agreement, should they regain consciousness.  All information 
regarding their medical records will be treated as strictly confidential and will only 
be used for medical purposes.  Their medical records may be inspected by 
competent authorities and properly authorised persons, but if any information is 
released this will be done so in coded form so that confidentiality is strictly 
maintained.  Participation in this study will in no way affect your relative’s legal 
rights.
The two investigators in this study, Mr Andrew McEvoy and Mr N D Kitchen can be 
contacted during working hours via Mr Kitchen’s secretary at the National Hospital 
on    ext.  .  In cases of emergency, Mr McEvoy can be contacted 
out of hours via the National Hospital switchboard and air call pager 24 hours per 
day.
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Glasgow outcome score
H   u   11  j i;  . ■  ju y j  a   '^ 1 ,   » .  i'  —   "   '  i  i  p   ■  i  '  ; '!      |.^J  ■  1          . u i i i ,  .  i.j   i
Grade  Neurologlcalstabis
1  Good recovery; patient can lead a full and  independent life with 
or without minimal neurological deficit
2  Moderately disabled; patient has neurological or intellectural impairment 
but is independent
3  Severely disabled patient, conscious but totally dependent on others 
to get through daily activities
4  Vegetative survival
5  Dead
(Jennett, Bond, 1975)
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Regression Statistics
Multiple R  0.27
R Square  0.07
Adjusted R  -0.04
Square
Standard Error  43209.63
Observations  20
ANOVA
df ss MS F Significance F
Regression 2 2.41 E+09 1.21 E+09 0.65 0.54
Residual 17 3.17E+10 1.87E+09
Total 19 3.42E+10
Coefficients  Standard  t Stat P-value  Lower 95%  Upper
Error 95%
Intercept -25745.27 50604.19 -0.51 0.61 -132511 81020.4
sex 12420.25 21462.71 0.58 0.57 -32862.2 57702.7
age 733.96 1167.49 0.63 0.54 -1729.23 3197.14
Table 50. Analysis of the effects of gender and age on the mean 
difference between R for day 0 and day 14.
Using p<0.05 to determine significance, regression analysis of R for effects 
of gender and age revealed that neither gender nor age produced a 
significant effect on R (p>0.05).
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Multiple R  0.22
R Square  0.05
Adjusted R  -0.06
Square
Standard Error  4616.56
Observations
ANOVA
20
df SS MS F  Significance F
Regression 2 20004672 10002336 0.47  0.63
Residual 17 362314408 21312612
Total 19 382319080
Coefficients Standard
Error
tStat P-value Lower 95% Upper
95%
Intercept -1277.13 5406.60 -0.24 0.82 -12684.08 10130
sex 2212.87 2293.10 0.97 0.35 -2625.15 7050.9
age -42.73 124.74 -0.34 0.74 -305.91 220.45
Table 51. Analysis of the effects of gender and age on the mean 
difference between K for day 0 and day 14.
Using p<0.05 to determine significance, regression analysis of K for effects 
of gender and age revealed that neither gender nor age produced a 
significant effect on K (p>0.05).
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Multiple R  0.18
R Square  0.03
Adjusted R  -0.08
Square
Standard Error  77.04
Observations  20
ANOVA
df ss MS F Significance F
Regression 2 3294.09 1647.04 0.28 0.76
Residual 17 100906.09 5935.65
Total 19 104200.18
Coefficients Standard
Error
tStat P-value Lower 95% Upper
95%
Intercept 9.27 90.22 0.10 0.92 -181.09 199.64
sex 28.51 38.25 0.74 0.47 -52.23 109.24
age -0.65 2.08 -0.31 0.76 -5.05 3.74
Table 52. Analysis of the effects of gender and age on the mean 
difference between Angle for day 0 and day 14.
Using p<0.05 to determine significance, regression analysis of Angle for 
effects of gender and age revealed that neither gender nor age produced a 
significant effect on Angle (p>0.05).
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Multiple R  0.36
R Square  0.13
Adjusted R  0.03
Square
Standard Error  109.86
Observations  20
ANOVA
df SS MS  F  Significance F
Regression 2 31427.31 15713.65  1.30  0.30
Residual 17 205187.5 12069.85
Total 19 236614.81
Coefficients  Standard t Stat  P-value  Lower 95%  Upper
Error 95%
Intercept -115.83 128.66 -0.90 0.38 -387.29 155.63
sex 86.83 54.57 1.59 0.13 -28.30 201.96
age -1.34 2.97 -0.45 0.66 -7.60 4.92
Table 53. Analysis of the effects of gender and age on the mean 
difference between MA for day 0 and day 14.
Using p<0.05 to determine significance, regression analysis of MA for effects 
of gender and age revealed that neither gender nor age produced a 
significant effect on MA (p>0.05).
308Regression Statistics
Multiple R 0.27
R Square 0.07
Adjusted R -0.03
Square
Standard Error 8165988
Observations 20
ANOVA
df  SS MS F Significance F
Regression
Residual
Total
2  9.10E+13 
17  1.13E+15 
19  1.23E+15
4.55E+13
6.67E+13
0.68 0.52
Coefficients  Standard 
Error
tStat P-value Lower 95%  Upper 95%
Intercept
sex
age
-4349734  9563451 
4736649  4056139 
-109631.9  220638
-0.45
1.17
-0.50
0.65
0.26
0.63
-24526881  15827413 
-3821068  13294366 
-575138  355874.12
Table 54. Analysis of the effects of gender and age on the mean 
difference between G for day 0 and day 14.
Using p<0.05 to determine significance, regression analysis of G for effects 
of gender and age revealed that neither gender nor age produced a 
significant effect on G (p>0.05).
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t-Test: Paired Two Sample for Means  t-Test: Paired Two Sample for Means
R RNS R R Gel
Mean 658.9 667.95 Mean 658.9 607.85
Variance 15021.67 18136.05 Variance 15021.67 7194.766
Observations 20 20 Observations 20 20
Pearson Correlation 0.345433 Pearson Correlation 0.56484
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 19
tStat -0.2744 tStat 2.230954
P(T<=t) one-tail 0.393368 P(T<=t) one-tail 0.018966
t Critical one-tail 1.729131 t Critical one-tail 1.729131
P(T<=t) two-tail 0.786737 P(T<=t) two-tail 0.037932
t Critical two-tail 2.093025 t Critical two-tail 2.093025
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means
R RHES RNS R Gel
Mean 658.9 679.75 Mean 667.95 607.85
Variance 15021.67 15456.83 Variance 18136.05 7194.766
Observations 20 20 Observations 20 20
Pearson Correlation 0.466701 Pearson Correlation 0.449762
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 19
tStat -0.73134 tStat 2.190488
P(T<=t) one-tail 0.236748 P(T<=t) one-tail 0.020581
t Critical one-tail 1.729131 t Critical one-tail 1.729131
P(T<=t) two-tail 0.473495 P(T<=t) two-tail 0.041162
t Critical two-tail 2.093025 t Critical two-tail 2.093025
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means
RNS RHES R Gel RHES
Mean 667.95 679.75 Mean 607.85 679.75
Variance 18136.05 15456.83 Variance 7194.766 15456.83
Observations 20 20 Observations 20 20
Pearson Correlation 0.63865 Pearson Correlation 0.541078
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 19
tStat -0.47763 tStat -3.03296
P(T<=t) one-tail 0.319182 P(T<=t) one-tail 0.003421
t Critical one-tail 1.729131 t Critical one-tail 1.729131
P(T<=t) two-tail 0.638363 P(T<=t) two-tail 0.006843
t Critical two-tail 2.093025 t Critical two-tail 2.093025
Table 55. t-tests for the TEG variable R for undiluted and diluted 
samples.
NS = Normal saline, Gel = Gelfusion, HES = Hydroxyethylstarch.
310t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means
Ang Ang NS Ang Ang Gel
Mean 47.175 48.625 Mean 47.175 54.15
Variance 62.58618 38.18092 Variance 62.58618 44.60789
Observations 20 20 Observations 20 20
Pearson Correlation 0.7209 Pearson Correlation 0.60087
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 19
tStat -1.1783 tStat -4.71884
P(T<*t) one-tail 0.126612 P(T<*t) one-tail 7.47E-05
t Critical one-tail 1.729131 t Critical one-tail 1.729131
P(T  <=t) two-tail 0.253224 P(T<=t) two-tail 0.000149
t Critical two-tail 2.093025 t Critical two-tail 2.093025
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means
Ang  Ang HES Ang NS  Ang Gel
Mean 47.175  44.825 Mean 48.625  54.15
Variance 62.58618  36.55987 Variance 38.18092  44.60789
Observations 20  20 Observations 20  20
Pearson Correlation 0.652592 Pearson Correlation 0.568312
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 19
tStat 1.734491 tStat -4.12492
P(T<=t) one-tail 0.049513 P(T<*t) one-tail 0.000288
t Critical one-tail 1.729131 t Critical one-tail 1.729131
P(T  <=t) two-tail 0.099026 P(T<=t) two-tail 0.000576
t Critical two-tail 2.093025 t Critical two-tail 2.093025
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means
AngNS  Ang HES Ang Gel  Ang HES
Mean 48.625  44.825 Mean 54.15  44.825
Variance 38.18092  36.55987 Variance 44.60789  36.55987
Observations 20  20 Observations 20  20
Pearson Correlation 0.712014 Pearson Correlation 0.454552
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 19
tStat 3.661909 tStat 6.254685
P(T<*t) one-tail 0.000829 P(T<*t) one-tail 2.63E-06
t Critical one-tail 1.729131 t Critical one-tail 1.729131
P(T<=t) two-tail 0.001658 P(T  <=t) two-tail 5.25E-06
t Critical two-tail 2.093025 t Critical two-tail 2.093025
Table 57. t-tests for the TEG variable Angle (Ang) for undiluted and 
diluted samples.
NS = Normal saline, Gel = Gelfusion, HES = Hydroxyethylstarch.
312t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means
MA MANS MA MA Gel
Mean 57.025 51.725 Mean 57.025 54.15
Variance 25.22303 12.06513 Variance 25.22303 20.81842
Observations 20 20 Observations 20 20
Pearson Correlation 0.602315 Pearson Correlation 0.604461
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 19
tStat 5.875542 tStat 3.002391
P(T<=t) one-tail 5.85E-06 P(T<=t) one-tail 0.003661
t Critical one-tail 1.729131 t Critical one-tail 1.729131
P(T  <=t) two-tail 1.17E-05 P(T<=t) two-tail 0.007323
t Critical two-tail 2.093025 t Critical two-tail 2.093025
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means
MA  MA HES MANS MA Gel
Mean 57.025  47.8 Mean 51.725 54.15
Variance 25.22303  15.27368 Variance 12.06513 20.81842
Observations 20  20 Observations 20 20
Pearson Correlation 0.745722 Pearson Correlation 0.348114
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 19
tStat 12.31477 tStat -2.3201
P(T<=t) one-tail 8.36E-11 P(T<=t) one-tail 0.01581
t Critical one-tail 1.729131 t Critical one-tail 1.729131
P(T<=t) two-tail 1.67E-10 P(T<=t) two-tail 0.031621
t Critical two-tail 2.093025 t Critical two-tail 2.093025
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means
MA NS  MA HES MA Gel  MA HES
Mean 51.725  47.8 Mean 54.15  47.8
Variance 12.06513  15.27368 Variance 20.81842  15.27368
Observations 20  20 Observations 20  20
Pearson Correlation 0.496852 Pearson Correlation 0.740397
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 19
tStat 4.71672 tStat 9.124259
P(T<=t) one-tail 7.51 E-05 P(T<=t) one-tail 1.13E-08
t Critical one-tail 1.729131 t Critical one-tail 1.729131
P(T<=t) two-tail 0.00015 P(T<=t) two-tail 2.26E-08
t Critical two-tail 2.093025 t Critical two-tail 2.093025
Table 58. t-tests for the TEG variable MA for undiluted and diluted 
samples.
NS = Normal saline, Gel = Gelfusion, HES = Hydroxyethylstarch.
313t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means
G GNS G G Gel
Mean 6643.75 5658.725 Mean 6643.75 5904.2
Variance 2495220 969424.2 Variance 2495220 1309572
Observations 20 20 Observations 20 20
Pearson Correlation 0.408187 Pearson Correlation 0.721011
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 19
tStat 2.973379 tStat 3.021602
P(T<**t) one-tail 0.003904 P(T<*t) one-tail 0.003509
t Critical one-tail 1.729131 t Critical one-tail 1.729131
P(T<=t) two-tail 0.007808 P(T<=t) two-tail 0.007018
t Critical two-tail 2.093025 t Critical two-tail 2.093025
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means
G G HES GNS G Gel
Mean 6643.75 4649.15 Mean 5658.725 5904.2
Variance 2495220 540518.5 Variance 969424.2 1309572
Observations 20 20 Observations 20 20
Pearson Correlation 0.676666 Pearson Correlation 0.144568
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 19
tStat 7.372104 tStat -0.7855
P(T<=t) one-tail 2.76E-07 P(T<=t) one-tail 0.220923
t Critical one-tail 1.729131 t Critical one-tail 1.729131
P(T<=t) two-tail 5.52E-07 P(T<=t) two-tail 0.441845
t Critical two-tail 2.093025 t Critical two-tail 2.093025
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means
GNS G HES G Gel G HES
Mean 5658.725 4649.15 Mean 5904.2 4649.15
Variance 969424.2 540518.5 Variance 1309572 540518.5
Observations 20 20 Observations 20 20
Pearson Correlation 0.576528 Pearson Correlation 0.681467
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 19
tStat 5.494302 tStat 6.692273
P(T<=t) one-tail 1.33E-05 P(T<=t) one-tail 1.07E-06
t Critical one-tail 1.729131 t Critical one-tail 1.729131
P(T  <=t) two-tail 2.67E-05 P(T<=t) two-tail 2.13E-06
t Critical two-tail 2.093025 t Critical two-tail 2.093025
Table 59. t-tests for the TEG variable G for undiluted and diluted 
samples.
NS = Normal saline, Gel = Gelfusion, HES = Hydroxyethylstarch.
314Appendix VIII
Fisher grades on CT imaging
Grade 1   Grade 2.
Grade 3 Grade 4.
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